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Abstract 
Poliomyelitis  is  a  seriously  debilitating  human  disease,  caused  by  poliovirus.  Since  the 
initiation  of  the  World  Health  Organisation  (WHO)  and  the  Pan  American  Health 
Organisation  (PAHO)  poliomyelitis  eradication  program,  mass  immunisation  of  the 
worldwide  population  and  better  monitoring  of  acute  flaccid  paralysis  (AFP)  cases  enabled 
the  reduction  in  the  number  of  poliomyelitis  cases  worldwide  and  the  eradication  of 
circulating  wild-type  polioviruses  in  a  large  number  of  countries.  The  oral  live-attenuated 
poliovirus  vaccine  (OPV)  and  inactivated  poliovirus  vaccine  (IPV)  have  been  used 
extensively  as  a  tool  for  achieving  poliomyelitis  eradication.  Since  the  introduction  of 
OPV,  neurovirulent  revertant  poliovirus  vaccine  strains  have  been  reported  to  cause  rare 
cases  of  paralysis  in  vaccinees  and/or  contacts  of  vaccinees.  However,  recent  reports  of 
vaccine-associated  acute  paralysis  (VAAP)  outbreaks,  caused  by  newly  emerging 
circulating  vaccine-derived  polioviruses  (cVDPVs),  in  Hispaniola  and  Madagascar  have 
raised  the  existing  concerns  about  the  potential  of  poliovirus  vaccine  strains  to  recombine 
with  human  enteroviruses  (HEV).  The  original  aim  of  the  project  was  to  determine  whether 
a  non-poliovirus  HEV  could  evolve  to  use  the  poliovirus  receptor  (PVR).  A  variety  of 
methods  were  used  to  exploit  aspects  of  the  evolutionary  capacity  of  viruses  to  achieve  this 
goal.  Although  the  aim  was  not  attained,  the  investigation  of  recombinants  between 
different  HEVs  yielded  interesting  results,  which  were  pursued  further.  Two  approaches 
were  developed:  in  vitro  generation  of  recombinant  viruses  and  phenotypic  analysis  of 
such  chimeras  and  the  selection  for  recombinant  viruses  in  vivo. 
In  vitro  generation  of  reciprocal  recombinants  between  the  structural  and  the  non-structural 
coding  region  of  coxsackievirus  A21  (CVA21)  and  poliovirus  type  3  (PV3)  was  initiated. 
Transfected  and  passaged  chimeras  did  not  produce  infectious  virions. iv 
Immunofluorescence  analysis  of  VP1  protein  expression  suggested  that  the  recombinants 
were  not  acytopathic.  A  series  of  assays  were  then  carried  out  to  investigate  the  nature  of 
the  defect.  HeLa  S10  translation/transcription  reactions  of  the  in  vitro  generated 
recombinants  expressed  the  correct  protein-processing  pattern  suggesting  efficient 
processing  occurred  in  vitro.  Replication  assays  demonstrated  that  the  chimeras  were 
replication  competent.  Trans-encapsidation  experiments  were  then  carried  out  and 
preliminary  results  strongly  suggested  that  the  defect  could  lie  at  the  packaging  level. 
Additional  studies  are  required. 
Selection  of  recombinants  in  vivo,  without  predetermining  the  crossover  sites,  was  also 
conducted.  Under  the  conditions  used,  recombination  between  CVA21  and  PV3  impaired 
genomes  and  echovirus  7  (EV7)  and  PV3  impaired  genomes  proved  to  be  unsuccessful. 
This  could  have  been  due  to  both  genomes  localising  to  separate  replication  compartments 
rendering  replication-dependent  recombination  impossible.  This  needs  to  be  verified. 
Characterisation  of  the  impaired  parental  genomes  used  for  the  experiment  needs  to  be 
carried  out.  However,  recent  reports  of  recombinants  between  Sabin  polioviruses  and 
HEV-C  confirm  the  possibility  of  such  a  recombination  event  occurring  and  emphasize 
concerns  regarding  the  success  of  the  polio  eradication  program. 
RNA  viruses  are  also  subjected  to  polymerase  error  rate,  another  evolutionary  mechanism. 
Ribavirin,  a  random  mutagen,  was  used  to  increase  the  error  rate  of  CVA2  1,  a  HEV-C,  to 
investigate  whether  this  particular  HEV-C  could  evolve  to  use  an  alternative  receptor  for 
attachment  and  entry.  However,  no  novel  tropic  viruses  were  recovered  under  the 
experimental  conditions  applied. V 
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database  (see  table  of  plasmids  and  appendix  2). viii 
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1  Introduction 
1.1  Picomaviruses 
Picornaviruses  are  some  of  the  smallest  RNA  viruses:  Pico  (very  small  unit  of 
measurement  10"12)  ma  (RNA)  viruses.  The  Picornaviridae  family  comprises  some  of  the 
oldest  known  viruses  such  as  the  foot  and  mouth  disease  virus  (FMDV),  one  of  the  first 
viruses  to  be  recognised  (Loeffler  &  Frosch,  1898),  and  poliomyelitis,  which  has  been 
prevalent  since  at  least  the  18th  Egyptian  dynasty  (1550-1333  BC)  as  is  shown  in  an 
illustration  of  a  doorkeeper  on  a  funeral  stone  (Melnick,  1982). 
1.2  Classification  of  the  Picornaviridae  family 
The  Picornaviridae  family  is  composed  of  over  200  serotypes.  The  original  taxonomy  was 
based  on  physical  properties  (particle  density  and  pH-sensitivity)  and  serological 
relatedness.  However,  picornavirus  classification  was  recently  revised  based  on  nucleotide 
sequences  and  divided  into  9  genera:  Aphthoviruses,  Cardioviruses,  Enteroviruses, 
Erboviruses,  Hepatoviruses,  Kobuviruses,  Parechoviruses,  Rhinoviruses  and  Teschoviruses 
(see  table  1.1).  The  nine  genera  include  pathogens  that  cause  a  wide  range  of  mild  to  acute 
diseases. Claire  Blanchard  Introduction  Chapter  12 
Genus  Species  Serotypes 
Aphthovirus  Foot  and  Mouth  Disease  Virus  FMDV-0,  A,  C,  Asia  1,  SAT1-3 
Equine  Rhinitis  A  virus  ERAV 
Cardiovirus  Encephalomycarditis  Virus  EMCV 
Theileovirus  TMEV,  VHEV 
Enterovirus  Poliovirus  PV  1-3 
Human  Enterovirus  A  CVA  2-8,10,12,14,16,  EV71 
Human  Enterovirus  B  CVB  1-6,  CVA9,  E1-33, 
EV69-73 
Human  Enterovirus  C  CVA  1,11,13,15,17-24 
Human  Enterovirus  D  EV-68,  EV-  70 
Bovine  Enterovirus  BEV-1,  BEV-2 
Porcine  Enterovirus  A  PEV-8 
Porcine  Enterovirus  B  PEV-9,  PEV  10 
Simian  Enterovirus  A  SEV-A 
Erbovirus  Equine  Rhinitis  virus  ERBV  1  and  2 
Hepatovirus  Hepatitis  A  virus  HAV 
Avian  Encephalomyelitis  Virus  AEV 
Kobuvirus  Aichi  virus  AN 
Bovine  Kobuvirus  BKV 
Parechovirus  Human  Parechovirus  HpeV-1  and  2 
Ljungan  Virus  LV 
Rhinovirus  Human  Rhinovirus  A  HRV  1,2,7,8,9  -13  etc 
Human  Rhinovirus  B  HRV  3-6,14,17,26  etc 
Teschovirus  Porcine  Teschovirus  PTV  1-11 
Table  1.1:  Classification  of  members  of  the  Picornaviridae. Claire  Blanchard  Introduction  Chapter  13 
1.3  Pathogenesis  within  a  host 
Pathogenesis  is  defined  by  the  broad  spectrum  of  symptoms  triggered  by  viral  infection 
and  the  host  range  or  tissues  susceptible  to  infection  by  specific  viruses.  Because  of  the 
nature  of  this  project,  emphasis  and  detailed  analysis  of  the  human  enterovirus  (HEV) 
pathogenesis  and  life  cycle,  and  not  that  of  other  genera  of  the  Picornaviridae  family,  is 
contained  in  this  chapter.  The  majority  of  HEV  infections  cause  asymptomatic  or  mild 
syndromes  (see  table  1.2).  However,  HEVs  have  also  been  involved  in  cardiac  and  central 
nervous  system  (CNS)  syndromes.  Invasion  of  the  CNS  is  characteristic  of  poliovirus,  the 
prototype  picomavirus,  resulting  in  acute  flaccid  paralysis  (AFP).  However, 
Coxsackieviruses  A  have  also  been  shown  to  cause  AFP.  In  fact  recent  studies  carried  out 
in  ICAM-1  transgenic  mice  have  shown  that  CVA21  could  cause  identical  symptoms  to 
those  seen  in  poliovirus  infected  PVR-transgenic  mice  (Dufresne  et  al.,  2004). Claire  Blanchard  Introduction  Chapter  14 
Clinical  diseases  associated  with  Infection 
Enteroviruses 
Poliovirus  type  1,2  Paralytic  poliomyelitis  and  mild  febrile  illness 
and  3 
Coxsackievirus  A  Aseptic  meningitis 
Hand,  foot  and  mouth  disease 
Common  cold 
Coxsackievirus  B  Aseptic  meningitis 
Myocarditis,  pleurodynia,  severe  systemic  disease  in  infants 
Upper  respiratory  tract  illness,  pneumonia 
and  post-viral  fatigue  syndrome 
Echoviruses  Aseptic  meningitis 
Paralysis 
Respiratory  disease 
Myocarditis 
Epidemic  myalagia 
Hepatic  disturbances 
Enterovirus  68  Pneumonia 
Enterovirus  70  Acute  haemorrhagic  conjunctivitis 
Enterovirus  71  Hand,  foot  and  mouth  disease 
Rhinoviruses 
Major  receptor  group  Common  cold 
rhinoviruses 
Minor  receptor  group  Common  cold 
rhinoviruses 
Parechoviruses 
Echoviruses  types  22  Respiratory  disease 
and  23  Encephalitis 
He  atoviruses  Hepatitis 
A  hthoviruses  Foot-and-mouth  disease 
Cardioviruses 
Encephalomyocarditis  Encephalitis  and  myocarditis 
virus  and  Mengovirus 
Theiler's  murine  Encephalomyelitis  (in  mice) 
encephalomyocarditis 
virus 
Table  1.2:  Clinical  diseases  associated  with  picornavirus  infection  and  exacerbation. Claire  Blanchard  Introduction  Chapter  15 
1.3.1  Poliovirus  pathogenesis  and  life  cycle  within  a  human  host 
Poliovirus  is  the  prototype  HEV  and  has  been  extensively  studied  since  it  was  first 
identified  as  the  etiologic  agent  of  poliomyelitis  in  1909  (Landsteiner  &  Popper,  1909). 
Infection  with  poliovirus  causes  mild  or  asymptomatic  syndromes  in  90%  of  cases  and 
infection  only  progresses  to  poliomyelitic  paralysis  in  1%  of  cases  (Melnick  et  al.,  1996  a). 
Poliovirus  infects  cells  of  the  digestive  tract  (oropharyngeal  cells  and  intestinal  cells), 
multiplies  locally  at  the  initial  sites  of  virus  ingestion  (tonsils,  Peyer's  patch)  and  virions 
are  shed  into  the  environment  through  faeces  (see  figure  1.3).  The  translocation  of 
poliovirus  particles  across  M-like  cells,  which  are  found  in  the  epithelial  sheet  of  the 
Peyers  patches  (Ouzilou  et  al.,  2002)  enables  the  virus  to  come  in  contact  with  cells  from 
the  immune  system,  which  are  then  thought  to  favour  spread  to  cervical  and  mesenteric 
lymph  nodes.  These  events  lead  to  a  primary  viraemia  during  which  poliovirus  can 
replicate  in  peripheral  blood  mononuclear  cells  (Freidstadt  &  Eberle,  1996).  Once  inside 
the  bloodstream  the  infectious  virus  particles  spread  to  other  susceptible  tissues  such  as 
other  lymph  nodes,  brown  fat,  muscle,  and  the  central  nervous  system  (CNS).  Poliovirus 
has  been  shown  to  cross  the  blood-brain  barrier  in  mice  (Yang  et  al.,  1997).  Invasion  of  the 
CNS  is  primarily  thought  to  occur  by  means  of  peripheral  or  cranial  nerve  retrograde 
axonal  transport,  stimulated  by  skeletal  muscle  injury  (Gromeier  &  Wimmer  1998),  and 
leads  to  the  development  of  poliomyelitis.  The  fast  retrograde  axonal  transport  pathway  of 
poliovirus  from  the  axon  to  the  neuronal  cell  body  occurs  in  a  PVR-dependent  manner  by 
the  PVR  interaction  with  the  dynein-motor  complex  component  Tctex-1  (Mueller  et  al., 
2002).  Poliovirus  is  then  able  to  attach,  enter,  infect  and  destroy  motor  neurons,  in 
particular  neurons  of  the  anterior  horn  of  the  spinal  cord  leading  to  paralytic  poliomyelitis Small  intestine: 
Invasion 
Multiplication 
Mesenteric  lymph  nodes: 
M  Iltiplication 
Initial  antibody 
appearance 
CNS: 
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Intraneural  spread 
12  Excretion  in  faeces 
Figure  1.3:  Poliovirus  pathogenesis 
This  schematic  illustration  represents  a  longstanding  view  of  the  pathogenesis  of 
poliovirus.  Note  that  additional  data  emphasize  the  importance  of  retrograde  axonal  flow 
of  virus  into  the  central  nervous  system.  Virus  enters  by  way  of  the  alimentary  tract  and 
multiplies  locally  at  the  initial  sites  of  virus  implantation  (tonsils,  Peyer's  patch)  or  the 
lymph  nodes  that  drain  these  tissues,  and  virus  begins  to  appear  in  the  throat  and  in  the 
feces-leading  to  virus  shedding  into  the  environment.  At  this  time,  it  is  possible  that 
virus  may  spread  to  the  CNS  by  peripheral  or  cranial  nerve  axonal  flow.  Secondary  virus 
spread  occurs  by  way  of  the  bloodstream  to  other  susceptible  tissues-namely,  other 
lymph  nodes,  brown  fat,  muscle,  and  the  CNS.  Virus  can  then  also  spread  into  the  CNS  at 
this  time  by  means  of  peripheral  or  cranial  nerve  retrograde  axonal  flow-for  example, 
from  muscle.  If  a  high  level  of  virus  replication  occurs  within  the  CNS,  motor  neurons  die 
and  paralysis  ensues.  (Diagram  and  legends  taken  from  Melnick  et  al.,  1996a) Claire  Blanchard  Introduction  Chapter  16 
in  humans,  primates  and  PVR  transgenic  mice  (Ren  et  al.,  1990).  The  following 
description  of  the  virus  life  cycle  focuses  on  poliovirus  unless  otherwise  specified. 
1.3.2  Host  cell  infection  and  poliovirus  life  cycle 
1.3.2.1  Overview  (see  figure  1.4) 
The  complete  life  cycle  of  poliovirus  within  a  host  cell  occurs  in  approximately  5  to 
10  hours  and  is  initiated  by  the  attachment  of  the  virus  to  its  receptor:  PVR  (CD  155) 
(Hogle  et  al.,  1985).  Conformational  changes  induced  by  receptor  attachment  lead  to  the 
uncoating  and  release  of  the  viral  genomic  RNA  into  the  host  cell  cytoplasm  (Belnap  et  al., 
2000),  in  which  the  entirety  of  the  reproductive  life  cycle  of  poliovirus  occurs.  Once  the 
genomic  RNA  has  entered  the  cell,  the  5'  covalently-linked  VPg  is  cleaved  off  by  a 
cellular  enzyme,  releasing  the  RNA  for  translation  into  a  single  polyprotein  (Pelletier  et  al., 
1988).  The  translated  polyprotein  undergoes  a  cascade  of  autocatalytic  events  known  as 
proteolytic  processing,  generating  functional  viral  proteins  (Schechter  et  al.,  1967; 
Ypma-Wong  et  al.,  1988).  Once  the  non-structural  proteins  are  generated,  the  host  cell 
endoplasmic  reticulum  membranes  are  altered  and  re-arranged  to  form  replication 
complexes  where  initiation  of  the  negative-sense  strand  synthesis  occurs  (Bienz  et  al., 
1987;  Beinz  et  al.,  1990).  The  negative-sense  strands  are  then  used  as  a  template  for  the 
positive-sense  strand  synthesis.  The  newly  synthesised  positive-sense  strand  progeny  RNA 
molecules  are  translated,  enhancing  the  number  of  replication  complexes  formed  and 
amplification  of  the  viral  genome  (Jarvis  et  al.,  1992).  The  VPg-linked  progeny  RNA 
genomes  are  then  packaged  into  the  virus  capsid  proteins  VP  I,  VP3  and  VPO,  resulting 
from  the  polyprotein  processing  (Arnold  et  al.,  1987).  Encapsidation  leads  to  the  final 
maturation  of  the  immature  virions  into  infectious  icosahedral  particles,  which  are  then 
released  into  the  intercellular  environment  (Hellen  et  al.,  1992).  Poliovirus  infection  can  be A 
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lytic  or  non-lytic  depending  on  the  host  cell  type  (Lopez-Guerrero  et  al.,  2000),  the  state  of 
differentiation  of  a  particular  cell  type,  the  genetic  make-up  of  the  virus  and  the  conditions 
of  infection  (Agol  et  al.,  1998,  Tolskaya  et  al.,  1995). 
1.3.2.2  Attachment 
The  recognition  and  the  attachment  to  the  PVR  cellular  receptor,  a  membrane-anchored 
immunoglobulin-like  glycoprotein  recognised  by  all  three  serotypes  of  poliovirus,  is  the 
first  step  of  the  poliovirus  replication  life  cycle. 
1.3.2.2.1  Virus  structure  and  receptor  attachment 
Poliovirus  is  a  non-enveloped  virus  that  has  an  RNA  genome  packaged  inside  an 
icosahedral  capsid  of  approximately  25nm  in  diameter,  composed  of  60  copies  of  the  VP1, 
VP2,  VP3  and  VP4  viral  capsid  proteins.  The  poliovirus  three-dimensional  structure  has  a 
deep  and  narrow  20  A-surface  depression  around  the  5-fold  axes,  also  known  as  the 
"canyon",  formed  by  the  assembled  VP  1,  VP2  and  VP3  proteins  (see  figure  1.5). 
Rossmann  first  developed  the  "canyon"  hypothesis  in  his  three-dimensional  analysis  of  the 
human  rhinovirus  14  (Rossmann  et  al.,  1985).  The  "canyon"  is  lined  by  conserved  residues 
(Rossmann  et  al.,  1988;  Rossmann  et  al.,  1989),  encircling  each  of  the  twelve  5-fold  axes, 
and  forms  a  docking  site  for  the  PVR  attachment  (He  et  al.,  2000).  The  membrane-distal 
N-terminal  domain  of  PVR  binds  to  the  viral  canyon  (He  et  al.,  2003).  Under  the  floor  of 
the  canyon,  in  the  VP1  capsid  protein  lays  a  hydrophobic  pocket,  which  contains  a 
sphingosine  or  palmitate-like  molecule  (Rossmann  et  al.,  1994)  or  "pocket  factor".  The 
"pocket  factor"  is  of  cellular  origin  and  is  thought  to  play  a  regulatory  role  in  viral 
assembly  and  uncoating  (Filman  et  al.,  1989)  as  well  as  stabilising  the  virions  during  the 
transit  phase  from  infected  cells  to  non-infected  cells.  Binding  of  the  PVR  to  the  canyon 
depression  of  the  poliovirion  destabilises  the  "pocket  factor",  which  triggers  a FAB 
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conformational  change  in  the  virus  particle  leading  to  the  uncoating  and  release  of  the  viral 
genomic  RNA  into  the  host  cell  cytoplasm  (Rossmann  et  al.,  1994). 
1.3.2.3  Viral  uncoating  and  genome  delivery 
The  interaction  of  a  mature  poliovirus  particle,  with  a  sendimentation  coefficient  of  160S, 
with  the  cognate  receptor  PVR  (He  et  al.,  2003)  has  been  demonstrated  to  cause 
conformational  changes  including  the  extrusion  of  the  internal  VP4  and  of  the  N-terminus 
of  VPl  (Fricks  &  Hogle,  1990;  Hogle  et  al.,  2002)  generating  A-particles.  A  model  for 
virus  entry  was  proposed  by  Belnap  in  2000  (see  figure  1.6.  A  and  1.6.  B)  (Belnap  et  al., 
2000)  whereby  myristylated  VP4  and  VP1  N-terminus  were  extruded  and  embedded  in  the 
cell  plasma  membrane  leading  to  the  formation  of  a  pore  and  triggering  a  change  in  the 
location  of  VP3,  which  acts  as  a  plug  to  prevent  leakage  of  the  viral  RNA  genome  from 
infectious  particles.  This  conformational  change  is  confirmed  by  the  previous  observations 
of  a  10%  size  expansion  of  poliovirus  particles  on  attachment  to  host  cell  surface 
(Incardona  et  al.,  1964).  These  events  are  followed  by  RNA  genome  entry  into  the  cell 
cytoplasm  through  the  newly  formed  pore  (see  figure  1.6  B),  confirmed  by  recent  VP4 
mutagenesis  studies  (Danthi  et  al.,  2003).  The  RNA  genome  delivery  to  the  host  cell 
cytoplasm  leads  to  a  decrease  in  the  extracellular  particle  sedimentation  coefficient  to  80S. 
Because  of  the  unstable  nature  of  the  A-particle  135S  intermediates,  up  to  50-90%  of  virus 
particles  are  eluted  or  unable  to  deliver  their  RNA  molecule.  This  contributes  to  the  very 
high  particle  to  infectivity  ratio  of  1000  to  1  (Fenwick  &  Cooper,  1962).  Alternative 
uncoating  and  entry  pathways  have  been  thought  to  exist.  Indeed  studies  of  various 
rhinovirus  serotypes  demonstrated  the  virus  entry  to  be  dependent  on  a  receptor-mediated 
endocytosis  pathway  (Nurani  et  al.,  2003;  Kronenberger  et  al.,  1998).  Alternative 
uncoating  pathways  are  not  discussed  in  this  thesis. 0 
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1.3.2.4  Genome  and  translation 
All  picomaviruses  have  a  similar  genome  organisation  (see  figure  1.7).  The  poliovirus 
genome  is  described  here.  The  infectious  poliovirus  genome  is  a  positive-sense  single 
stranded  -7.5  kilobase-long  RNA  molecule  (Holland  et  al.,  1960a;  Holland  et  al.,  1960b) 
that  is  covalently  linked  to  a  small  virus  specific  protein  VPg  via  a  phosphodiester  bond  at 
its  5'end  (Flanegan  et  al.,  1977;  Lee  et  al.,  1977,  Lee  et  al.,  1976),  and  is  polyadenylated  at 
its  3'end  (Yogo  et  al.,  1972).  The  genome  is  divided  into  three  regions,  the  5'untranslated 
region  or  non-coding  region  (5'UTR:  Agol  et  al.,  1991),  the  coding  region  and  the  3'UTR. 
The  UTR  regions  contain  RNA  structures  involved  in  the  regulation  of  translation  and 
RNA  synthesis.  The  RNA  genome  has  one  functional  open  reading  frame,  which  directs 
synthesis  of  a  single  polyprotein  (Warner  et  al.,  1963).  The  polyprotein  then  undergoes 
proteolytic  processing  generating  four  structural  proteins  (VP  I,  VP3,  VP2  and  VP4: 
Maizel  et  al.,  1963)  and  ten  non-structural  proteins  (2A,  2B,  2C,  2BC,  3A,  3B,  3AB,  3C, 
3D,  3CD:  Summers  et  al.,  1965),  which  are  involved  in  RNA  replication,  virion  assembly 
and  progeny  release  from  the  infected  host  cell. 
Once  inside  the  cell,  translation  of  the  genome  is  initiated  by  a  cap-independent 
mechanism  involving  a  5'UTR  internal  ribosome  entry  site  structure,  known  as  the  IRES 
(Jang  et  al.,  1988,  Pelletier  et  al.,  1988;  Trono  et  al.,  1988).  The  IRES  is  a  cis-acting 
element  with  a  tertiary  structure  that  interacts  with  RNA-binding  proteins  to  generate  a 
functional  `ribosome-landing  site'  (Palmenberg  et  al.,  1997).  The  IRES  structure  binds  the 
40S  subunit  of  the  ribosome  in  a  specific  orientation  and  forms  a  productive  translation 
complex  with  the  template  limited  RNA  segment  `starting  window'  (Pilipenko  et  al., 
1994).  Other  cis-acting  elements  such  as  the  5'  cloverleaf  structure  are  known  to  play  a 
role  in  RNA  replication  and  there  is  evidence  of  its  role  in  the  viral  translation  initiation 
process  (Gamarnik  et  al.,  1998;  Simoes  et  al.,  1991). Enterovirus  and  Rhinovirus 
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Other  proteins  such  as  PTB  (pyrimidine  tract  binding  protein:  Hellen  et  al.,  1994;  Hellen  et 
al.,  1993;  Niepmann  et  at.,  1997),  PCBP-2  (poly  C-binding  protein  2:  Blyn  et  al.,  1996; 
Blyn  et  at.,  1997;  Herman  et  al.,  1998),  autoantigen  La  (Meerovitch  et  al.,  1993;  Shiroki  et 
at.,  1999;  Svitkin  et  at.,  1994)  and  unr  (Hunt  et  al.,  1999)  are  important  nuclear 
RNA-binding  proteins  also  involved  in  efficient  translation  of  the  viral  RNA  genome 
(Gosert  et  al.,  2000).  Certain  translation  factors  can  act  as  chaperones  or  bridges  between 
the  IRES  and  the  ribosome  (Pilipenko  et  al.,  2000).  2A  has  been  shown  to  stimulate 
translation  (Roberts  et  al.,  1998;  Hambidge  et  at.,  1992)  whereas  3CD  has  been  shown  to 
inhibit  the  process  (Gamarnik  et  al.,  1998). 
1.3.2.5  Polyprotein  processing 
The  poliovirus  polyprotein  precursor  undergoes  proteolytic  processing,  co-translationally, 
driven  by  viral  proteases  (see  figure  1.8).  There  are  three  viral  proteinases  involved  in  the 
proteolytic  cleavage  events  and  the  generation  of  mature  viral  proteins:  the  2A,  3C  and 
3CD  proteases.  The  primary  cleavage  event  is  autocatalytic  occurring  both  in  cis  or  trans 
and  is  directed  by  the  2A  protease  cleaving  the  tyrosine-glycine  (Y-G)  amino  acid 
sequence  at  the  junction  between  the  P1  structural  protein  precursor  and  the  P2/P3 
non-structural  protein  precursors  thereby  separating  the  structural  proteins  from  the 
non-structural  proteins  (Schechter  et  al.,  1967).  The  3C  and  the  3CD  proteases 
preferentially  cleave  glutamine-glycine  (Q-G)  residues  leading  to  the  generation  of  the 
remainder  of  the  viral  proteins  (Luke  et  al.,  2001).  In  poliovirus  only  9  of  the  13  Q-G 
residues  are  cleaved  (Hanecak  et  al.,  1982;  Kitamura  et  al.,  1981).  The  lack  of  conservation 
of  residues  surrounding  the  Q-G  amino  acid  sequences  indicates  that  processing  is  not  only 
sequence-dependent  but  that  preferential  processing  must  occur  (Kusov  et  al.,  1999). 
Studies  demonstrating  enhanced  activity  of  3CD  protease  over  3C  protease  (Parsley  et  al., 
1999)  and  complete  P1  processing  solely  achieved  by  3CD  protease  confirms  that  the on 
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amino  acid  sequence  cannot  alone  account  for  proteolytic  activity  of  3C  and  3CD  proteases 
and  that  structural  conformations  are  also  involved  in  specific  protease  activity  (Harris  et 
al.,  1992;  Ypma-Wong  et  al.,  1988).  The  3C  and  the  3CD  proteases  process  the  P1 
precursor  into  VPO,  VP3  and  VP1  structural  proteins  and  the  non-structural  protein 
precursors  P2  and  P3  into  2A,  2B,  2C,  2BC,  3A,  3B,  3AB,  3C,  3D  and  3CD. 
1.3.2.5.1  Capsid  proteins 
The  capsid  proteins  VPO,  VP3  and  VP  1  assemble  to  form  empty  virus  capsids,  a  process 
discussed  further  in  section  1.3.2.7.1. 
1.3.2.5.2  Non-structural  proteins 
The  P2  and  P3  protein  precursors  contain  most  of  the  proteins  important  for  the  replication 
of  the  virus.  P1  deletion  mutants  have  been  shown  to  replicate  in  tissue  culture  (Percy  et 
al.,  1992;  Collis  et  al.,  1992;  Kaplan  et  al.,  1988).  The  non-structural  proteins  have  a 
variety  of  functions  in  the  poliovirus  life  cycle  within  an  infected  host  cell  such  as  protease 
activity,  membrane  rearrangements,  RNA  replication  and  regulation  of  host  cell  functions. 
1.3.2.5.3  The  viral  proteins  and  their  cellular  targets 
Viral  proteases  are  capable  of  hijacking  host  proteins,  employing  them  for  viral  functions 
and  shutting  down  the  key  cellular  functions  such  as  translation  and  transcription  leading 
to  cell  cycle  arrest  and  cell  death. 
1.3.2.5.3.1  Translation 
Upon  virus  infection  the  host  cell  translation  machinery  shuts  off.  This  mechanism  is 
regulated  by  cellular  and  viral  proteins.  The  poliovirus  2A  protease  exerts  its  proteolytic 
activity  on  host  cell  proteins  by  cleaving  eIF4G  (Etchison  et  al.,  1982;  Krausslich  et  al., 
1987;  Sommergruber  et  al.,  1994),  a  cellular  translation  initiation  factor,  and  more Claire  Blanchard  Introduction  Chapter  1  12 
specifically  eIF4G-I  (Haghighat  et  at.,  1996)  and  eIF4G-II  (Svitkin  et  al.,  1999;  Gradi  et 
al.,  1998),  essential  components  of  the  host  cell  cap-dependent  translation  initiation 
complex.  Moreover,  the  cleavage  of  the  poly  (A)-binding  protein  (PABP)  by  the  poliovirus 
2A  and  3C  proteases  contributes  to  host  cell  translation  shut  off  (Joachims  et  al.,  1999). 
Once  complete  host  cell  protein  synthesis  shut  off  has  occurred,  2  to  4  hours  post  infection, 
eIF4G  is  used  for  the  viral  cap-independent  IRES-mediated  translation  (Ohlmann  et  al., 
1996). 
1.3.2.5.3.2  Transcription 
Similarly,  viral  proteases  regulate  both  the  viral  and  the  cellular  transcription  machineries. 
The  poliovirus  3C  and  3CD  proteases  bind  viral  RNA  secondary  structures  such  as  the 
5'cloverleaf  of  the  positive-sense  RNA  molecule  (Andino  et  al.,  1993;  Leong  et  al.,  1993) 
and  the  poly(rC)-binding  protein  (PCBP:  Parsley  et  al.,  1997)  thereby  forming  a  complex 
required  for  poliovirus  replication.  3CD  has  been  suggested  to  be  involved  in  genome 
circularisation  as  it  bridges  the  5'cloverleaf  structure-PCBP  complex  with  polyA-binding 
protein  (PABP),  bound  to  the  3'  poly-A  tail  of  the  RNA  molecule  (Herold  et  al.,  2001). 
The  3C  and  2A  proteases  are  also  involved  in  the  regulation  of  the  host  cell  transcription 
and  apoptotic  pathways  upon  viral  infection,  by  exerting  a  proteolytic  activity  on  a  variety 
of  host  cell  proteins  such  as  TATA-binding  proteins  (Clark  et  al.,  1993;  Yalamanchili  et 
al.,  1997),  the  cAMP-responsive  element  (Deitz  et  al.,  2000),  the  transcriptional  activator 
Oct-1  (Yalamanchili  et  al.,  1997),  the  PABP  (Joachims  et  al.,  1999;  Kerekatte  et  al.,  1999), 
and  anti-apoptosis  and  PKR  phosphorylation  pathways  (Black  et  al.,  1993). Claire  Blanchard  Introduction  Chapter  1  13 
13.2.5.3.3  Membrane  re-arrangement  and  replication  compartments 
1.3.2.5.3.3.1  P2  proteins 
P2  proteins  are  involved  in  membrane  rearrangements  within  a  host  cell,  disrupting  cellular 
functions  and  creating  replication  compartments  for  the  generation  of  progeny  viral  RNA. 
2B  is  thought  to  be  involved  in  alteration  of  intracellular  membrane  permeability, 
facilitating  the  release  of  progeny  virus  (van  Kuppeveld  et  al.,  1997),  inhibition  of  cellular 
exocytosis,  dissociation  of  Golgi  complexes  and  viral  RNA  amplification  (Aldabe  et  al., 
1996;  Barco  et  al.,  1998;  Doedens  et  al.,  1995;  Sandoval  et  al.,  1997;  van  Kuppeveld  et  al., 
1995;  van  Kuppeveld  et  al.,  1997;  Johnson  et  al.,  1991). 
2B  and  2BC  proteins  play  a  role  in  the  formation  of  viral  replication  vesicles  (Bienz  et  al., 
1987;  Bienz  et  al.,  1983;  Aldabe  et  al.,  1995;  Cho  et  al.,  1994;  Suhy  et  al.,  2000; 
Teterina  et  al.,  1997)  and  results  showing  that  2C  is  involved  in  positive  strand  synthesis 
give  further  evidence  of  the  role  taken  by  2C  during  viral  replication  (Barton  et  al.,  1997; 
Molla  et  al.,  1991). 
1.3.2.5.3.3.2  P3  Proteins 
3A  and  3AB  proteins  have  also  been  shown  to  be  associated  with  intracellular  membranes 
(Datta  et  al.,  1994;  Semler  et  al.,  1982;  Towner  et  al.,  1996).  Indeed,  3AB,  which  delivers 
3B,  known  as  VPg,  (Kusov  et  al.,  1999)  and  the  3D  polymerase  (Hope  et  al.,  1997;  Xiang 
et  al.,  1998)  to  replication  compartments,  is  involved  in  rearrangement  of  intracellular 
membranes  into  replication  vesicles  (Doedens  et  al.,  1997;  Doedens  et  al.,  1995;  Lama  et 
al.,  1992). 
3D  is  the  essential  RNA-dependent  RNA-polymerase  that  catalyses  the  positive-sense  and 
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1.3.2.5.3.4  Immune  evasion  and  immune  response  interference 
Some  poliovirus  proteins  have  been  shown  to  interfere  with  the  host  immune  response, 
probably  indicating  that  poliovirus  has  evolved  to  evade  the  immune  response  induced 
following  viral  infection.  The  poliovirus  proteins  2BC  and  3A  modulate  the  host  immune 
response  by  interfering  with  exocytotic  pathways  (Barco  et  al.,  1995),  secretion  of  antiviral 
cytokines  (ß-IFN,  IL-6,  IL-8)  (Dodd  et  al.,  2001),  and  antigen  presentation  via  major 
histocompatibility  complex  class  I  (MHC-I)  molecules  (Doedens  et  al.,  1995;  Deitz  et  al., 
2000). 
1.3.2.6  RNA  replication 
1.3.2.6.1  Replication  complex  formation  and  membrane  rearrangement 
Genomic  RNA  replication  is  driven  by  the  virally  encoded  RdRp  and  occurs  in  rearranged 
cellular  membrane  vesicles  also  known  as  replication  complexes.  The  use  of  membranous 
replication  compartments  enables  the  localisation  and  concentration  of  proteins  required 
for  replication  and  assembly,  provides  protection  from  degradation  by  any  cellular  factors 
or  proteins  (Ahlquist  et  al.,  2002)  and  could  be  a  means  of  hiding  the  presence  of  double 
stranded  RNA  thereby  avoiding  the  induction  of  a  dsRNA  activated  immune  response  such 
as  the  protein  kinase  R  (PKR)  response  and  RNA  silencing  (Ahlquist  et  al.,  2002). 
Poliovirus  replication  complexes  have  been  shown  to  contain  viral  and  cellular  proteins, 
replicative-intermediate  RNA  and  newly  synthesised  progeny  RNA  (Bienz  et  al.,  1994, 
Bienz  et  al.,  1992;  Egger  et  al.,  1996;  Troxler  et  al.,  1992;  Egger  et  al.,  2002)  and  are 
assembled  on  membrane  vesicles  (Bienz  et  al.,  1987;  Bienz  et  al.,  1990).  In  fact  it  has  been 
demonstrated  that  HeLa  S  10  nuclear  extracts  contained  cellular  proteins  inducing  the 
formation  of  replication  complexes  (Jurgen  et  al.,  2003).  During  poliovirus  infection, 
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the  ER  but  unlike  other  vesicles  from  that  particular  pathway,  they  are  unable  to  fuse  with 
the  Golgi  system  or  the  ER-Golgi  intermediate  compartment  (Rust  et  al.,  2001).  The 
involvement  of  the  COP  Il-dependent  pathway  was  supported  by  inhibition  studies 
(Sandoval  et  al.,  1997).  However,  replication  complex  formation  is  not  solely  dependent  on 
COP  II-mediated  pathways  and  studies  using  Brefeldin  A  (BFA)  demonstrated 
COP  I-dependent  poliovirus  replication  inhibition  (Cuconati  et  al.,  1998;  Irurzun  et  al., 
1992;  Maynell  et  al.,  1992). 
1.3.2.6.2  Cis-acting  replication  elements 
The  viral  RNA  genome  possesses  signals,  cis-acting  elements,  that  allow  the  polymerase  to 
differentiate  between  viral  and  cellular  RNAs. The  5'UTR  and  3'UTR  cis-acting  elements 
as  well  as  elements  within  the  genome-coding  region  have  been  identified  to  be  involved  in 
replication.  The  5'UTR  IRES  ensures  the  formation  of  a  pre-initiation  template/ribosome 
complex.  The  5'UTR  cloverleaf  stemloop  d  has  been  shown  to  interact  with  the  3CDP`°  and 
PCBP  has  been  shown  to  interact  with  the  stem  loop  b  of  the  cloverleaf  thereby  forming  a 
ternary  ribonucleoprotein  complex  (Andino  et  at.,  1990a;  Andino  et  al.,  1990b).  The 
cloverleaf  structure  has  also  been  involved  in  the  switch  between  translation  and 
replication,  as  the  two  processes  are  mutually  incompatible  on  a  single  template  (Barton  et 
at.,  1999). 
The  CRE,  a  secondary  RNA  structure,  initially  identified  in  the  P  1-coding  region  of 
HRV  14  (McKnight  et  al.,  1998),  is  involved  in  replication.  Subsequent  studies  identified 
the  presence  of  similar  structures  in  the  P1-coding  region  of  cardioviruses  (Lobert  et  al., 
1999)  and  in  the  2C-coding  region  of  poliovirus  (Goodfellow  et  al.,  2000).  These  structures 
contain  a  conserved  GXYXAAAXXXXXXA  motif  (Yang  et  al.,  2002),  where  the  first  two 
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(VPg-pUpU)  (Paul  et  al.,  2000;  Rieder  et  al.,  2000)  is  then  used  as  a  primer  for  the 
initiation  of  the  positive-sense  strand  synthesis  but  not  negative-sense  strand  synthesis 
(Goodfellow  et  al.,  2003;  Morasco  et  al.,  2003;  Murray  et  al.,  2003). 
As  opposed  to  the  5'UTR,  the  3'UTR  has  not  been  studied  extensively  and  the  precise  role 
of  the  latter  in  replication  of  picomaviruses  is  still  unclear.  The  3'UTR  is  not  essential  for 
viability  of  picornaviruses  and  mutagenesis  and  deletion  of  the  3'UTR  did  not  prevent 
viability,  though  a  reduction  in  viral  fitness  was  observed  (Meredith  et  al.,  1999;  Todd  et 
al.,  1997).  The  3'UTR  of  enteroviruses  has  been  identified  to  have  two  or  three  stem  loops 
(Pilipenko  et  al.,  1992),  supported  by  thermodynamic  studies  (Jacobson  et  al.,  1993; 
Melchers  et  al.,  1997)  and  phylogenetic  studies  (Pilipenko  et  al.,  1992).  The  3'UTR  can  be 
exchanged,  between  PV3  and  HRV14  (Rohll  et  al.,  1995)  and  a  defect  in  replication  can  be 
seen  in  viruses  containing  an  altered  3'UTR  (Melchers  et  al.,  1997,  Mirmomeni  et  al., 
1997,  Pilipenko  et  al.,  1996).  The  3'UTR  of  poliovirus  has  also  been  shown  to  interact 
with  cellular  factors  such  as  p105,  p68  and  p45  (Waggoner  et  al.,  1998).  Further  studies 
expressing  these  cellular  proteins  and  investigating  the  nature  and  functions  of  the 
interactions  need  to  be  conducted  in  order  to  understand  the  precise  role  of  the  3'UTR 
cis-acting  element.  The  poly-A  tail,  attached  to  the  3'end  of  the  genome,  is  essential  for 
poliovirus  infectivity  (Rohll  et  al.,  1995;  Sarnow  et  al.,  1989),  however  other  functions  of 
the  poliovirus  poly-A  tail  still  remain  to  be  investigated. 
1.3.2.6.3  Model  of  poliovirus  replication 
The  model  of  the  poliovirus  replication  has  been  proposed  to  occur  in  two  phases:  the 
synthesis  of  negative-sense  strands  followed  by  the  production  of  positive-sense  strands 
templated  from  the  negative-sense  strands.  The  first  step  to  occur  is  that  of  genome 
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of  a  bridge  between  two  molecules  of  3CDpr°.  The  uridylylated  VPg  is  then  thought  to 
serve  as  a  primer  for  negative  strand  synthesis  and  elongation,  catalysed  by  the  RdRp  3Dp°I 
(Goodfellow  et  al.,  2003;  Morasco  et  al.,  2003;  Murray  et  al.,  2003).  Following  the 
termination  of  the  negative-sense  strand  synthesis,  the  viral  RdRp  uses  VPg-pUpU 
complexed  with  the  3'  termini  of  double  stranded  negative-sense  strands,  known  as  the 
replicative  form  or  RF,  as  a  primer  for  initiation  of  positive  strand  synthesis  (see  figure 
1.9).  Binding  of  the  3D'°'-VPg-pUpU  complex  to  the  RF  is  responsible  for  unwinding  and 
disrupting  the  double-stranded  helices  thereby  generating  partially  double-stranded 
negative  strands  or  replication  intermediates  (RI).  This  event  leads  to  the  exposure  of  more 
residues  free  for  interaction  with  numerous  polymerase/primer  complexes.  The 
CRE-generated  VPg-pUpU  primer  is  then  released  from  the  template  (Goodfellow  et  al., 
2003).  The  large  number  of  released  VPg-pUpU  primers,  during  negative-sense  strand 
synthesis,  enables  the  polymerase  to  initiate  multiple  rounds  of  positive  strand  synthesis 
from  a  single  RF  template.  This  asymmetric  replication  gives  rise  to  high  ratios  of  readily 
packageable  positive-sense  progeny  RNA  molecules  to  negative-sense  template  strands 
(Jarvis  et  al.,  1992). 
1.3.2.7  Encapsidation 
1.3.2.7.1  Viral  particle  assembly  and  RNA  encapsidation 
Viral  particle  assembly  and  encapsidation  of  the  newly  synthesised  viral  genome  are 
essential  steps  of  the  poliovirus  life  cycle.  These  processes  have  been  hypothesised  to 
occur  via  two  alternate  pathways. 
Copies  of  the  structural  proteins  VPO,  VP!  and  VP3  assemble  into  60  protomers  to  form 
poliovirus  capsids.  A  late  VPO  cleavage  event  during  the  maturation  of  the  virus  particles 
gives  rise  to  VP4  which  is  located  inside  the  mature  virus  particle  and  VP2.  The  carboxyl A-,, 
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Figure  1.9:  Poliovirus  translation,  poliovirus  genome  circularisation  and  genome 
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end  of  VPO  is  associated  with  the  amino  end  of  VP3  and  the  carboxyl  end  of  VP3  is 
associated  with  the  amino  end  of  VP  1  (Arnold  et  al.,  1987)  forming  a  6S  protomer.  Five  6S 
protomers  then  assemble  to  form  14S  pentamers.  Cleavages  and  repositioning  of  the  ends 
of  VP1,  VP3  and  VPO  lead  to  the  assembly  of  twelve  14S  pentamers  into  immature 
icosahedral  80S  procapsids,  which  encapsidate  genomic  RNA  to  form  -160S  particles  (see 
figure  1.10). 
Alternatively,  it  has  been  hypothesised  that  the  pentamers  could  assemble  around  a  newly 
synthesised  progeny  viral  RNA  genome  to  form  the  160S  particles.  Some  viral  proteins, 
such  as  2C,  could  be  involved  in  the  assembly  of  poliovirions  (Li  et  al.,  1990;  Vance  et  al., 
1997).  Assembly  and  encapsidation  processes  involve  protein-protein  interactions  of 
capsid  proteins,  RNA-protein  interaction  between  the  viral  genome  and  the  capsid  proteins, 
potential  host  protein-viral  protein  and  host  protein-viral  RNA  interactions  and 
autocatalytic  cleavage,  however  the  exact  succession  of  events  and  the  precise  mechanisms 
remain  unclear. 
1.3.2.7.2  Poliovirus  encapsidation  signals 
The  process  by  which  the  poliovirus  genome  is  encapsidated  into  capsid  proteins  has  yet  to 
be  resolved.  Poliovirus  genome  encapsidation  is  a  specific  process  and  the  existence  of  a 
specific  encapsidation  signal  is  strongly  supported  by  work  carried  out  by  Barclay  and 
co-workers.  Indeed,  Barclay  and  co-workers  showed  that  the  HRV  14  and  CB4  capsid 
proteins,  provided  in  trans,  could  not  encapsidate  a  replication  competent  poliovirus  CAT 
(Chloramphenicol  acetyl  transferase)  replicon,  lacking  most  of  the  P1  coding  region. 
However,  poliovirus  type  1,  poliovirus  type  2  and  poliovirus  type  3  capsid  proteins  were 
able  to  specifically  encapsidate  the  poliovirus  CAT  replicon  (Barclay  et  al.,  1998). I 
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Figure  1.10:  Model  of  poliovirus  particle  assembly 
l-  VPO,  VPI  and  VP3  assembly  into  6S  protomer;  2-  assembly  of  five  protomers  into 
pentamers;  3-  assembly  of  12  pentamers  into  empty  80S  procapsids  and  encapsidation 
of  newly  synthesised  RNA  genome  leading  to  maturation  cleavage  and  generation  of 
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The  exact  localisation  of  the  specific  encapsidation  signal  remains  unidentified.  Defective 
interfering  poliovirus  genomes,  containing  deletions  within  the  VP2/VP3-coding  regions, 
were  shown  to  be  encapsidated  even  though  these  lacked  as  much  as  13%  of  the  genome 
(Ansardi  et  al.,  1993a,  Kuge  et  al.,  1986).  These  studies  were  supported  by  more  recent 
data.  The  observation  that  poliovirus  replicons,  lacking  all  but  the  last  two  amino  acids  of 
the  P1-coding  region,  could  be  encapsidated  by  capsid  proteins  provided  in  trans  showed 
that  the  specific  poliovirus-packaging  signal  could  not  be  located  within  the  P  1-coding 
sequence  (Ansardi  et  al.,  1993b;  Barclay  et  al.,  1998).  Other  genome-encoded  proteins 
have  been  thought  to  play  a  role  in  packaging  with  the  exception  of  the  2A  protein  that 
does  not  appear  to  be  involved  in  encapsidation  (Ansardi  et  al.,  1995).  The  substitution  of 
the  poliovirus  type  1  2A-coding  region  with  the  CVB4  2A-coding  region  and  the 
generation  of  a  hybrid  CVB3/PV  2B  protein  proved  to  have  no  effect  on  the  virus  viability 
(Lu  et  al.,  1995;  van  Kuppeveld  et  al.,  1997)  suggesting  that  2A  and  the  first  30  amino 
acids  of  2B  did  not  contain  a  specific  encapsidation  signal.  There  is  no  direct  evidence  of 
the  VPg  viral  protein  playing  a  role  in  encapsidation,  which  was  previously  thought  to  be 
the  case  (Nomoto  et  al.,  1977a;  Nomoto  et  al.,  1977b).  An  exchange  of  the  poliovirus  type 
3  VPg-coding  sequence  with  the  CVB4  VPg-coding  region  did  not  cause  an  encapsidation 
defect  (unpublished  data  of  Percy  and  Moon;  see  Barclay  et  al.,  1998).  Moreover  the 
5'UTR  (Rohll  et  al.,  1994;  Xiang  et  al.,  1995)  and  the  3'UTR  (Rohll  et  al.,  1994)  of 
poliovirus  can  be  exchanged  for  those  of  certain  picornaviruses  suggesting  that  if  an 
encapsidation  signal  exists  it  is  most  likely  to  reside  in  the  region  of  the  genome  encoding 
2B  to  3D  (Barclay  et  al.,  1998)  or  to  be  discontinuous. 
However,  the  previous  results  do  not  exclude  2A,  part  of  2B,  capsid  proteins  and  RNA 
structures  from  playing  a  role  in  the  packaging  of  the  poliovirus  genome.  Indeed  the 
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statement  (Johansen  et  al.,  2000).  Moreover  the  specificity  of  the  encapsidation  process  is 
not  absolute  as  some  poliovirus  RNA  appears  to  be  packageable  by  coxsackievirus 
(Holland  et  al.,  1964;  Soloviev  et  al.,  1968;  Barclay  et  al.,  1998),  HRV  and  mengovirus 
particles  (Jia  et  al.,  1998).  The  overall  encapsidation  efficiency  of  the  poliovirus  genome 
by  heterologous  capsid  proteins  provided  in  trans  is  however  significantly  lower  than 
encapsidation  efficiency  of  the  poliovirus  genome  by  homologous  capsid  proteins.  The 
specificity  of  the  interspecies  trans-encapsidation  process  could  be  due  to  the  existence  of 
specific  replication  compartments  and  thus  inefficient  mixing  (Ansardi  et  al.,  1993a),  or  to 
a  requirement  for  specific  interactions  between  genomic  RNA  sequences  or  structures  and 
the  capsid  proteins  (Barclay  et  al.,  1998). 
13.2.7.3  Maturation  cleavage 
Juxtaposition  of  catalytically  active  amino  acid  residues  in  the  immature  virion  (Hindiyeh 
et  al.,  1999)  and  encapsidation  of  the  RNA  genome  (Arnold  et  al.,  1987)  trigger  the  final 
stages  of  assembly  by  "maturation"  cleavage  of  the  VPO  precursor  protein  between  the 
C-terminal  asparagines  (N)  of  VP4  and  the  N-terminal  serine  (S)  of  VP2  (Basavappa  et  al., 
1994;  reviewed  in  Hellen  et  al.,  1992).  This  autocatalytic  event  provides  the  concluding 
stage  to  the  production  of  mature  infectious  progeny  virions  (Ansardi  et  al.,  1996;  Rueckert 
et  al.,  1996)  and  release  into  the  extracellular  environment. 
1.3.2.8  Release 
Lytic  release  of  newly  synthesised  virions,  seen  in  poliovirus  infection,  can  occur  via 
virus-induced  cytopathic  effect  or  host-cell  apoptosis  defense  mechanism,  triggered  by  2A 
(Barco  et  al.,  2000b;  Goldstaub  et  al.,  2000)  and  3C  (Barco  et  al.,  2000a)  protease  damage. 
Apoptosis  can  be  interrupted  by  the  activation  of  anti-apoptotic  pathways,  which  have  been 
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regulatory  protein  (Henke  et  al.,  2000).  Recent  studies  have  provided  evidence  that  the 
enterovirus  2B  protein  was  able  to  form  pores  in  the  ER  and  Golgi  membranes  thereby 
reducing  Ca2+  levels  and  interefering  with  the  ER-mitochondrial  Ca  2+  signalling.  This 
prevented  premature  apoptosis  and  allowed  completion  of  the  virus  reproductive  cycle 
(van  Kuppeveld  et  al.,  2005).  Most  poliovirus  apoptotic  and  anti-apoptotic  pathways  have 
been  reviewed  by  Blondel  (Blondel  et  al.,  2004). 
Several  poliovirus  proteins  have  been  involved  in  host  cell  translation/transcription  shut 
off.  PV  2A  mutagenesis  studies  demonstrated  that  2A  was  involved  in  specific  host  cell 
shut  off,  a  process  different  from  that  induced  by  the  use  of  non-viral  host  inhibitors 
(Bernstein  et  al.,  1985).  PV  3A  is  a  protein  involved  in  the  rearrangement  of  host  cell 
membrane  structures  and  was  also  shown  to  have  a  cytopathic  effect  on  poliovirus-infected 
cells  (Lama  et  al.,  1998).  Furthermore,  accumulation  of  progeny  virions  and  increase  in 
size  of  the  infected  host  cell  causes  cell  burst  and  release  of  progeny  virions  into  the 
intercellular  environment,  where  these  are  then  able  to  infect  the  neighbouring  cells. 
1.4  Receptors:  pathogenesis  and  tropism 
1.4.1  Picornavirus  receptors  and  diseases 
The  pathogenesis  of  picornaviruses  or  range  of  clinical  symptoms  observed  as  a  result  of 
virus  infection  varies  depending  on  a  number  of  factors  such  as  the  receptor  and  tissue 
tropism,  the  dose  required  for  infectivity  and  the  cellular  immune  response  to  a  particular 
viral  infection.  Picornaviruses  are  pathogens  that  cause  a  wide  range  of  diseases  such  as 
respiratory  diseases,  encephalitis,  hepatitis,  foot-and-mouth  disease,  myocarditis, 
non-specific  febrile  symptoms,  aseptic  meningitis,  congenital  and  neonatal  infections, 
encephalomyelitis,  the  common  cold  and  poliomyelitis  (see  table  1.11).  Picornaviruses Claire  Blanchard  Introduction  Chapter  1  22 
have  evolved  to  use  a  variety  of  cell  surface  molecules  as  receptors  for  attachment  and 
entry  of  picornaviruses  into  the  cell.  This  section  discusses  enterovirus  receptors  and 
tropism  in  more  detail. Claire  Blanchard  Introduction  Chapter  1  23 
Virus  genus/species  Receptors  Accessory  factors  Pathogenesis 
Enteroviruses 
Poliovirus  type  1,2  Paralytic 
and  3  PVR  (Ig-like)  N/A  poliomyelitis  and 
mild  febrile  illness 
Coxsackievirus  A13, 
18,21 
ICAM-1  (Ig-like)  N/A  Aseptic  meningitis 
Coxsackievirus  A9  avß3  Vitronectin 
N/A 
Hand,  foot  and 
mouth  disease 
receptor  inte  rip 
Coxsackievirus  A21  DAF  (SCR-like)  ICAM-1  I  -like 
Common  cold 
Coxsackievirus  BI,  3,  DAF  (SCR-like)  av06  (integrin)  Aseptic  meningitis 
5  Myocarditis, 
pleurodynia, 
severe  systemic 
disease  in  infants 
Coxsackievirus  BI,  6  CAR  (SCR-like)  N/A  Upper  respiratory 
tract  illness, 
pneumonia 
and  post-viral 
fatigue  syndrome 
Echoviruses  1  a2  1  inte  rip  2m  Aseptic  meningitis 
Echoviruses  3,6,7,  Paralysis 
11-13,20,21,24,29,  DAF  (SCR-like)  02m  Respiratory 
33  disease 
Myocarditis 
Echoviruses  22  av03  Vitronectin 
N/A 
Epidemic 
myalagia  receptor  (integrin) 
Hepatic 
disturbances 
Acute 
Enterovirus  70  Sialic  acid  N/A  haemorrhaging 
conjunctivitis 
Rhinoviruses 
Major  receptor  group  ICAM-1  like  (g-)  N/A 
rhinoviruses 
LDLR  (low 
Minor  receptor  group  density 
rhinoviruses  lipoprotein  N/A  Common  cold 
receptor) 
Rhinovirus  87 
Sialic  acid 
(carbohydrate  N/A 
He  atoviruses 
HAV 
HAVcr-1  (Ig-like 
and  mucin-like) 
N/A  Hepatitis Claire  Blanchard  Introduction  Chapter  1 
Aphthoviruses 
a305  Vitronectin 
receptor,  aß(36 
FMDV 
(Jackson  et  al.,  Heparan  sulphate  Foot-and-mouth 
2000),  av3i  proteoglycan  disease 
(Jackson  et  al., 
2003)-  integrins 
Cardioviruses 
VCAM-1  (Ig-like) 
Encephalomyocarditis  or or  Sialylated 
A  N/A 
Encephalitis  and 
virus  (carbohydrate)  myocarditis 
24 
Table  1.11:  Picornavirus  receptors  and  accessory  molecules  involved  in  cell  infection. 
Table  was  adapted  from  Evans  &  Almond  (1998).  A  list  of  clinical  diseases  associated 
with  picomavirus  infection  and  exacerbation  was  added  to  provide  a  complete  picture  of 
receptors  and  role  in  pathogenesis.  Abbreviations  used:  ß2m,  ß2-microglobulin;  CAR, 
coxsackievirus  and  adenovirus  receptor;  DAF,  decay-accelerating  factor;  HAVcr-1, 
hepatitis  cellular  receptor  type  1;  N/A,  not  applicable  (no  accessory  molecules  are  currently 
implicated  in  virus  infection);  PVR,  poliovirus  receptor;  SCR,  short  consensus  repeat  (s); 
VCAM-1,  vascular  adhesion  molecule  type  1. Claire  Blanchard  Introduction  Chapter  1  25 
1.4.2  Identified  enterovirus  receptor 
1.4.2.1  Receptors 
Human  enteroviruses  exhibit  great  diversity  in  the  range  of  molecules  used  as  cell  surface 
molecules  for  attachment.  Enteroviruses  have  evolved  to  use  cell  surface  receptors  that 
have  a  defined  role  in  cell  recruitment,  attachment,  infiltration  or other  aspects  of  the 
immune  system.  Certain  enteroviruses,  such  as  some  coxsackieviruses  and  poliovirus, 
appear  to  have  evolved  to  attach  immunoglobulin-like  molecules.  It  is  possible  either  that 
the  viruses  have  evolved  to  use  immunological  molecules  or  that  the  receptor  bound  by 
these  viruses  are  immunoglobulin-like  as  the  structural  fold  of  these  molecules  is  stable. 
The  majority  of  enterovirus  receptors  are  immunoglobulin-like  molecules,  other  proteins 
such  as  integrins  or  SCR-like  molecules,  glycosaminoglycans  (GAGs),  sialic  acid  and 
other  molecules  such  as  heparan  sulphate,  which  are  all  involved  in  a  broad  number  of 
cellular  functions  (see  figure  1.12). 
The  intracellular  adhesion  molecule  type  1  (ICAM-1),  the  poliovirus  receptor  PVR,  CD  155 
and  the  Coxsackievirus  and  adenovirus  receptor  (CAR)  belong  to  the  inununoglobulin-like 
family  of  cell  surface  molecules. 
ICAM-1,  a  molecule  involved  in  the  adhesion  between  leukocytes  and  endothelial  cells, 
has  been  identified  as  the  receptor  for  human  enterovirus  species  C  coxsackieviruses  A 
(Colonno  et  al.,  1986;  Shafren  et  al.,  1997a)  and  the  major  receptor  group  human 
rhinoviruses  (HRV)  (Greve  et  al.,  1989;  Staunton  et  al.,  1989). --ll 
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Figure  1.12:  (lasses  of  molecules  that  serve  as  cell  receptors  for  picornaviruses. 
inn J  1:  1 
The  structures  shown  are  generic  structures.  CAR:  coxsackie-adenovirus  receptor,  PVR: 
polio%irus  receptor.  ICAM-l  :  intracellular  adhesion  molecule  type  1,  VCAM-l:  vascular 
cell  adhesion  molecule  type  1.  DAF:  decay-accelerating  factors.  SCR:  short  consensus 
repeat.  GPI:  glycosylphosphatidylinositol,  LDL-R:  low  density  lipoprotein  receptor, 
[.  [)l.:  Ios  density  lipoprotein.  HAVCR-1:  hepatitis  A  cellular  receptor  type  1.  T/S/P: 
threonine/serine/proline.  The  domains  indicated  in  white  are  the  domains  implicated  in 
virus  binding.  The  domains  in  black  are  the  domains  that  do  not  play  a  role  in  virus 
binding.  All  the  other  domains  are  domains  for  which  no  information  is  available.  Figure 
taken  from  Evans  &  Almond  (1998). Claire  Blanchard  Introduction  Chapter  1  26 
CD155  is  an  80kDa  cell  surface  molecule,  expressed  as  four  splice  variants  of  which  a  and 
5  act  as  a  receptor  for  poliovirus  attachment  and  entry  (PVR)  (Mendelsohn  et  al.,  1989). 
Subsequent  studies  demonstrated  that  infection  of  non-transgenic  mice  with  the 
mouse-adapted  strain  of  poliovirus  type  2  (Lansing)  induced  fatal  poliomyelitis  in  mice 
(Murray  et  al.,  1988),  as  seen  in  infection  of  PVR-transgenic  mice  with  poliovirus  type  1 
(Ren  et  al.,  1990).  These  two  pathogens  were  shown  to  infect  different  cell  types  by 
histopathological  analysis.  The  study  of  the  PVR-transgenic  mice  infected  with  poliovirus 
type  1  Mahoney  strain  implies  that  the  use  of  PVR  is  involved  in  causing  poliomyelitis 
(Ren  et  al.,  1990)  and  defines  a  virus  as  a  poliovirus.  However  the  precise  role  of  the  PVR 
in  the  host  still  remains  to  be  identified  even  though  it  is  involved  in  embryonic  CNS 
development  and  cell  to  matrix  contacts  by  specific  binding  to  vitronectin  (Lange  et  al., 
2001).  The  PVR  was  recently  shown  to  be  a  ligand  for  the  natural  killer  cell  (NK) 
triggering  receptor  DNAM-1  (CD226).  Upon  binding  of  CD  155  to  DNAM-1,  activation  of 
lysis  of  PVR-expressing  cells  by  NK  occurred.  This  was  inhibited  by  the  use  of 
anti-DNAM-1  monoclonal  antibody  (Bottino  et  al.,  2003).  Until  the  identification  of  a 
CD155  mouse  homolog  (Morrison  et  al.,  1992),  poliovirus  was  believed  to  only  infect 
primates  as  no  non-primate  CD155  homologs  were  thought  to  exist  (Koike  et  al.,  1992). 
Transgenic  mice  expressing  the  human  PVR  (Koike  et  al.,  1991;  Ren  et  al.,  1990)  have 
proved  to  be  a  very  useful  animal  model  for  the  study  of  poliovirus  pathogenesis  in  a 
laboratory  environment.  Studies  investigating  the  expression  of  CD155  have  suggested  that 
the  protein  seems  to  be  regulated  on  a  developmental  level.  CD155  expression  in 
embryonic  anatomical  structures  giving  rise  to  spinal  cord  anterior  horn  motor  neurons 
may  contribute  to  the  restricted  host  cell  tropism  of  poliovirus  for  these  compartments  of 
the  CNS  (Gromeier  et  al.,  2000).  The  PVR  has  also  been  suggested  to  have  a  part  in 
intracellular  transport  (Mueller  et  al.,  2002)  and  maybe  retrograde  axonal  transport. Claire  Blanchard  Introduction  Chapter  1  27 
The  CAR  molecule,  the  identified  receptor  for  CVBs  and  adenoviruses  type  2  and  type  5 
(Bergelson  et  al.,  1997),  is  expressed  during  the  embryonic  development  in  the  central  and 
peripheral  nervous  systems  (Tomko  et  al.,  2000)  as  well  as  in  many  other  human  tissues. 
CAR  has  cell  adhesion  functions  (Honda  et  al.,  2000). 
The  enteroviral  receptor  DAF,  a  GPI-anchored  complement  regulatory  cell  surface 
molecule  protecting  host  cells  from  autologous  lysis  (Lublin  et  al.,  1989)  has  four  short 
consensus  repeats  (SCRs),  which  mediate  binding  with  human  enteroviruses  species  B,  C 
and  D.  DAF  was  demonstrated  to  be  the  human  receptor  for  enterovirus  70  (Karnauchow 
et  al.,  1996).  Haemagglutinating  echovirus  strains  (Ward  et  al.,  1994;  Powell  et  al.,  1997; 
Williams  et  al.,  2004),  echovirus  7  (Powell  et  al.,  1997),  CVA21  (Shafren  et  al.,  1997a; 
Newcombe  et  al.,  1994;  Johansson  et  al.,  2004)  and  CBV1,3  and  5  (Bergelson  et  al.,  1995; 
Shieh  et  al.,  2002)  have  since  been  shown  to  interact  with  DAF.  DAF-inhibition  studies 
have  shown  that  EV6,  EV7,  EV  12  and  EV21  infections  were  DAF-dependent  (Powell  et 
al.,  1998;  reviewed  in  He  et  al.,  2002).  Many  picornaviruses  have  been  shown  to  bind  DAF 
indicating  that  adaptation  to  use  DAF  as  a  receptor  is  likely  to  result  from  evolutionary 
selective  pressure.  DAF  may  therefore  offer  a  selective  advantage  over  other  cell  surface 
molecules.  DAF  has  been  thought  to  facilitate  internalisation  of  virus  receptor  or 
recruitment  of  naive  cells  and  activation  of  the  apoptotic  pathway  and  therefore  virus 
release  and  spread  (Evans  et  al.,  1998).  DAF  is  also  a  molecule  involved  in  controlling  the 
host  immune  response  and  adaptation  of  viruses  to  use  DAF  could  enable  masking  and 
inhibition  of  the  immune  system. 
Heparan  sulphate  is  a  ubiquitous  cell  surface  glycosaminoglycan  (GAG)  that  interacts  with 
a  wide  range  of  virus  families,  such  as  a  herpesviruses  (Shieh  et  al.,  1992)  and 
picornaviruses  (Jackson  et  al.,  1996).  A  number  of  human  enteroviruses  have  been 
reported  to  use  heparan  sulphate  as  a  receptor  for  attachment  and  entry.  Coxsackievirus  B3 Claire  Blanchard  Introduction  Chapter  1  28 
uses  heparan  sulphate  as  well  as  CAR  for  virus  entry  (Zautner  et  al.,  2003)  and  echovirus  6 
clinical  isolates  use  heparan  sulphate  as  an  alternative  receptor  to  DAF  for  virus 
attachment  and  entry  (Goodfellow  et  al.,  2001). 
Sialic  acid,  a  family  of  unique  9-carbon  monosaccharides,  plays  an  essential  role  in 
enterovirus  70-attachment  (Alexander  et  al.,  2002).  Indeed  EV70  is  able  to  bind 
neuraminidase-treated  cells,  in  which  DAF  was  neutralised,  as  the  molecule  is  sensitive  to 
neuraminidase.  This  is  further  supported  by  Haddad's  work  demonstrating  that 
DAF-binding  is  not  required  for  EV70  infection  of  a  human  leukocyte  cell  line  (Haddad  et 
al.,  2004).  It  is  thought  that  EV70  primarily  binds  sialic  acid.  EV70  is  likely  to  have 
evolved  to  use  DAF  as  a  receptor  by  passage  in  cell  culture  (Karnauchow  et  al.,  1996). 
Increasing  evidence  indicates  that  dual  tropism  (simultaneous  or  sequential  binding  of  a 
virus  to  two  cell  surface  molecules)  can  be  used  for  attachment  and  entry  of  enteroviruses 
into  cells.  The  CVB3-Nancy  strain  uses  the  CAR  receptor  for  attachment  and  entry  and  is 
unable  to  infect  RD  cells,  as  they  do  not  express  the  CAR  receptor.  CVB3  serially 
passaged  in  RD  cells  (CVB3-RD)  was  able  to  productively  infect  these  cells  by  DAF  entry 
(Bergelson  et  al.,  1995;  Schmidtke  et  al.,  2000)  whilst  retaining  its  ability  to  bind  CAR 
(Schmidtke  et  al.,  2000).  CVB3-RD  was  however  unable  to  infect  CHO-DAF  cells 
suggesting  that  accessory  factors,  molecules  involved  in  subsequent  stages  of  entry  and 
uncoating,  present  in  RD  cells  but  not  in  CHO-DAF  cells  might  play  a  role  in  infection 
with  CVB3-RD  adapted  strain.  Recent  studies  demonstrated  that  CVB3  was  also  able  to 
use  heparan  sulphate  as  well  as  CAR  for  virus  entry  (Zautner  et  al.,  2003).  CVA9  is 
another  enterovirus  that  is  able  to  use  more  than  one  cell  surface  molecule  for  attachment. 
CVA9  uses  the  vitronectin  receptor  as  a  molecule  for  attachment  to  host  cell  (Roivainen  et 
al.,  1991).  The  inactivation  of  an  RGD  motif  of  the  virus,  by  trypsin  cleavage,  does  not 
prevent  infection  of  African  green  monkey  cells  thereby  indicating  that  there  is  an Clare  Blanchard  Introduction  Chanter  1  29 
alternative  cell  surface  molecule  used  by  CVA9  for  attachment  and  entry  (Roivainen  et  al., 
1994).  Echoviruses  use  DAF  as  a  receptor  (Bergelson  et  al.,  1994;  Powell  et  al.,  1998; 
Ward  et  al.,  1994)  however  recent  studies  suggested  the  potential  use  of  DAF  and  heparan 
sulphate,  a  second  receptor,  by  these  viruses  (Goodfellow  et  al.,  2001) 
Dual  tropism  could  be  due  to  capsid  surfaces  having  evolved  to  contain  two 
receptor-binding  sites.  However,  distinguishing  between  molecules  only  involved  in 
binding  and  molecules  required  for  subsequent  stages  of  infection  such  as  entry  and 
uncoating  (known  as  accessory  factors)  can  be  difficult. 
1.4.2.2  Accessory  factors 
As  we  understand  more  about  viruses  it  is  clear  that  accessory  factors  are  important  for 
infection.  A  number  of  accessory  factors  have  been  identified  for  different  families  of 
viruses  and  are  thought  to  be  important  determinants  of  tissue  specific  pathogenesis  and 
tropism.  Accessory  factors  still  need  to  be  established  for  picornaviruses,  however  studies 
strongly  suggest  the  involvement  of  such  factors  in  the  infection  process  (see  table  1.11). 
Moreover,  several  entities  have  been  reported  to  enhance  infectivity  of  enteroviruses;  in 
fact  DAF  has  been  demonstrated  to  enhance  efficiency  of  CVA21  uptake,  an  ICAM-1 
using  virus  (Shafren  et  al.,  1997a;  Johansson  et  al.,  2004).  MAP70,  an  MHC  class  I 
protein,  has  been  suggested  to  be  an  accessory  factor  in  infection  with  CVA9  (Triantafilou 
et  al.,  2000).  CD59,  a  complement  control  protein,  appears  to  be  important  in  echovirus 
infection,  in  particular  infection  with  echovirus  7  (Goodfellow  et  al.,  2001).  a,.  ß6  is  thought 
to  enhance  CVB  lytic  infection  of  human  colon  cancer  cells  (Agrez  et  al.,  1997). 
ß2-microglobulin  (ß2-m),  a  component  of  the  MHC  class  I  has  been  indirectly  implicated  in 
the  infection  of  RD  cells  with  echoviruses,  since  treatment  with  02-m  antibody  was  able  to 
block  infection  but  not  binding  in  RD  cells  (Ward  et  al.,  1998).  A  similar  event  was Claire  Blanchard  Introduction  Chapter  1  30 
observed  in  CVA9  infection  of  CHO  cells,  where  CVA9  was  able  to  bind  a￿ß3  but  no 
infection  was  observed  after  ß2-m  antibody  treatment  (Triantafilou  et  al.,  1999)(see  table 
1.11).  In  all  these  cases,  the  role  of  these  accessory  factors  remains  ill  defined. 
1.4.3  Tropism  and  its  determinants 
It  is  clear  that  several  factors  are  involved  in  the  determination  of  pathogenesis  and 
tropism,  the  affinity  of  picornaviruses  for  a  population  of  host  cells  or  a  specific  host  tissue 
composed  of  susceptible  cells  (Shafren  et  al.,  1997a;  Johansson  et  al.,  2004;  Triantafilou  et 
al.,  2000;  Goodfellow  et  al.,  2001;  Agrez  et  al.,  1997;  Triantafilou  et  al.,  1999).  The 
tropism  of  a  virus  is  often  defined  by  the  receptor  usage.  Within  each  genus  exist 
sub-divisions  of  viruses  using  the  same  receptor  for  attachment  and  entry.  Some  genera  are 
directly  correlated  to  receptor  usage  such  as  aphthoviruses  that  use  the  vitronectin  receptor, 
and  rhinoviruses  and  Coxsackievirus  A2  1,  both  causing  respiratory  tract  infections,  that 
use  either  the  intracellular  adhesion  molecule  type  1  (ICAM-1:  major  receptor  group)  or 
the  low-density  lipoprotein  receptor  (LDLR:  minor  receptor  group).  However  there  is  little 
or  no  direct  correlation  between  the  genetic  similarity  and  receptor  use  for  the  remaining 
picornaviruses,  for  which  the  receptor  has  been  identified,  in  particular  for  human 
enteroviruses  as  they  exhibit  the  most  diversity  in  receptor  usage. 
Pathogenesis  is  also  variable.  Different  viruses  can  cause  the  same  clinical  symptoms 
(Melnick,  1996).  Indeed  Coxsackievirus  B3  and  Coxsackievirus  B4  (CVB3  and  CVB4) 
strains  can  vary  in  their  ability  to  cause  particular  syndromes  such  as  cardiovirulence  and 
diabetes  (Cao  et  al.,  1991;  Dunn  et  al.,  2000).  The  two  different  viruses,  closely  related  in 
their  non-structural  coding  region  of  the  genome,  can  infect  the  same  cell  type  through 
attachment  to  the  same  receptors  DAF  or  different  receptors:  DAF  and  CAR  (Bergelson  et 
al.,  1995;  Shafren  et  al.,  1997b).  This  and  the  recent  recombination  data  (described  in Claire  Blanchard  Introduction  Chapter  1  31 
Chapter  3)  suggest  that  the  predominant  -  if  not  the  primary  -  determinant  of  virus 
pathogenesis  is  the  receptor  to  which  it  attaches. 
Similarly,  the  same  virus  can  infect  different  cell  types,  expressing  the  same  cellular 
receptors,  situated  at  distinct  locations  in  the  host,  causing  different  symptoms.  Poliovirus 
is  a  very  good  example  as  it  can  infect  cells  of  the  intestinal  epithelium  causing  mild 
enteric  syndromes  whereas  infection  of  the  CNS  motor  neurons,  expressing  the  same  PVR 
cell  surface  receptor  molecule,  causes  AFP. 
The  choice  of  receptor  or  cell  surface  molecule,  determining  the  cell  type  infected,  is  a 
major  factor  contributing  to  symptoms  observed  in  a  viral  infection.  Receptors  are 
therefore  very  important  pathogenesis  and  tropism  determinants.  However,  it  is  unclear 
whether  these  cell  surface  molecules  are  the  sole  determinants  of  tropism  or  whether  other 
factors  are  involved.  Factors  such  as  the  immune  status  of  a  particular  host  and  different 
environmental  conditions  may  be  involved  in  the  determination  of  tropism  and 
pathogenesis.  Whilst  poliovirus  appears  not  to  require  additional  factors  for  cellular 
infection  to  occur,  this  is  not  the  case  for  all  enteroviruses. 
Non-poliovirus  enteroviruses,  like  CVA7,  CVA9  (Grist  et  al.,  1970),  EV70  (Wadia  et  al., 
1983),  EV71  (Chumakov  et  al.,  1979)  and  recently  CVA21  (Shaffren  et  al.,  1997)  are 
nonetheless  able  to  cause  poliomyelitis-like  syndromes.  Despite  acquiring  particular 
receptor  af'inity,  infection  by  some  of  these  viruses  can  be  blocked  by  antibodies  to  their 
original  receptors.  EV70  and  EV71  have  been  shown  to  cause  acute  haemorrhagic 
conjunctivitis  and  hand-foot-and-mouth  disease  (Wang  et  al.,  1999;  Yin-Murphy  et  al., 
1984).  It  has  been  thought  by  many  that  non-poliovirus  enteroviruses  could  potentially 
acquire  affinity  for  CD  155  through  adaptive  changes  in  the  P1  structural  proteins  coding Claire  Blanchard  Introduction  Chapter  1  32 
region  (Gromeier  et  al.,  1999).  The  hypothesis  still  needs  to  be  tested  and  the  following 
project  was  an  attempt  to  determine  whether  such  an  evolutionary  event  could  occur. 
1.5  Evolution 
RNA  virus  evolution  occurs  under  selective  pressure,  provided  by  physical,  selective, 
functional,  developmental  and/or  genetic  constraints,  and  is  driven  by  two  mechanisms 
enabling  the  viruses  to  adapt,  survive  and  multiply  in  a  new  cellular  environment: 
polymerase  error  rate  leading  to  the  introduction  of  mutations  within  progeny  genomes  and 
RNA  recombination.  The  evolution  of  picomaviruses  is  driven  by  accumulation  of  point 
mutations,  short  insertions/deletions  and  genomic  changes  due  to  the  exchange  of  genetic 
material,  with  related  or  non-related  sequences,  that  lead  to  the  generation  of  divergent 
RNA  and  protein  sequences,  with  conservation  of  essential  functions  and  viability  of  the 
virus.  The  evolution  of  picornaviruses  occurs  via  both  these  mechanisms. 
1.5.1  Evolution  of  picornaviruses 
1.5.1.1  Mechanisms  of  evolution 
1.5.1.1.1  RdRp  mutation  rate  and  error  polymerase  rate 
Replication  of  all  positive-sense  strand  RNA  viruses  is  driven  by  RNA-dependent 
RNA-polymerases  (RdRp),  apart  from  retroviruses  that  replicate  using  RNA-dependent 
DNA-polymerases.  RdRps  lack  a  proofreading  mechanism  (Ishihama  et  al.,  1986)  and  are 
therefore  unable  to  correct  mutations  or  mismatches  introduced  during  viral  replication. 
The  polymerase  error  rate  of  picornaviruses  has  been  shown  to  be  as  high  as  2.1x10  to 
5.9x104  substitutions  per  nucleotide  (Crotty  et  al.,  2001;  Sierra  et  al.,  2000).  As  a  result 
positive-sense  strand  RNA  viruses  exist  as  quasispecies,  or  an  ensemble  of  related  but 
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discussed  further  in  chapter  2.  Existing  as  a  quasispecies  is  an  evolutionary  advantage  as 
the  mutant  spectrum  contains  viral  sequences  that  may  be  efficient  at  evading  the  immune 
response,  having  increased  resistance  to  antiviral  agents,  escaping  specific  antibodies  and 
cytotoxic  T  cells  and  altering  their  induction  of  interferon  capacity  (Ruiz-Jarabo  et  al., 
2000). 
1.5.1.1.2  Recombination 
1.5.1.1.2.1  Definition  and  description 
The  second  process  that  drives  positive-sense  single  strand  RNA  virus  evolution  is  that  of 
recombination  between  viral  RNA  genomes  and  was  first  described  in  poliovirus  in  the 
1960's  (Hirst  et  al.,  1962;  Ledinko  et  al.,  1963).  It  is  a  widespread  mechanism  known  to 
occur  in  animal,  plant  and  human  viruses  (Chetverin  et  al.,  1997;  Lai  et  al.,  1992b; 
Slobodskaya  et  al.,  1996)  and  it  enables  the  generation  of  fitter  viruses,  able  to  survive  in 
an  altered  environment,  or  the  preservation  of  wild-type  viral  sequences.  Recombination  is 
the  generation  of  a  new  combination  of  genes  that  are  more  advantageous  for  the  survival 
of  a  specific  viral  population.  Recombination  between  two  pieces  of  RNA  can  be  either 
homologous,  and  occur  between  two  identical  or  similar  molecules  recombining  in  a 
precise  (junction  sites  occupy  different  positions  in  recombining  molecules)  or  imprecise 
(producing  molecules  with  duplications  and  deletions)  manner,  or  non-homologous,  and 
occur  between  two  different  RNA  molecules. 
1.5.1.1.2.2  Different  processes  of  recombination 
Recombination  of  positive-sense  single  strand  non-segmented  RNA  genomes  can  occur  via 
two  distinct  mechanisms:  a  replication-dependent  copy-choice  mechanism  where  the  viral 
replicase-nascent  strand  complex  switches  from  one  template  to  another  during  replication 
(Coffin  et  al.,  1979;  Kirkegaard  et  al.,  1986;  Figleworicz  et  al.,  1997;  Figleworicz  et  al., Claire  Blanchard  Introduction  Chapter  1  34 
1998)  and  a  replication-independent  mechanism  of  breakage  and  rejoining  of  pieces  of 
genetic  material  (Kirkegaard  et  al.,  1986).  Until  recently,  very  few  studies  had  investigated 
the  second  process,  however  recent  studies  have  provided  definitive  evidence  of 
recombination  occurring  via  a  replication-independent  mechanism  of  template  breakage 
and  rejoining  (Chetverin  et  at.,  1997;  Gallei  et  al.,  2004;  Gmyl  et  al.,  2003). 
1.5.1.1.2.2.1  RdRp  copy  choice  mechanism 
Copy-choice  recombination  is  the  result  of  the  RdRp  template  switching  during  replication 
(Figlerowicz  et  al.,  1998;  Jarvis  et  al.,  1992;  Kirkegaard  et  al.,  1986;  Lai  et  al.,  1992a; 
Nagy  et  al.,  1997;  Nagy,  1998;  Pilipenko,  1995),  a  process  described  in  studies  of 
pseudorevertant  genomes  in  Theiler's  murine  encephalomyelitis  virus  (TMEV)  and 
poliovirus  (Pilipenko  et  al.,  1995).  Pausing  of  the  nascent  strand  due  to  misincorporation 
by  the  RdRp,  dissociation  of  the  RNA  polymerase  from  the  nascent  strand,  re-annealing  of 
nascent  and  template  strands  and  resumption  of  the  synthesis  are  the  various  stages  of  the 
copy-choice  mechanism  (reviewed  Nagy  et  al.,  1997).  Studies  in  the  1960's  demonstrated 
that  poliovirus  recombinants  could  arise  as  a  result  of  mixed  infection  of  a  cell  with  two 
different  serotypes  of  polioviruses  (Hirst  et  al.,  1962;  Ledinko  et  al.,  1963).  This  was  later 
shown  to  occur  inside  specific  compartments  used  for  RNA  replication  (Bienz  et  al.,  1990). 
1.5.1.1.2.2.2  Replication-independent  recombination 
Unlike  template  switching,  non-replicative  recombination  has  not  been  studied  extensively. 
Chetverin  carried  out  experiments  on  Qß  replication  demonstrating  non-replicative 
recombination  of  RNA  fragments  (Gmyl  et  al.,  1999;  Chetverin  et  al.,  1997).  These  in  vitro 
studies,  however,  did  not  exclude  the  possible  low  levels  of  replication  due  to  the  presence 
of  the  Qß  replicase  required  for  amplification  of  the  recombinant  molecules. 
Recombination  could  still  be  accounted  for  by  a  copy-choice  mechanism.  Even  if  we 
assume  that  Chetverin's  studies  demonstrate  non-replicative  recombination  in  vitro  it  has Claire  Blanchard  Introduction  Chapter  1  35 
not  been  demonstrated  in  an  in  vivo  system  until  recently.  Experiments  studying  the 
co-transfection  of  incomplete  poliovirus  RNA  sequences  demonstrated  the  generation  of 
viable  viruses  and  gave  strong  but  not  definitive  evidence  of  a  replication-independent 
recombination  mechanism  (Gmyl  et  al.,  2003).  However,  the  definitive  evidence  of  such  an 
event  occurring  was  provided  by  the  recent  studies  carried  out  in  BVDV,  where  viable 
recombinants  would  arise  from  co-transfection  of  segments  of  RNA,  each  containing 
deletions  in  the  RdRp-coding  genes  thereby  completely  ruling  out  the  possible 
involvement  of  replication  in  the  process  (Gallei  et  al.,  2004). 
1.5.1.2  Evidence  of  emergence  of  recombinants  in  nature 
The  emergence  of  viruses  as  a  result  of  recombination  represents  an  important  threat  to  the 
world  as  they  have  the  potential  to  cause  major  outbreaks  and  pandemics.  Indeed  virus 
recombination,  leading  to  the  emergence  of  completely  new  viruses,  has  been  a  concern  for 
many  years.  The  recent  outbreak  of  SARS,  a  coronavirus  that  is  thought  to  have  recently 
evolved  from  its  natural  reservoir  to  infect  humans,  illustrates  the  impact  such  emerging 
viruses  can  have  both  economically  and  demographically.  Another  example  of 
recombination  occurring  in  nature  is  that  of  bovine  viral  diarrhea  viruses  (BVDVs).  Recent 
phylogenetic  studies  of  BVDVs  suggested  that  recombination  between  different  virus 
strains  had  occurred  in  animal  hosts  (Nagai  et  al.,  2004).  HIV  is  an  RNA  human  retrovirus 
that  has  had  a  huge  impact  on  the  world.  Recombination  has  been  reported  to  be  a  frequent 
event  contributing  to  the  generation  of  genetically  diverse  strains  of  HIV  with  different 
pathogenesis  characteristics  (Robertson  et  al.,  1995). 
1.5.1.3  Evolution  amongst  enteroviruses 
Recombination  plays  a  major  role  in  enterovirus  evolution.  In  fact,  numerous 
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laboratory  environment.  Certain  human  enteroviruses  are  thought  to  have  arisen  from 
ancient  recombination  events  and  this  was  suggested  to  have  occurred  for  CVA16  and 
bovine  enteroviruses  as  sequence  comparison  studies  of  these  viruses  indicated  strong 
phylogenetic  relationships  (Hyypiä  et  al.,  1997).  Genetic  recombination  between  different 
human  enteroviruses  type  B  echovirus  serotypes  has  been  reported  to  occur  when  multiple 
epidemic  strains  were  circulating  simultaneously  (Oprisan  et  al.,  2002).  This  was 
confirmed  by  recent  work  studying  the  phylogenetic  relationships  between  various 
enteroviruses  species  B  (Oberste  et  al.,  2004a).  Further  phylogenetic  analysis  of 
enteroviruses  species  C  (Brown  et  al.,  2003)  and  enteroviruses  species  A  (Oberste  et  al., 
2005)  included  strong  evidence  that  recombination  amongst  enteroviruses  is  a  common 
occurrence.  CVA2  1,  currently  defined  as  an  enterovirus  expressing  the  same  tissue  tropism 
as  HRV  and  causing  respiratory  infections,  was  suggested  to  be  a  recombinant  between  a 
rhinovirus  and  a  poliovirus  in  studies  carried  out  in  the  mid  1980's  (Stanway  et  al.,  1984). 
1.5.1.4  VDPV  and  vaccine  revertants 
Live-attenuated  strains  of  poliovirus,  containing  mutations  rendering  the  strains  unable  to 
cause  poliomyelitis  but  still  able  to  infect  cells;  have  proved  to  an  essential  tool  for 
vaccination  and  eradication  of  poliovirus.  Sabin  was  one  of  the  first  generated 
live-attenuated  poliovirus  vaccine  strains  (Krugman  et  al.,  1961),  and  these  are  now  used  in 
many  countries  as  means  of  immunisation  through  vaccination  with  OPV,  a  live-attenuated 
vaccine  containing  three  serotypes  of  live-attenuated  poliovirus  wild-type  strains.  Since  the 
first  use  of  live-attenuated  poliovirus  strains,  the  secretion  of  neurovirulent  revertants  have 
been  reported  (reviewed  Dowdle  et  al.,  2003)  and  have  been  shown  to  cause  infection  in 
immunodeficient  patients  and  the  non-immune  population  in  close  contact  with  the 
excreting  vaccinee.  However,  recent  data  from  retrospective  studies  have  shown  the 
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VDPDs  isolates  were  circulating  in  Egypt  for  over  10  years,  between  1983  and  1993,  and 
circulation  ceased  with  rising  coverage  of  OPV  vaccination  (Yang  et  al.,  2003).  These 
studies  not  only  suggest  that  OPV  vaccine  strains  can  recombine  and  cause  acute  flaccid 
paralysis  (AFP)  but  that  VDPVs  can  circulate  for  extended  periods  of  time  in  an 
environment  where  low  vaccination  coverage  is  prevalent.  Further  retrospective  studies  of 
the  poliovirus  Sabin  type  3-associated  outbreak  in  Poland  in  1968  (Martin  et  al.,  2000) 
demonstrated  that  VDPV-related  outbreaks  were  not  restricted  to  tropical  developing 
countries  such  as  Hispaniola  (Kew  et  al.,  2002)  and  that  VDPVs  were  able  to  cause  AFP  in 
developed  countries  with  temperate  climates  and  moderate  population  densities  if  the 
population  immunity  to  one  of  the  vaccine  strains  of  poliovirus  is  low.  Moreover  studies  of 
1963-1966  VDPV  isolates  in  Belarus  (Korotkova  et  al.,  2003)  reinforced  the  point  that 
maintenance  of  sufficient  levels  of  OPV  vaccination  coverage  is  essential  to  avoid 
circulating  VDPVs  from  occurring. 
1.5.1.5  Recent  outbreaks  and  recombinants  between  poliovirus  and  human 
enterovirus  C 
The  outbreak  of  recombinant  vaccine  strains  in  Hispaniola  in  2000-2001  (Kew  et  al.,  2002) 
caused  an  immediate  public  health  concern,  as  the  country  had  been  free  of  wild-type 
poliovirus  since  1991.  Isolates  were  collected,  sequenced  and  had  Sabin  poliovirus  type  1 
5'UTR  and  P  1/2A-coding  sequences  and  unidentified  human  enterovirus  C  3'UTR, 
2B/2C/P3-coding  sequences,  thereby  giving  evidence  for  a  recombination  event.  This 
recombination  event  is  the  first  report  of  human  enteroviruses  C  recombining  with  a  Sabin 
poliovirus  vaccine  strain  with  a  crossover  point  within  the  2A/2B-coding  region  (see  figure 
3.38).  Other  circulating  VDPVs  were  also  identified  in  the  Philippines  in  2001  (MMWR 
2001).  More  recent  studies  carried  out  by  Delpeyroux's  group  isolated  strains  from 
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enterovirus  C  strains  that  were  circulating  at  the  time  of  vaccination  (Rousset  et  al.,  2004). 
Studies  of  both  Haitian  and  Madagascan  cVDPVs  suggested  that  live-attenuated  poliovirus 
vaccine  strains  were  able  to  recombine  with  circulating  enterovirus  C  causing  a 
poliomyelitis-like  disease.  In  fact,  further  studies  carried  out  by  Delpeyroux's  group 
identified  two  unspecified  recombination  crossover  points  within  the  2A-coding  region  and 
a  definitive  recombination  between  vaccine  strains  Sabin  type  2  and  enteroviruses  species 
C  (Rousset  et  at.,  2004).  These  studies  not  only  highlighted  the  risk  of  recombinant  viruses 
emerging  and  causing  outbreaks,  as  a  result  of  low  vaccination  coverage,  but  the  fact  that 
enteroviruses  C  were  able  to  recombine  just  confirmed  the  difficult  obstacles  the  WHO 
would  have  to  overcome  in  order  to  succeed  in  eradicating  poliovirus  from  the  world.  The 
emergence  of  such  recombinant  viruses  may  lead  to  a  persistence  of  circulating 
polioviruses  in  the  wild.  So  far  the  circulating  recombinant  VDPVs  isolated  and  analysed 
from  outbreak  cases  had  structural  proteins  of  a  vaccine  strain  and  the  remainder  of  the 
virus  genome  had  sequences  of  unidentified  viruses  within  species  of  HEV-C  (Stanway  et 
al.,  2000).  An  urgent  understanding  of  such  recombinants  is  essential  for  the  monitoring 
and  control  of  transmission  or  re-emergence  of  poliomyelitis  post-eradication.  Failure  to 
investigate  concerns  regarding  the  polio  eradication  programme  could  lead  to  the 
re-emergence  of  poliovirus  and  actually  reverse  the  efforts  and  progress  already  achieved 
by  the  WHO. 
1.5.1.6  Vaccines  and  revertants 
Vaccine-derived  polioviruses  have  been  responsible  for  many  reported  acute  flaccid 
paralysis  (AFP)  cases.  Stability  of  live-attenuated  vaccines  has  been  a  concern  since  the 
first  evidence  of  the  appearance  of  vaccine-associated  paralytic  poliomyelitis  VAPP  soon 
after  the  OPV  vaccine  was  licensed  for  commercial  use.  With  a  large  part  of  the  world 
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vaccine.  However,  recent  retrospective  studies  and  outbreaks  of  paralytic  poliomyelitis 
associated  with  circulating  vaccine-derived  polioviruses  (cVDPVs)  have  highlighted 
pre-existing  concerns. 
1.5.2  WHO  eradication  program  and  rising  concerns 
In  the  1950's  poliomyelitis  was  an  important  disease  prevalent  in  both  the  developed  and 
the  developing  world.  Salk  vaccine,  a  poliovirus  inactivated  vaccine  (IPV),  was  initially 
used  as  a  prevention  method  and  is  still  used  in  many  countries.  Since  the  1960's  Sabin's 
OPV  (trivalent  live-attenuated  oral  poliovirus  vaccine)  has  been  used,  in  most  parts  of  the 
world,  as  the  preferred  prevention  method.  IPV  and  OPV  are  still  being  used  but  the  low 
cost  of  OPV  production  makes  its  administration  in  developing  countries  more  manageable 
and  realistic.  This  pattern  is  likely  to  change  as  eradication  is  achieved  and  every  means 
possible  will  be  made  to  exclude  the  potential  reintroduction  of  circulating  paralytic 
poliovirus. 
The  1979  smallpox  eradication  prompted  the  Pan  American  Health  Organisation  (PAHO) 
and  World  Health  Organisation  (WHO)  to  initiate  a  poliovirus  eradication  program,  in 
1985,  aiming  to  eliminate  poliomyelitis  worldwide  by  1990  using  the  OPV  as  the  means  to 
the  end.  Mass  immunisation  campaigns  were  initiated  with  national  immunisation  days 
(NIDS),  in  which  millions  of  children  in  a  country  are  immunised  in  a  single  day,  and 
sub-national  immunisation  days  (SNIDS),  in  which  smaller  areas  are  immunised  in  one 
day.  These  have  shown  to  abruptly  reduce  the  number  of  susceptible  individuals  thereby 
interrupting  transmission  of  the  virus.  However,  widespread  vaccination  can  prove  to  be 
challenging  and  some  parts  of  tropical  and  developing  countries  have  very  low 
immunisation  coverage.  This  leads  to  the  emergence  of  vaccine-associated  paralytic 
poliomyelitis  (VAPP)  caused  by  circulating  vaccine-derived  poliovirus  strains  (cVDPVs). Claire  Blanchard  Introduction  Chapter  1  40 
The  WHO  polio  eradication  program  has  achieved  the  eradication  of  circulating  wild-type 
poliovirus  in  many  parts  of  the  world  (figure  1.13),  however  the  transmission  of  wild-type 
poliovirus  still  occurs  in  India,  Pakistan,  Afghanistan,  Egypt,  Niger  and  Nigeria  and  the 
emergence  of  more  VAPP  cases  by  cVDPVs  in  Haiti  (Kew  et  al.,  2002),  Egypt  (Yang  et 
al.,  1997),  Philippines  (MMWR  2001)  and  Madgascar  (Rousset  et  al.,  2003)  have  raised 
issues  about  the  successful  eradication  of  poliomyelitis.  Better  monitoring  has  enabled  the 
detection  of  emerging  recombinant  viruses  between  vaccine  strains  and  human  enterovirus 
species  C  (Kew  et  at.,  2002;  Rousset  et  al.,  2003),  able  to  cause  outbreaks,  highlighting  the 
importance  of  vaccine-derived  polioviruses  (VDPV)  and  the  need  for  a  better 
understanding  of  recombinants  both  in  vitro  and  in  vivo. 
The  re-emergence  of  poliomyelitis  due  to  undetected  circulating  wild-type  strains  or 
recombinant  vaccine  strains  is  a  major  concern.  Monitoring  and  control  methods  need  to  be 
carried  out  and  extended  to  the  post-eradication  era  as  poliovirus  could  escape  or  be 
released  from  laboratories  and  potentially  cause  a  pandemic  in  a  non-immune  susceptible 
population.  Vaccine  strains  need  to  be  kept  in  case  such  an  event  was  to  happen  and  it  is 
likely  that  vaccination  in  the  developed  world  will  switch  to  IPV  in  the  end  stages  of  the 
eradication  program.  Non-poliovirus  enteroviruses  are  known  to  be  capable  of  causing  a 
poliomyelitis-like  disease  in  humans.  The  eradication  of  poliovirus  does  not  remove  the 
possibility  of  another  enterovirus  evolving  to  use  the  poliovirus  ecological  niche  left  vacant 
post-eradication  and  cause  poliomyelitis. 
1.6  Aims  of  the  project 
As  the  world  gets  closer  to  poliomyelitis  eradication,  progress  in  vaccination  distribution, 
detection  methods  and  laboratory  containment  are  becoming  more  important.  The 
emerging  VDPVs  causing  outbreaks  of  AFP  are  a  major  source  of  concern  and  various Claire  Blanchard  Introduction  Chapter  1  41 
issues  need  to  be  tackled.  How  do  recombinants  arise  and  do  recombination  hotspots  exist? 
With  the  eradication  of  poliovirus  and  the  ecological  niche  being  left  vacant,  what  are  the 
chances  that  a  non-poliovirus  enterovirus  could  evolve  to  use  the  poliovirus  receptor  and 
cause  poliomyelitis?  What  are  the  implications  of  such  recombinants?  Would  these 
recombinants  cause  poliomyelitis  due  to  their  PVR  usage  and  what  are  the  determinants  of 
tropism  and  pathogenesis? 
The  initial  aim  of  the  project  was  to  investigate  the  tropism  of  enteroviruses  and  to 
determine  whether  enteroviruses  could  evolve  to  use  a  novel  receptor.  Receptor 
interactions  are  important  determinants  of  tissue  tropism  and  numerous  experiments  have 
been  carried  out  describing  the  evolution  of  a  particular  picornavirus  to  use  an  alternate 
receptor  in  a  tissue  culture  environment.  Evidence  of  Coxsackievirus  A  21  adapting  to  use 
DAF  as  a  receptor  in  tissue  culture  as  opposed  to  its  identified  receptor  ICAM-1  was 
recently  provided  by  Johansson  (Johansson  et  al.,  2004).  FMDV  tissue  culture  adaptation 
to  use  heparan  sulphate  as  a  receptor  is  another  interesting  example  of  novel  tropism 
(Jackson  et  al.,  1996).  Infection  of  ICAM-1  negative  cells  by  human  rhinovirus  14 
(HRV  14)  was  also  shown  (Reischl  et  al.,  2001).  Recent  studies  demonstrating  enterovirus 
70  sialic  acid  usage  (Alexander  et  al.,  2002)  and  suggesting  that  EV70  had  evolved  to  use 
DAF  as  a  receptor  again  provided  evidence  that  picornaviruses  can  evolve  to  use  alternate 
receptors. 
Furthermore,  the  Haitian  and  Madagascan  outbreaks  caused  by  emerging  recombinant 
viruses  indicate  that  recombinants  provide  a  source  of  continued  circulation  of  PVR-using 
enteroviruses,  which  are  known  to  be  capable  of  causing  poliomyelitis. 
The  project  was  designed  to  investigate  these  issues.  The  project  was  divided  into  three 
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and  characterisation  of  recombinant  viruses  and  in  vivo  selection  for  novel  tropic 
recombinant  viruses. 
Mutagenesis  studies  to  select  for  novel  tropic  viruses  using  an  antiviral  mutagen  were 
carried  out.  These  were  designed  to  enable  the  generation  of  divergent  mutant  viruses 
using  a  process  reproducing  evolution. 
In  vitro  generation  of  recombinants  with  pre-determination  of  the  crossover  sites  was 
initiated  to  investigate  heterologous  processing  requirements  of  enteroviruses.  The  aim  was 
to  generate  recombinant  viruses  that  had  the  capsid-coding  region  of  a  non-poliovirus 
enterovirus  and  the  remainder  of  the  genome  of  a  poliovirus.  Reciprocal  recombinants 
were  also  constructed  in  attempt  to  provide  a  better  understanding  of  the  VDPVs 
recombined  with  enterovirus  species  C  (Kew  et  al.,  2002;  Rousset  et  al.,  2003).  The 
circulating  VDPVs,  isolated  from  outbreak  cases  in  Haiti  and  Madagascar,  were 
demonstrated  to  be  recombinants  between  the  structural  protein-coding  region  of  vaccine 
strains,  Sabin  poliovirus  type  1  (Haiti)  and  Sabin  poliovirus  type  2  (Madagascar),  and  the 
non-structural  protein-coding  region  of  human  enteroviruses  species  C.  The  viability  of 
these  isolates  indicated  that  the  3CD  of  an  enterovirus  type  C  could  efficiently  process  the 
P1  of  a  poliovirus  vaccine  strain. 
In  vivo  selection  for  novel  tropic  recombinant  viruses  by  co-transfection  of  two  defective 
viral  RNA  sequences  constituted  the  final  part  of  the  project.  Previous  evidence  of 
successful  generation  of  recombinants  by  co-transfection  of  incomplete  viral  RNA 
transcripts,  reports  of  emergence  of  recombinants  between  human  enteroviruses  C  and 
Sabin  poliovirus  vaccine  strains  and  the  implication  of  such  recombinants  in  view  of 
poliomyelitis  eradication  formed  the  basis  of  the  next  set  of  experiments.  Successful 
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points/exact  recombination  sites  and  characterisation  of  such  recombinants  could  provide 
valuable  information  on  properties,  stages  of  life  cycle  affected,  tropism  determinants, 
potential  location  of  recombination  hotspots  of  enteroviruses  and  the  potential  emergence 
of  a  virus  with  a  novel  sequence  to  occupy  the  ecological  niche  that  would  be  left  vacant 
following  poliovirus  eradication.  Generation  of  such  recombinants  could  also  potentially 
be  a  tool  for  enabling  identification  of  compatible  domains  of  the  genome  involved  in 
packaging  and  give  us  insights  into  protein-protein,  protein-RNA  and  potentially 
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2  Selection  of  novel  tropic  viruses  using  a  mutagen 
2.1  Introduction 
All  RNA  viruses,  except  for  retroviruses,  use  RNA-dependent  RNA-polymerases  (RdRps) 
as  a  catalytic  enzyme  for  RNA  synthesis.  RdRps  lack  proofreading  activity  thereby 
introducing  errors  to  the  newly  synthesised  progeny  genomes.  RNA  viruses  can  therefore 
exhibit  a  high  mutation  rate.  These  viruses  exist  as  quasispecies  or  large  population  of 
related  but  divergent  viral  sequences,  which  may  be  an  evolutionary  advantage.  The 
frequency  at  which  errors  occur  in  a  viral  genome  is  known  as  error  frequency,  which  is 
the  measure  of  genetic  drift  or  gradual  adaptation  to  new  environments  due  to  external 
stresses  also  known  as  selective  pressure. 
However,  the  evolution  rate  of  RNA  viruses  is  not  solely  determined  by  the  fixation  rate  of 
mutations  as  it  is  also  dependent  on  environmental  factors.  Measles  virus  exhibits  a  high 
mutation  rate  but  has  evolved  slowly  due  to  a  low  fixation  rate  of  mutations  (Schrag  et  al., 
1999)  whereas  HIV  shows  a  higher  evolution  rate  even  though  its  mutation  rate  is  similar 
to  that  of  measles  virus.  The  evolution  rate  of  HIV  has  been  extensively  documented  and 
has  been  shown  to  be  dependent  on  mutation  rate  as  well  as  on  the  host  immune  system 
(Wolinsky  et  al.,  1996)  and  other  factors,  which  select  for  viruses  that  exhibit  particular 
phenotypes.  Indeed  a  virus  could  evolve  faster  in  a  new  host  but  keep  the  same  polymerase 
error  rate  or  fidelity,  due  to  a  variability  in  the  fixation  rate  of  mutations.  Recent  studies 
carried  out  by  Andino  (Crotty  et  al.,  2001),  Domingo  (Ruiz-Jarabo  et  al.,  2000;  Sierra  et 
al.,  2000)  and  co-workers  confirmed  the  mutation  rate  of  picornaviruses  to  be  between 
2.1x10  and  5.9x104  substitutions  per  nucleotide.  These  figures  were  obtained  by  direct 
sequencing  analysis  of  many  viral  genomes  and  by  using  the  frequency  at  which  genetic 
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poliovirus  mutation  rate  calculation  (Ward  et  al.,  1988).  More  investigations  have 
quantified  the  poliovirus  mutation  rate  in  a  long-term  immunodeficient  excretor  to  be  1% 
per  base  per  annum  (Martin  et  al.,  2000;  Minor,  1996),  again  supporting  initial  calculations 
(Ward  et  al.,  1988).  Recent  investigations  demonstrated  that  the  VP1-coding  region  of 
Sabin  type  1  VDPV,  isolated  from  the  gut  of  a  healthy  child,  exhibited  a  sequence  drift  of 
over  2%  per  base  per  annum.  This  figure  proves  that  certain  VDPVs  exhibit  higher 
mutation  rates  than  that  initially  observed  for  poliovirus,  and  that  these  viruses  are  able  to 
replicate  in  the  gut  of  healthy  individuals  for  long  periods  of  time  (Martin  et  al.,  2004). 
Selective  pressure  occurs  during  processes  such  as  replication,  cell  lysis  and  virion  release 
into  the  intercellular  environment,  where  these  come  into  contact  with  cells  from  the 
immune  system.  The  combination  of  variation  and  large  replication  yield  during  infection 
is  considered  to  be  advantageous  to  virus  populations.  If  the  host  specific  immune  response 
results  in  the  near  elimination  of  wild-type  viruses,  quasispecies  may  contain  escape 
mutants  that  do  not  express  the  specific  epitopes  recognised  by  cytotoxic  T  cells, 
antibodies  or  innate  responses.  These  escape  mutants  will  then  quickly  replicate  and  give 
rise  to  a  new  population  of  quasispecies,  allowing  the  survival  of  the  viral  population  as 
was  shown  for  Hepatitis  C  virus  (HCV)  (Erickson  et  al.,  2001)  and  HIV  (Pircher  et  al., 
1990).  However,  errors  can  lead  to  the  generation  of  non-viable  viruses  and  the  extinction 
of  a  particular  virus  population  in  the  event  of  excessive  number  of  mutations  being 
introduced,  a  consequence  known  as  error  catastrophe  (see  figure  2.4  and  2.5). 
RNA  virus  recombination  can  be  beneficial  to  mutant  viral  sequences  and  can  allow 
recovery  of  fitness-impaired  sequences  (Chao  et  al.,  1997).  However,  recombination  can 
also  lead  to  the  generation  of  non-viable  viruses  due  to  incompatibility  between  genomes, 
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In  an  environment  where  the  mutation  rates  are  high,  a  significant  proportion  of  mutations 
are  deleterious.  This  leads  to  the  generation  of  non-viable  or  otherwise  disadvantaged 
genomes.  Miiller's  ratchet  is  the  selection  by  serial  passages  of  virus  populations  through  a 
narrow  genetic  bottleneck,  an  evolutionary  process  whereby  a  significant  percentage  of  a 
virus  population  is  killed  or  prevented  from  reproducing,  which  leads  to  the  reduction  in 
the  population  and  survival  of  a  subset  of  viruses  (transmitted  from  host  to  host)  (Duarte  et 
al.,  1992;  Chao  et  al.,  1990;  Domingo  et  al.,  1985).  In  this  context,  wild-type  viruses  are 
defined  as  viruses  that  have  sufficient  fitness  to  survive  and  be  transmitted  from  host  to 
host.  Mailer's  ratchet  could  have  significant  implications  for  variability  of  disease  severity 
during  virus  outbreaks. 
Evolution  of  picornaviruses,  and  more  specifically  poliovirus,  occurs  via  two  mechanisms: 
the  introduction  of  mutations  due  to  the  error  rate  of  RdRp  and  intra-/inter-typic 
recombination.  The  fixation  rate  and  phenotypic  selection  may  result  in  viruses  with 
altered  tropism  at  an  enhanced  level  of  mutation.  The  use  of  a  mutagen  in  vitro  may  enable 
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2.1.1  Ribavirin:  a  mutagen  and  its  effect  on  virus  life  cycle 
Ribavirin,  1-0-D-ribofuranosyl-1;  2,4-triazole-3-carboxamide  (see  figure  2.1),  is  a 
synthetic  broad-spectrum  non-specific  ribonucleoside  analog  with  antiviral  activity. 
Ribavirin  is  currently  used  for  the  treatment  of  a  variety  of  RNA  virus  infections.  In 
humans,  the  drug  is  used  as  monotherapy  for  Lassa  fever  virus  infections  and  severe 
respiratory  syncytial  virus  infections,  and  in  combination  with  interferon-a  as  treatment  for 
Hepatitis  C  virus  (HCV)  infections  (Crotty  et  al.,  2002a). 
Despite  the  extensive  use  of  ribavirin,  the  detailed  understanding  of  the  activity  of  the  drug 
is  still  unclear  thereby  preventing  further  development  of  enhanced  derivatives  with 
improved  properties  for  clinical  use.  Recent  studies  have  shown  that  ribavirin  is  an  RNA 
virus  mutagen  (Crotty  et  al.,  2000)  and  lethal  mutagenesis  has  been  proposed  to  be  its 
mechanism  of  action  (Crotty  et  al.,  2001). 
Once  inside  the  cell  ribavirin  is  phosphorylated  by  adenosine  kinase  to  generate  ribavirin 
monophosphate  (RMP).  Sequential  phosphorylation  events  then  give  rise  to  ribavirin 
triphosphate  (RTP).  RMP  is  an  inosine  monophosphate  dehydrogenase  (IMPDH)  inhibitor 
(Muller  et  al.,  1977;  Streeter  et  al.,  1973).  IMPDH  is  a  cellular  enzyme  used  for  de  novo 
synthesis  of  guanosine  triphosphate  (GTP),  which  is  itself  required  for  translation, 
transcription  and  replication  of  all  viruses.  IMPDH  inhibition  triggers  a  decrease  of 
intracellular  levels  of  GTP,  which  could  account  for  antiviral  activity. 
RTP  is  a  substrate  for  the  poliovirus  RNA-dependent  RNA  polymerase  and  acts  as  a  purine 
nucleoside  analog  by  presenting  two  distinct  hydrogen-bonding  conformations  to 
complementary  bases.  Low  intracellular  GTP  levels  favour  the  incorporation  of  RTP  into O 
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Figure  2.1:  Chemical  structure  of  ribavirin  (1-ß-D-ribofuranosyl-1,  -2,4-triazole-3- 
carboaamide). 
Figure  taken  from  Crotty  et  al.  (2002  b). 
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Figure  2.2:  Hydrogen-bonding  conformations  of  ribavirin,  a  purine  analog,  with  cytosine 
and  uracil,  pyrimidine  bases. 
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the  genome,  promoting  G  to  A  and  A  to  G  transitions  due  to  its  ability  to  base  pair  with  C 
and  U  (see  figure  2.2)  and  disrupting  RNA  structures,  which  can  be  critical  for  virus 
replication  (Crotty  et  al.,  2000). 
Number  of  mutations  Total  mutation  Total  mutation 
Ribavirin 
observed  in  the  frequency  (/104  frequency 
concentration 
sequenced  window  nucleotides)  (/genome) 
G-->A  C-4T 
0  µM  0.5  1.2  2.1  1.5 
100  µM  0  1.3  2.5  1.8 
400  µM  4.4  5  9.3  6.9 
1,000  µM  6.8  12  20.8  15.6 
Table  2.3:  Mutation  frequency  in  ribavirin-treated  RNA  poliovirus  populations.  Data 
was  taken  from  Crotty  et  al.  (2001). 
2.1.2  Effect  of  ribavirin  on  poliovirus  infection  life  cycle 
Andino  and  co  workers  (Crotty  et  al.,  2000)  established  a  relationship  between  ribavirin 
concentration  and  the  mutation  rate  of  poliovirus.  In  their  study  they  also  showed  the  effect 
ribavirin  exerted  on  viral  translation  and  production.  The  increase  of  the  mutation 
frequency  caused  by  ribavirin,  shown  in  table  2.3  and  the  effect  of  ribavirin  on  translation 
and  production  of  poliovirus  were  demonstrated  by  Andino  and  co-workers  (Crotty  et  al., 
2000).  Poliovirus  replication  and  translation,  determined  using  a  subgenomic  replicon,  is 
reduced  only  very  slightly  in  the  presence  of  up  to  1mM  ribavirin.  Under  similar 
conditions  virus  yield  is  reduced  by  up  to  3  loglo.  The  normal  mutation  rate  of  poliovirus, 
1.5  mutations  per  genome  (Crotty  et  al.,  2001),  was  increased  to  approximately  6.9 
mutations  per  genome  in  the  presence  of  0.4  mM  ribavirin.  This  was  shown  to  cause  a  95% Claire  Blanchard  Selection  of  novel  tropic  viruses  using  a  mutagen  Chapter  2  49 
decrease  in  the  fitness  of  the  viral  population  compared  to  that  of  wild  type  (Crotty  et  al., 
2001).  Because  the  normal  poliovirus  population  exists  on  the  threshold  of  error 
catastrophe,  accumulation  of  too  many  mutations  can  lead  to  lethal  mutagenesis  of 
poliovirus  leading  to  a  decrease  in  virus  titres  to  near  background  levels  (see  figure  2.4: 
Crotty  et  al.,  2001).  RNA  viruses  are  unstable  and  a  small  increase  in  mutation  levels  can 
result  in  a  reduction  of  virus  viability.  This  has  been  shown  for  poliovirus,  vesicular 
stomatitis  virus  (Holland  et  al.,  1990),  and  HIV  (Loeb  et  al.,  2000).  Moreover,  serial 
passages  in  the  presence  of  a  mutagen  were  shown  to  be  sufficient  for  viral  extinction  of 
HIV  populations  (Loeb  et  al.,  2000).  The  relationship  between  virus  survival  and  error 
catastrophe  is  fragile  and  the  application  of  random  mutagenesis  experiments  might  cause 
a  shift  in  the  equilibrium  relationship  towards  error  catastrophe  (see  figure  2.5). 
2.2  Aims 
Will  the  poliovirus  niche  remain  vacant  after  the  eradication  of  poliomyelitis  or  could 
viruses  evolve  to  occupy  the  empty  ecological  niche?  Enteroviruses  exhibit  a  high 
mutation  rate  in  nature.  Over  time,  mutations  cause  changes  in  the  capsid-coding  region 
that  could  lead  to  a  change  in  receptor  usage.  Moreover,  it  has  been  extensively  reported 
that  picornaviruses  can  adapt  to  use  alternative  receptors  in  tissue  culture.  Various 
examples  provide  evidence  that  picornaviruses  can  use  more  than  one  cell  surface 
molecules  for  cell  attachment.  Indeed,  FMDV  can  adapt  through  a  single  mutation  to  use 
heparan-sulphate  as  a  receptor  in  tissue  culture  as  opposed  to  the  identified  receptor  avß3, 
(Jackson  et  al.,  1996).  Human  rhinovirus  14  has  been  shown  to  be  able  to  infect  ICAM-1 
negative  cells  (Reischl  et  al.,  2001).  Coxsackieviruses  have  adapted  to  attach  DAF  and 
infect  RD  cells  (Reagan  et  al.,  1984).  A  DAF-binding  echovirus  6  has  been  demonstrated 
to  have  the  ability  to  use  heparan  sulphate  as  a  receptor  (data  not  published  David 
Williams).  An  echovirus  11  variant  has  also  adapted  to  not  use  DAF  as  a  receptor  for 120 
ý  wt  virus 
=  100  ý 
ý 
80 
60 
E  40 
. 
ý.  ý 
20 
.. 
~..  'ýý 
0 
400  µ'\1  ribavirin 
treated 
a 
LI50 
1000  µ\l  ribavirin 
treated 
02ý68  10  12  14  16 
mutations  RNA  ilenome 
Figure  2.4:  Error  catastrophe 
Relationship  of  mutation  frequency  to  genomic  RNA  infectivity  (Crotty  et  al..  2002  b).  Specific 
infectivity  of  normal  poliovirus  RNA  was  set  to  100°0.  The  graph  shows  that  poliovirus 
populations  exist  near  the  edge  of  error  catastrophe,  as  there  is  a  rapid  decline  in  RNA  genome 
infectivity  at  levels  of  mutagenesis  only  slightly  higher  than  normal.  The  L150  (50°°  loss  of 
specific  infectivity)  is  defined  as  the  mutation  frequency  at  which  50°0  of  the  viral  genomes  are 
lethally  mutated.  indicated  by  the  dashed  line.  Wild-type  poliovirus  genomes  contain  an  average 
1.5  mutations  genome.  Poliovirus  genomes  from  cells  treated  with  400  µM  and  1000  µM 
ribavirin  respectively  contain  an  average  -6.9  mutations/genome  and  -15.5  mutations/genome. 
Taken  from  Crotty  et  al.  (2001). 
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Figure  2.  ý:  Model  of  error  catastrophe 
A  Ive  viruses 
=  dead  %  Iru;  ý; 
'I  'he  majority  of  viruses  in  a  normal  picornavirus  population  are  viable.  But  a  small  increase  in 
mutation  frequency  is  predicted  to  push  the  virus  population  into  error  catastrophe  (the 
mutagenised  population.  Right),  where  the  number  of  errors  per  viral  genome  is  sufficiently  high 
to  lethally  mutate  a  majority  of  the  virus  population.  White  indicates  live  virus,  gray  indicates 
dead  virus.  Figure  and  legend  taken  from  Crotty  et  al.  (2001). 
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infection  (Stuart  et  al.,  2001).  Finally,  CVA21  DAF-binding  has  been  demonstrated  and 
confirmed  (Shafren  et  al.,  1997;  Johansson  et  al.,  2004). 
The  aim  of  the  experiment  was  to  investigate  whether  accelerating  evolution  in  vitro,  by 
combining  the  use  of  a  non-specific  mutagen  with  the  natural  variability  exhibited  by 
enteroviruses,  would  generate  key  mutations  resulting  in  a  virus  receptor-usage  shift. 
Selection  of  mutagen-treated  virus  populations,  by  conducting  serial  passages  on  a  variety 
of  cell  lines,  could  enable  the  isolation  of  specific  tissue-tropic  viruses.  The  potential 
outcome  of  such  experiments  could  be  the  selection  of  a  population  of  enteroviruses  that 
have  evolved  to  use  an  alternative  receptor  or  the  selection  of  a  population  of 
non-poliovirus  enteroviruses  that  use  the  PVR. 
To  investigate  this,  a  closely  related  human  enterovirus  species  C  to  poliovirus  was  used  as 
a  HEV  representative  for  this  experiment.  CVA21  is  a  REV-C  closely  related  to  PV3  with 
an  amino  acid  sequence  identity  of  84.2%.  CVA21  and  PV3  have  evolved  from  a  common 
ancestor  to  use  different  virus  receptors.  The  aim  of  this  experiment  was  to  try  and  select 
for  mutated  CVA21  virus  populations  that  bind  the  PVR.  However,  divergence  from  the 
common  ancestor  is  an  ancient  event  and  it  is  possible  that  CVA21  is  too  genetically 
distant  from  poliovirus  to  be  able  to  evolve  to  use  the  PVR  (see  figure  2.6).  However,  there 
are  similarities  in  virus-receptor  interaction  of  both  viruses,  as  they  both  interact  with 
Ig-like  receptor  molecules  via  a  canyon  interface.  It  is  therefore  possible  that  CVA21  could 
evolve  to  use  the  PVR  as  opposed  to  the  ICAM-1  cell  surface  molecule.  Can  CVA2  1,  a 
well-characterised  HEV-C,  undergo  a  shift  in  receptor  usage  in  the  presence  of  ribavirin? 
Can  CVA21  evolve  to  use  PVR?  Such  findings  would  be  crucial  information  for  the  WHO 
poliomyelitis  eradication  program  and  would  contribute  to  our  understanding  of  virus 
evolution  and  the  evolution  of  receptor  tropism. I 
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Figure  illustrating  different  possible  outcome  of  the  designed  strategy:  switch 
from  ICAM-1  usage  to  PVR-usage,  switch  to  non-PVR  alternate  receptor-usage 
and  death  of  mutated  virus  population  due  to  introduction  of  fatal  errors  or 
mutations  that  do  not  allow  alternate  recptor  usage.  The  switch  from  ICAM-1 
usage  to  PVR-usage  could  occur,  however  it  is  also  possible  that  the  shift  in 
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2.2.1  Experimental  model 
Initial  titration  of  ribavirin  was  carried  out  to  determine  a  concentration  that  would  lead  to 
the  introduction  of  a  number  of  mutations  whilst  retaining  significant  fitness  levels  of  a 
CVA21  viral  population.  Once  determined,  CVA21  infection  of  a  permissive  cell  line  was 
conducted  in  the  presence  of  ribavirin.  RD  cells  (rhabdomysarcoma  cells)  express  both 
PVR  and  DAF  molecules  on  their  cell  surface  and  fully  support  replication  of 
enteroviruses.  RD-ICAM  cells  are  RD  cells  engineered  to  express  the  ICAM-1  receptor  for 
CVA21  attachment  and  entry  and  were  used  for  the  rounds  of  CVA21  infection  in  the 
presence  of  ribavirin.  The  resulting  mutated  progeny  viral  population  would  then  be 
submitted  to  selection  by  passage  on  a  variety  of  cell  lines:  RD  cells,  L20B  cells  and  L 
cells  (see  figure  2.7).  RD  cells  would  allow  for  selection  of  DAF  or  PVR-tropic  viruses.  L 
cells,  a  murine  fibroblast  cell  line,  lack  any  identified  human  enterovirus  receptors  but  are 
fully  permissive  for  enterovirus  replication  and  L20B  cells  are  L  cells  expressing  PVR 
(Wood  &  Hull,  1999).  Compared  analysis  of  selection  experiments  carried  out  in  L  cells 
and  L20B  cells  would  be  the  most  restrictive  strategy.  Mutated  enterovirus  populations 
growing  on  L20B  cells  but  not  L  cells  would  be  PVR-tropic.  This  could  lead  to  the  first  in 
vitro  report  of  an  enterovirus  that  had  evolved  to  use  PVR. 
2.3  Results  and  Discussion 
2.3.1  Effect  of  ribavirin  on  CVA21  yields  and  determination  of 
concentration  to  use  for  experimental  system 
The  introduction  of  6-9  mutations  per  poliovirus  genome  resulted  in  a  95%  reduction  in 
fitness  of  the  viral  populations  (Crotty  et  al.,  2001).  The  effect  of  a  range  of  ribavirin 
concentrations  on  CVA21  was  not  expected  to  differ  greatly  from  those  observed  with 
poliovirus,  due  to  the  similarity  of  the  virus,  the  replication  cycle  and  the  similarity  of 1mM  ribavirin 
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Figure  2.7:  Selection  of  noel  tropic  viruses:  infection  of  CNA21  in  the  presence  of 
ribavirin  (a  random  mutagen). 
FIow  chart  representing  a  diagram  of  the  experimental  procedures.  Rn  indicates  passage  in 
the  presence  of  ribavirin.  where  n  is  the  passage  number,  and  rn  indicates  passage  in  the 
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growth  of  the  viruses  in  vitro.  Only  concentrations  spanning  the  upper  limits  of  ribavirin 
concentrations  used  by  Andino  and  co-workers  were  tested  during  PV3  and  CVA21  viral 
infections  were  used  in  this  assay. 
Pre-treatment  with  ribavirin  concentrations  ranging  from  0.5  mM  to  6  mM  was  carried  out 
and  repeated  four  times.  Pre-treatment  with  the  mutagen  would  be  expected  to  cause  a 
reduction  in  intracellular  levels  of  GTP  and  an  increase  in  the  levels  of  RTP  incorporated 
in  viral  genomes  (Muller  et  al.,  1977;  Streeter  et  al.,  1973),  as  a  GTP  analog.  Cells  were 
then  infected  with  CVA21  or  PV3  viruses  at  an  MOI  of  1.  CVA21  and  PV3  infections  of 
untreated  cells  in  the  presence  and  absence  of  a  virus  replication  inhibitor  GuHCI  were 
conducted  to  check  that  the  observed  CPE  were  virally  induced.  Mock  infections  in  the 
presence  of  ribavirin,  to  monitor  the  effect  the  mutagen  exerted  on  cells,  were  carried  out 
in  parallel.  The  samples  were  incubated  until  full  CPE  was  observed,  progeny  virus  was 
harvested  and  the  titre  determined  by  TCID50  assay  (Figure  2.8). 
An  initial  sharp  decrease  in  viral  titre  followed  by  a  drop  in  the  rate  of  decrease  of  viral 
yields  in  the  presence  of  increasing  concentrations  of  ribavirin  was  observed.  The  CPE 
exhibited  by  PV3  infection  of  ribavirin  pre-treated  RD-ICAM  cells  and  the  effect  of 
ribavirin  on  virus  titres  was  similar  to  those  previously  observed  (Crotty  et  al.,  2000). 
Unlike  PV3,  CVA21  did  not  show  as  strong  a  decrease  in  titre  at  lower  concentrations  of 
ribavirin.  A  1-log  titre  reduction  of  CVA21  was  observed  in  the  presence  of  1mM 
ribavirin,  a  2-log  decrease  was  observed  when  CVA21  was  treated  with  3mM  ribavirin  and 
a  4-log  decrease  was  seen  in  the  presence  of  6mM  of  the  mutagen.  With  such  a  significant 
decrease  the  overall  fitness  of  the  mutated  viral  populations  was  expected  to  be  too  low 
due  to  an  excessive  number  of  mutations  being  introduced  and  the  volume  handled  in  the 
assay  would  need  to  be  too  high.  1  mM  of  ribavirin  was  the  chosen  concentration  for  the 
following  assays,  as  a  sufficient  decrease  in  CVA21  virus  titres  (1-log)  was  achieved  and  a Ribavirin  titration  of  Poliovirus  type  3  Leon  and  CVA21 
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Figure  2.8:  Titration  of  CVA21  and  PV3  in  the  presence  of  increasing 
concentrations  of  ribavirin,  a  nucleoside  analog. 
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TCID50  assays  of  PV3  and  CVA21  virus  grown  in  the  presence  of  a  range  of 
ribavirin  concentrations  were  carried  out  four  times.  Plates  were  fixed  and  stained. 
Titres  were  calculated  and  plotted  using  a  log  scale.  The  4  repeats  of  the  assay 
exhibited  similar  results.  Standard  deviation  values  were  calculated  and  are 
represented  as  error  bars  on  the  graph.  10mM  ribavirin  concentrations  exerted  a 
cytotoxic  effect  on  mock  infected  cells  and  was  therefore  not  used  in  the  experiment. Claire  Blanchard  Selection  of  novel  tropic  viruses  using  a  mutalten  Chapter  2  53 
significant  number  of  mutations  were  expected  to  have  been  introduced.  None  of  the 
ribavirin  concentrations  used  (with  the  exception  of  the  10mM  samples),  had  a  cytotoxic 
effect  on  the  cells.  This  basic  titration  assay  did  not  enable  any  direct  comparison  with  the 
data  observed  in  the  Crotty  papers,  as  it  did  not  analyse  the  effect  of  ribavirin  on  different 
stages  of  the  virus  life  cycle. 
To  detect  the  introduction  of  mutations  in  the  genomes  of  a  population  of  progeny  viruses, 
vRNA  was  extracted  from  harvested  viruses  grown  in  the  presence  of  0.5  mM,  0.75  mm  (a 
concentration  not  tested  in  the  previous  assay),  1  mM,  3  mM  and  6  mM  ribavirin.  Reverse 
transcription  reactions  were  carried  out  using  the  extracted  vRNA  as  a  template.  The  VP  1 
coding  region  of  CVA21  was  amplified  by  PCR  (using  CVA21  specific  oligonucleotide 
primers)  and  sequenced.  The  results  are  shown  in  figure  2.9.  No  product  could  be 
amplified  and  sequenced  from  the  samples  of  the  virus  grown  in  the  presence  of  3mM  and 
6mM  ribavirin.  Mutations  of  the  primer  binding  sites  or  poor  sensitivity  of  the  PCR 
reaction  could  both  be  responsible  for  this  phenomenon.  A  window  of  the  CVA21 
VP  1-coding  region  of  the  virus  samples  grown  in  the  presence  of  0.5  mM,  0.75  mM  and 
1  mM  ribavirin  was  amplified  by  PCR  and  sequenced.  The  results  are  shown  in  figure  2.9. 
The  sequencing  results  show  that  within  a  1778-bp  window  two  C  to  T  coding  changes, 
reflecting  C  to  U  substitutions  in  the  original  viral  sequence,  that  were  absent  from  the 
original  CVA21  viral  sequence,  were  introduced  when  the  virus  was  grown  in  the  presence 
of  1  mM  ribavirin  and  no  third-base  changes  were  seen.  No  changes  were  detected  in  the 
sequences  of  the  0.5mM  and  0.75mM  ribavirin  samples.  Amplification  reactions  were 
carried  out  from  a  population  of  DNA  molecules  since  the  fragments  were  not  cloned 
therefore  the  mutations  seen  are  likely  to  have  been  fixed  at  early  stages  of  the  replication 
cycle  and  calculation  of  mutation  rates  would  therefore  be  inaccurate. Pl  P2 
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Figure  2.9:  Sequencing  analysis  of  input  CV%21  virus  and  CN  A21  virus  sequences 
passaged  in  the  presence  of  0.5mNI,  0.75m11  and  1.0mM1  ribavirin. 
The  RNA  of  the  various  samples  was  extracted  using  a  QlAamp®  Viral  RNA  mini  kit, 
%RNA  as  reverse  transcribed  and  newly  synthesised  cDNA  was  amplified  by  PCR  using 
CVA21  Pl  specific  oligonucleotide  primers  (CVA21-F0,  CVA2I-R11).  The  PCR  products 
were  purified  and  sent  for  sequencing.  Here  the  two  nucleotide  changes,  both  from  C  to  T, 
due  to  the  presence  of  ribavirin  are  illustrated  and  cause  two  coding  amino  acid  changes. 
---  ---  ---  ---  ---  --- 
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It  is  unclear  how  many  mutations  are  needed  for  a  receptor  shift  to  happen.  However,  it  has 
recently  been  suggested  that  minimal  changes  in  viral  genomes  could  lead  to  a  shift  in 
receptor  usage  (Baranowski  et  al.,  2001).  There  are  27  amino  acids  involved  in  the 
interface  interaction  between  poliovirus  and  the  PVR,  19  of  which  differ  between  PV3  and 
CVA21.  A  normal  poliovirus  has  a  mutation  frequency  of  1.5  mutations  per  genome  or  1 
mutation  per  5000  nucleotides.  To  have  19  amino  acid  changes,  assuming  that  a  single 
nucleotide  change  is  sufficient  to  lead  to  an  amino  acid  change,  every  virus  would  have  a1 
in  (5x103)19  or  2x1070  chance  to  mutate  the  correct  19  nucleotides.  Even  with  a  mutation 
rate  of  1  mutation  per  600  nucleotides,  increase  induced  by  treatment  with  a  mutagen  such 
as  ribavirin,  every  virus  would  have  a1  in  (6x102)19  or  6x1052  chance  to  mutate  the  correct 
19  nucleotides  and  therefore  amino  acids  for  a  shift  in  receptor  usage.  However,  it  is  likely 
that  more  than  one  nucleotide  change  is  required  for  an  amino  acid  change  and  the  chance 
of  getting  all  19  amino  acid  mutations  would  therefore  be  expected  to  be  even  lower.  This 
describes  the  worst-case  scenario  whereby  all  19  amino  acids  involved  in  the  interface  that 
differ  between  CVA21  and  PV3  would  need  to  be  changed  for  a  switch  in  the  receptor 
usage  of  CVA21  to  occur. 
However,  due  to  the  nature  of  the  interaction  of  the  canyon  with  the  virus  receptor,  the 
importance  of  all  amino  acids  involved  in  the  interaction  between  a  virus  particle  and  a 
receptor  molecule  is  not  equal.  For  example,  only  3  amino  acids  out  of  the  30 
residue-interface  contribute  80%  of  the  total  energy  of  the  interaction  between  EV7  and 
DAF  (Bhella  2004).  Similarly,  Akio  Nomoto's  group  suggested  that  only  3  amino  acids  are 
key  to  the  interaction  between  PV  1  and  the  PVR  (Arita  et  al.,  1998).  A  single  amino  acid 
change  has  been  shown  to  alter  Echovirus  type-6  receptor  usage  (unpublished  data  by 
David  Williams).  So  it  is  very  likely  that  significantly  fewer  amino  acids  than  all  19  of 
those  that  differ  between  PV3  and  CVA21,  involved  in  the  interaction,  would  need  to  be Claire  Blanchard  Selection  of  novel  tropic  viruses  using  a  mutagen  Chapter  2  55 
changed  for  the  virus  to  use  a  different  cell  surface  molecule  as  a  receptor  for  attachment 
and  entry.  If  three  amino  acids  need  to  be  changed  for  the  receptor  swap  to  occur  at  a 
mutation  rate  of  1  in  5x103  then  a  population  of  (5x103)3  or  1.25x1011  would  have  to  be 
screened,  a  more  reasonable  and  manageable  number.  In  fact  in  a  hypothetical  case  where 
the  mutation  rate  was  increased  to  1  mutation  in  600  nucleotides  the  minimum  population 
screened  would  have  to  be  (6x102)3  or  2.1x108  viruses.  A  smaller  number  of  mutations 
than  that  required  for  CVA21  adaptation  to  use  the  PVR  could  be  required  for  CVA21  to 
adapt  to  use  DAF,  heparan  sulphate  or  other  enterovirus  receptor  molecules.  The  use  of  a 
random  mutagen  to  accelerate  evolution  and  select  for  a  human  enterovirus  type  C  that  has 
evolved  to  use  an  alternate  receptor,  and  more  specifically  the  PVR,  is  a  feasible 
experiment,  due  to  the  small  number  of  mutations  actually  required  for  a  receptor  shift  to 
occur  and  due  to  the  possible  handling  of  large  population  sizes  in  small  volumes. 
2.3.2  Determination  of  optimal  concentration  of  ribavirin 
The  assays  carried  out  in  this  chapter  do  not  enable  the  determination  of  the  optimal 
ribavirin  concentration  to  attain  the  correct  equilibrium  of  introducing  enough  mutations 
and  maintaining  sufficient  fitness  of  the  mutated  viral  populations.  Sequencing  of 
independent  clones  from  PCR  reactions  at  each  concentration  and  overlaying  graphs 
plotting  the  number  of  mutations  introduced  versus  ribavirin  concentrations  and  the  viral 
titre  drop  versus  ribavirin  concentrations  (see  figure  2.10)  could  be  carried  out.  There  is 
likely  to  be  a  balance  between  the  number  of  mutations  introduced  and  the  decrease  in 
viral  titres.  It  would  therefore  be  possible  to  determine  the  optimal  ribavirin  concentration 
needed  to  introduce  a  maximal  number  of  mutations  in  a  virus  population  without  shifting 
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Figure  2.10:  Graph  of  a  hypothetical  determination  of  optimal  ribavirin 
concentration  to  use  for  the  selection  of  novel  tropic  mutant  viruses  experiment. 
The  optimal  concentration  is  determined  based  on  the  amount  of  ribavirin  needed  to 
cause  a  signficant  number  of  mutations  whilst  retaining  the  ability  to  replicate  and 
produce  progeny  viruses.  In  this  hypothetical  situation  the  optimal  concentration  to  use, 
shown  by  the  red  arrow,  would  be  that  causing  a  2-log  reduction  in  titre  whilst 
introducing  2.5  mutations  per  genome.  Such  an  assay  needs  to  be  carried  out  and  the 
experiment  needs  to  be  repeated  using  the  determined  optimal  ribavirin  concentration. Claire  Blanchard  Selection  of  novel  tropic  viruses  using  a  mutagen  Chanter  2  56 
2.3.3  Results  and  discussion  of  the  selection  experiment 
RD-ICAM  cells,  pre-treated  with  1mM  ribavirin,  were  infected  with  CVA21  at  an  MOI  of 
1.  Each  sample  was  harvested  and  passaged  onto  fresh  pre-seeded  RD-ICAM  cells.  Four 
subsequent  serial  passages  or  rounds  of  selection  were  carried  out  using  the  same 
pre-incubation,  infection  and  incubation  stages  in  the  presence  of  ribavirin,  in  which  1  ml 
out  of  5mls  were  transferred.  The  first  round  of  selection  was  named  r1  (samples  incubated 
in  the  absence  of  the  mutagen)  or  R1  (for  the  samples  incubated  in  the  presence  of  1  mM 
ribavirin),  the  second  round  r2  or  R2  and  so  on  (see  figure  2.7).  The  samples  were  then 
screened  on  various  cell  lines.  The  selection  strategy  applied  would  allow  a  population  of 
mutated  viruses  to  evolve  to  use  other  receptors  such  as  heparan  sulphate,  DAF  alone, 
murine  DAF  or  PVR,  by  comparison  of  infection  of  L  cells  and  L20B  cells.  Each  sample 
from  each  round  of  selection  was  tested  on  each  cell  line  and  serially  passaged  on  the 
respective  cell  lines  in  order  to  enable  potential  infection  and  amplification  of  less  fit  novel 
tropic  mutant  CVA21  populations.  The  results  are  shown  in  table  2.11.  The  assay  was 
repeated  four  times.  On  no  occasion  were  novel  tropic  mutant  viruses  detected  and  isolated 
from  the  reactions. Claire  Blanchard  Selection  of  novel  tropic  viruses  using,  a  mutagen  Chapter  2  57 
Cell  line  infected 
Test  samples  RD-ICAM  RD  L  L20B 
CVA21  r'     MI  Q  Q 
CVA21  R'     Q  Q 
Cells  R'  Q  Q  Q  Q 
CVA21  r2     Q  Q 
CVA21  R     L  Q  Q 
cells  R`  c  Q  Q  Q 
CVA21  r3     Q 
Q 
CVA21  R3     M  Q  Q 
cells  +  R3  Q  Q  Q 
CVA21  r4     Q  Q 
CVA21  R4     Q  Q 
cells  R4  Q  Q  Q  Q 
CVA21  r'   a  Q  Q 
CVA21  R'   a  Q  Q 
cells  R'  Q  Q  Q  Q 
Table  2.11:  Results  of  screening  of  samples  of  CVA21  serially  selected  in  the  presence 
of  ribavirin.  The  read-out  of  the  experiment  was  the  presence  ( )  or  absence  (E)  of 
('PE  observed  in  the  transfected  cell  sheet.:,  represent  very  low  levels  of  CPE 
observed  on  the  infected  cell  sheet  (-20%  CPE). Claire  Blanchard  Selection  of  novel  tropic  viruses  using  a  mutagen  Chapter  2  58 
Ribavirin  did  not  have  a  cytotoxic  effect  on  any  of  the  cell  lines  and  serial  passaging  in  the 
presence  of  the  mutagen  did  not  affect  the  readout  of  the  experiment.  No  CPE  was 
observed  in  L  cells  or  L20B  cells  implying  that  CVA21  had  not  evolved  to  use  murine 
fibroblast  cell  surface  molecules  or  the  PVR.  As  expected  RD-ICAM  cells  always 
exhibited  CPE  in  the  passaged  virus  samples  tested,  but  not  in  the  absence  of  the  virus.  The 
ribavirin-independent  result  in  RD  cells  was  however  intriguing.  CVA21  virus  alone  and 
CVA21  virus  incubated  in  the  presence  of  1  mM  ribavirin  caused  low  levels  of  CPE  in  RD 
cells.  This  outcome  could  be  due  to  a  positive  selection  for  a  subpopulation  of  virus  that  is 
able  to  grow.  However  the  CPE  levels  were  not  amplified  after  several  passages  in  the  cell 
line  indicating  that  low  CPE  due  to  a  positive  selection  is  unlikely.  Possible  contaminations 
of  either  the  CVA21  virus  stocks  with  RD-tropic  virus  or  the  RD  cells  with  low  levels  of 
RD-ICAM  or  another  cell  line  permissive  for  CVA21  growth  were  checked  and  different 
virus  stocks  were  tested  on  different  batches  of  RD  cells.  No  contamination  was  detected. 
A  likely  explanation  for  the  limited  CPE  observed  in  RD  cells  could  be  that  CVA21  is  able 
to  use  DAF  as  a  cell  surface  receptor  (Shafren  et  al.,  1997;  Johansson  et  al.,  2004). 
Although  the  strain  of  CVA21  used  for  the  experiment  was  not  adapted  to  grow  in  RD 
cells,  the  limited  CPE  observed  in  the  assay  could  be  due  to  the  fact  that  in  the  absence  of 
ICAM-1  cell  surface  molecules  CVA21  is  able  to  attach  DAF  to  some  extent  and  actually 
cause  some  CPE. 
Under  the  conditions  tested,  the  selection  for  novel  tropic  viruses  was  not  successful, 
however  the  use  of  different  parameters  could  potentially  allow  for  the  selection  of  such 
viruses.  Several  factors,  such  as  the  ribavirin  concentration,  the  incubation  time,  the  cell 
type  chosen  and  the  pre-incubation  stage,  might  have  biased  the  experiment.  Reducing  the 
pre-incubation  time  could  mean  that  the  intracellular  levels  of  GTP  were  still  significant. Claire  Blanchard  Selection  of  novel  tropic  viruses  using  a  mutagen  Chapter  2  59 
Intracellular  GTP  could  therefore  have  been  used  during  virus  replication  as  opposed  to 
RTP,  leading  to  the  generation  of  wild-type  virus  sequences  and  the  absence  of  mutations. 
It  would  be  interesting  to  repeat  the  experiment  with  a  longer  pre-incubation  period  so  that 
a  better  environment  for  the  introduction  of  mutations  may  be  created. 
A  ribavirin  concentration  of  1mM  caused  a  1-log  reduction  in  CVA21  viral  titres  which, 
combined  with  the  long  incubation  stage  after  infection  of  RD-ICAM  cells,  could  have 
affected  the  outcome  of  the  experiment.  Indeed  the  risk  of  carrying  out  a  long  incubation  is 
that  of  allowing  fitter  viruses,  like  wild-type  viruses,  to  outgrow  novel  tropic  mutants  of 
lesser  fitness.  High  mutation  rates  could  lead  to  the  introduction  of  lethal  mutations 
affecting  essential  protein  coding  sequences  and  the  overall  RNA  structure.  Using  random 
mutagenesis  as  a  selection  method  combined  with  high  mutation  rates  increases  the  risk  of 
lethal  mutagenesis.  If  random  mutations  are  introduced  at  a  high  rate  the  probability  of 
affecting  a  key  sequence  is  increased  and  the  mutated  virus  is  less  likely  to  be  able  to 
survive  and  outgrow  wild-type  viruses  during  the  first  round  of  infection  in  RD-ICAM 
cells  in  the  presence  of  ribavirin.  Multiple  nucleotide  changes  may  disrupt  the  overall  RNA 
structure  and  therefore  seriously  impair  downstream  events  that  are  dependent  on  such  a 
structure.  By  attempting  to  speed  up  evolution  there  is  a  risk  of  reaching  extinction  without 
going  through  the  various  transitional  stages.  RNA  viruses  such  as  CVA21  and  PV3 
already  exist  on  the  brink  of  error  catastrophe  and  random  mutagenesis  might  have 
destroyed  a  fine  equilibrium  and  might  have  accelerated  extinction.  However,  the 
experiment  provides  no  evidence  for  error  catastrophe  in  the  studied  virus  populations,  as 
virus  titres  were  still  significant  (3.6  x  104  TCID50/ml,  data  not  shown)  after  multiple 
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2.3.4  Future  work 
Some  variables  of  the  described  experiment  could  be  altered.  Indeed,  repeating  the 
experiment  using  high  multiplicity  of  infection  coupled  with  rapid  passages  could 
potentially  alter  the  outcome.  Furthermore,  determination  of  the  optimal  ribavirin 
concentration  to  use  for  the  introduction  of  a  sufficient  number  of  mutations  is  essential. 
Moreover,  a  variety  of  alternative  assays  with  a  more  stringent  selection  applied  to  a 
variety  of  reference  viruses,  could  be  designed. 
The  selection  for  novel  PVR-tropic  viruses  would  potentially  mean  the  loss  of  ICAM-1 
affinity  by  the  emerging  virus  populations.  One  way  to  select  for  recombinants  in  vivo  is  to 
select  against  parental  viruses  using  ICAM-1,  by  repeating  the  assay  in  the  presence  of 
both  ribavirin  and  soluble  ICAM-1.  The  samples  would  then  be  washed  to  get  rid  of 
ICAM-1  tropic  viruses  allowing  for  recovery  and  growth  of  non-ICAM-1  binding  novel 
tropic  recombinant  viruses.  Should  novel  tropic  mutant  viruses  be  selected  for, 
characterisation  of  such  viruses  by  assays  such  as  antigenicity  testing,  specific  infectivity 
assessment  and  nucleotide  sequence  analysis  would  be  carried  out. 
Due  to  time  restrictions  and  progress  on  the  generation  of  recombinants  in  vitro  project  it 
was  not  possible  to  carry  out  the  described  assays. Claire  Blanchard  In  vitro  recombination 
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3.1  Introduction 
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Human  enterovirus  (HEV)  evolution  is  a  consequence  of  selective  pressure,  error  rate  and 
recombination.  Recombination  plays  a  major  role  in  the  emergence  of  viruses  with  novel 
sequences.  Emerging  recombinant  enteroviruses  have  been  a  major  concern  for  the  WHO 
poliomyelitis  eradication  program  and  have  been  reported  to  occur  both  in  the  laboratory 
environment  and  in  nature.  The  exact  circumstances,  processes  and  factors  contributing  to 
the  emergence  of  such  recombinant  viruses  are  unclear. 
So  far  the  circulating  vaccine-derived  polioviruses  (cVDPVs),  isolated  from  outbreak 
cases,  were  found  to  have  a  structural  protein-coding  region  derived  from  a  vaccine  strain 
and  the  remainder  of  the  genome  from  an  unidentified  virus  strain  from  the  same  species  as 
poliovirus  (Stanway  et  al.,  2000).  This  was  the  case  of  the  cVDPVs  isolated  in  Egypt 
(Yang  et  al.,  2003)  and  the  Philippines  (WMMR,  2001).  Recently,  cVDPVs  isolated  from 
Haiti,  Egypt,  the  Philippines  and  Madagascar  seemed  to  have  arisen  from  a  recombination 
event  between  Sabin  poliovirus  strains  and  enteroviruses  circulating  in  the  gut  of  vaccinees 
at  the  time  of  vaccination  (Kew  et  al.,  2002;  Rousset  et  al.,  2003).  These  emerging 
cVDPVs  (reviewed  in  Kew  et  al.,  2004)  highlight  the  importance  recombination  plays  in 
enterovirus  evolution. 
The  initial  aim  of  the  project  was  to  generate  and  study  viruses  with  mosaic  non-poliovirus 
HEV-C  P1-coding  sequence  resulting  from  shuffling  that  may  use  the  PVR,  thereby 
mimicking  evolution.  The  generation  of  viable  viruses  would  require  cis-processing  of  the 
polyprotein.  However,  the  exact  requirements  for  the  processing  of  the  P1-coding  region 
by  a  heterologous  3CD  protease  to  occur  in  trans  were  unclear.  The  cis-processing Claire  Blanchard  In  vitro  recombination  Chapter  3  62 
requirements  were  therefore  investigated  prior  to  shuffling  by  constructing  and  analysing 
recombinants  with  a  precise  exchange  of  the  P  1-coding  region.  These  in  vitro  generated 
recombinants  exhibited  interesting  phenotypes  and  further  characterisation  was  conducted. 
3.1.1  Aims 
To  attempt  to  provide  a  greater  understanding  of  the  different  factors  involved  in  the 
generation  and  infection  of  recombinant  enteroviruses,  chimeras  between  a  poliovirus  and 
a  human  enterovirus  type  C  (HEV-C)  were  generated  in  vitro.  The  studies  described  in  this 
chapter  were  designed  to  broaden  the  understanding  of  key  factors  and  mechanisms  and 
enable  a  better  knowledge  of  processing  requirements. 
It  was  proposed  to  generate  recombinants  with  a  precise  exchange  of  the  P1-coding  region 
between  a  poliovirus  and  a  non-poliovirus  ITV-C,  using  basic  molecular  cloning 
techniques.  The  source  of  the  genomes  used  for  the  experiments  were  selected  on  the 
availability  of  infectious  clones.  Poliovirus  type  3  Leon  (PV3),  a  neurovirulent  poliovirus, 
was  chosen  as  one  of  the  wild-type  viral  sequences.  Sabin  poliovirus  type  1  (Sabin  1),  a 
vaccine  poliovirus  strain,  was  an  additional  parental  genome  used  for  the  experiments 
(kindly  provided  by  Dr  A.  Macadam,  National  Institute  for  Biological  Standards  and 
Control). 
As  the  non-poliovirus  HEV-C,  a  genome  closely  related  to  that  of  poliovirus  type  3  Leon 
was  chosen.  CVA21  exhibits  84.2%  identity  of  the  polyprotein  with  PV3  (Brown  et  al., 
2003).  The  amino  acid  identity  deduced  from  nucleotide  sequence  relationships  of  a  range 
of  HEV-C  viral  proteins  is  illustrated  in  appendices  3,4  and  5  of  this  thesis.  Other  HEV-Cs 
are  more  closely  related  to  PV3;  for  example  CVA20  has  90.2%  amino  acid  identity  to 
PV3.  However,  CVA21  was  the  closest  relative  to  PV3  for  which  an  infectious  clone  was Claire  Blanchard  In  vitro  recombination  Chapter  3  63 
available.  Recombinants  between  Sabin  1  P1-coding  region  and  the  remainder  of  the 
CVA21  genome  and  PV3  P1  coding  region  and  the  remainder  of  the  CVA21  genome 
were  generated  for  subsequent  investigation.  Reciprocal  recombinants  between  the 
structural  coding  region  of  CVA21  and  the  remainder  of  the  PV3  genome  were  also 
constructed. 
3.2  In  vitro  generation  of  recombinants 
3.2.1  Construction  of  recombinant  plasmid  DNA 
The  recombinant  sequences  were  generated  so  as  to  have  reciprocal  precise  exchanges  of 
heterologous  P  1-coding  regions  without  modifying  the  backbone  sequences.  The 
phenylalanine/glycine  (F/G  in  the  case  of  CVA21)  and  tyrosine/glycine  (Y/G  in  the  case  of 
PV3  and  Sabin  1)  amino  acid  sequences  at  the  VP  1/2A  junctions,  essential  for  correct 
processing  to  occur,  were  retained  (Luke  et  al.,  2001).  This  would  therefore  create  a  perfect 
exchange  of  the  P1-coding  region. 
3.2.1.1  Generation  of  backbone  cassette  vectors 
CVA21  and  PV3  backbone  vectors  lacking  the  P1-coding  regions  were  constructed.  The 
first  14  amino  acids  of  VP4  are  identical  in  human  enteroviruses.  Synonymous  codon 
variation  was  used  to  maintain,  in  the  case  of  PV3,  or  introduce,  in  the  case  of  CVA2  1,  a 
Sac  I  cloning  site  at  the  start  of  the  P1-coding  region  for  the  construction  of  backbone 
vectors. 
Synonymous  codons  were  also  used  to  maintain  the  native  amino  acid  sequence  at  the  start 
of  the  2A-coding  region  of  the  backbone  vectors.  PV3  and  CVA21  2A-coding  regions  start 
with  respective  GGC  and  GGG  codons  encoding  a  glycine  (G).  A  Sma  I  site  was  created Claire  Blanchard  In  vitro  recombination  Chapter  3  64 
by  PCR  in  the  PV3  backbone  vector,  where  the  second  half  of  the  site  (GGG)  replaced  the 
original  GGC  sequence  thereby  maintaining  the  amino  acid  at  the  start  of  the  PV3  2A. 
Similarly  a  Nae  I  site  was  introduced  by  PCR  in  the  CVA21  backbone  vector.  The  second 
half  of  the  Nae  I  site  has  a  GGC  sequence  coding  for  a  glycine  and  again  enabled 
conservation  of  the  glycine  present  at  the  start  of  the  native  CVA21  2A. 
3.2.1.1.1  PV3  backbone  vector  (PV3BK) 
The  PV3  backbone  vector  was  derived  from  pT7FLC/REP3  (Barclay  et  al.,  1998),  using 
GEN-3'BK'F  and  GEN-3'BK-R  oligonucleotide  primers  and  the  Nsi  I  restriction 
endonuclease.  The  PV3  backbone  vector  cloning  strategy  is  illustrated  figure  3.1. 
3.2.1.1.2  CVA21  backbone  vector  (CVA21BK) 
The  CVA21  backbone  vector  was  derived  from  pRibo-CAV21-NaelDel  (David  Williams). 
A  5'  fragment  of  the  5'UTR  and  start  of  the  coding-region  was  amplified  by  PCR  using 
T7-F  forward  primer  and  CA21-5'-BK-R  Sac  I-containing  reverse  primer.  The  5'  PCR 
fragment  was  ligated  to  a  Sac  I  digested  3'  fragment,  amplified  by  PCR,  using 
GEN-3'BK-F-Nae  (a  Sac  I  and  Nae  I-  containing  primer)  and  GEN-3'BK-R  (reverse 
primer  annealing  the  3C  coding-region).  A  3.9kb  ligated  fragment  was  re-amplified  by 
PCR  using  T7-F  and  GEN-3'BK-R.  The  Mlu  I  and  Bgl  II  double-digested  PCR  fragment 
was  then  ligated  to  a  Mlu  I  and  Bgl  II  double-digested  pRibo-CAV21-NaelDel.  The 
CVA21  backbone  vector  cloning  strategy  is  illustrated  figure  3.2.  The  clones  were  checked 
by  RFLP  analysis  and  sequencing  of  the  ligation  junctions. 
Once  the  backbone  vectors  were  constructed,  P1-coding  regions  were  introduced  to 
generate  recombinants.  The  complete  P1  sequences  were  generated  by  PCR  using  forward 
oligonucleotide  primers,  containing  a  Sac  I  site,  and  virus-specific  blunt  ended  reverse 
oligonucleotide  primers. Sac  1  (752) 
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Figure  3.1:  The  construction  of  pT7FLC/REP3-BK  (henceforth 
referred  to  as  PV3BK). 
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Figure  3.2:  The  construction  of  pRibo-CAV21-NaeDel-BK  (henceforth 
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First  the  backbone  vectors  had  to  be  checked  to  ensure  that  they  were  competent  to  make 
viable  vectors.  The  PV3  P1-coding  region  and  the  CVA21  P1-coding  region  were 
respectively  introduced  into  the  PV3  backbone  vector  (PV3BK)  and  the  CVA21  backbone 
vector  (CVA2IBK),  thereby  re-creating  full-length  sequences  of  the  source  genomes 
(figures  3.3  and  3.4).  The  clones  were  sequenced  at  the  key  junctions.  The  expected 
non-coding  changes,  introduced  by  PCR,  were  present  thereby  excluding  the  possible 
presence  of  contaminant  wild-type  sequences.  When  transfected  into  RD-ICAM  cells,  the 
homologous  recombinants  caused  a  cytopathic  effect  (CPE)  and  were  therefore  assumed  to 
be  viable.  Subsequent  cloning  of  heterologous  recombinants  was  then  carried  out. 
3.2.1.3  Generation  of  heterologous  P1  recombinants 
The  cloning  strategies  for  individual  clones  are  illustrated  in  figure  3.5,3.6  and  3.7. 
Sac  I-digested  blunt-ended  P1-coding  regions  amplified  by  PCR  were  introduced  to 
respective  Sac  I  and  Sma  I  double-digested  PV3  backbone  vector  and  Sac  I  and  Nae  I 
double-digested  CVA21  backbone  vector.  The  same  strategy  was  applied  to  all  the  clones. 
The  P1-coding  region  PCR  products  were  derived  from  pT7/SL3,  pRiboCAV21  and  pS1F 
using  a  generic  forward  primer  (P1-GEN-F)  and  specific  blunt-ended  reverse  primers 
(PV3-P1-R,  CVA21-PI-R  and  Sabin  1-P1-R).  The  remainder  of  the  genome  was  derived 
from  PV3BK  and  CVA21BK.  The  clones  were  checked  by  RFLP  analysis  and  sequencing 
of  the  5'UTR/P1,  complete  PI  and  VP1/2A  coding  regions  (see  table  3.8.2  and  figure  3.9). 
The  CVA2IBK  based  clones  were  constructed  in  practical  collaboration  with  David 
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The  in  vitro  generated  recombinants  were  named  in  two  parts.  The  second  part  of  the  name 
corresponded  to  the  origin  of  the  P  1-coding  region  and  the  first  part  of  the  name 
corresponded  to  the  source  of  the  remainder  of  the  genome  (see  table  3.8.1). 
Name  of  the  plasmid  as  indicated  in  the 
laboratory  database 
Henceforth  simplified  name  of  the 
plasmids 
pT7FLC/REP3-BK  PV3BK 
pRiboCAV21-NaeDel-BK  CVA21BK 
pT7FLC/REP3-BKSL3P1  PV3BKPV3P1 
pRibo-CAV21-NaeDel-BKCVA21  P1  CVA21  BKCVA21  P1 
pT7FLC/REP3-BK-CA21-P  1  PV3BKCVA21  1 
pRibo-CAV21-NaeDel-BKSabinlP1  CVA21BKSabinlP1 
pRibo-CAV21-NaeDel-BKSL3P1  CVA21BKPV3P1 
Table  3.8.1:  Names  of  constructed  plasmids Claire  Blanchard  In  vitro  recombination  Chapter  3  67 
Digested  plasmid  DNA  Bam  HI  (sizes  in  bp)  Bgl  H  (sizes  in  bp) 
pT7FLC/PV3  10996  8241 
133  1643 
1244 
PV3BK  8513  5626 
1643 
1244 
PV3BKCVA21P1  10998  8244 
133  1643 
1244 
pRiboCAV21  10429  10429 
CVA21BKCVA21P1  10429  10429 
CVA21  BKPV3P  1  10426  10426 
CVA21BKSabinlPl  10405  10435 
30 
pS1F  5721  10101 
2471 
1879 
30 
Table  3.8.2:  Predicted  RFLP  analysis  of  the  in  vitro  generated  P1  recombinants.  The 
fragments  expected  from  the  restriction  digests  reactions  are  in  base  pairs  (see  figure 
3.9  for  actual  result). 
The  RFLP  analysis  data  indicated  that  the  clones  constructed  were  correct.  The  key 
junctions  5'UTR/P1-coding  region  and  the  VP1/2A-coding  regions  of  the  constructed 
clones  were  checked  by  sequencing.  The  cDNA  sequence  of  the  entire  P  1-coding  region  of 
the  CVA21BKSabin1P1  61-9,  CVA21BKPV3P1  c6  and  PV3BKCVA21P1  3  clones  were 
also  determined  and  shown  to  be  correct  (data  not  shown).  The  clones  were  amplified, 
purified  from  bacterial  cultures  and  stored  in  the  laboratory  communal  stocks.  Subsequent 
analyses  were  then  initiated. A 
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Figure  3.9:  Restriction  length  polymorphism  analysis  of  in  vitro  generated 
Pl  recombinants  and  controls. 
Recombinants  and  controls  plasmid  DNA  was  digested  with  Bgl  11  (A)  and 
Bam  HI  (B)  and  run  on  a  I%  agarose  gel. Claire  Blanchard  In  vitro  recombination 
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Phenotypic  analysis  of  in  vitro  generated  recombinants  was  carried  out  by  transfection  of 
T7  RNA  transcripts  derived  from  linearised  plasmid  DNAs  in  both  RD-ICAM  cells  and 
HeLa  cells,  and  the  samples  were  screened  for  the  presence  or  absence  of  cytopathic  effect. 
3.3.1  Transfection  of  Pl  recombinants 
Transfection  of  the  chimeras  was  carried  out  in  a  Containment  Level  3  laboratory  (CL3). 
Recombinants  with  enhanced  pathogenicity  or  altered  tropism  could  be  generated  and 
higher  safety  levels  should  be  applied  when  handling  the  potential  viruses  resulting  from 
the  reaction.  The  CL3  rules  prevented  transfected  cells  from  being  imported.  All 
transfections  were  therefore  carried  out  in  a  CL3  laboratory  and  were  conducted  so  as  to 
avoid  the  production  of  aerosols. 
T7  RNA  transcripts  were  derived  from  linearised  plasmid  DNA,  purified,  quantified  by 
spectrophotometric  analysis  and  normalised.  Either  1  µg  or  5  gg  of  RNA  were  transfected, 
by  DEAE-dextran  or  Lipofectamine  2000,  into  RD-ICAM  cells  and  HeLa  cells.  RD-ICAM 
cells  and  HeLa  cells  support  infection  and  replication  of  both  parental  viruses  and  should 
therefore  be  permissive  for  infection  with  potential  chimeric  viruses.  The  transfection 
samples  were  incubated  at  37°C  with  5%  CO2  for  3-5  days  to  allow  for  any  recombinant 
viral  genomes  of  lesser  fitness  to  recover  and  be  amplified  by  repeated  replication/infection 
cycles.  Cells  were  examined  by  light  microscopy  to  observe  a  cytopathic  effect.  The  results 
are  shown  in  table  3.10.  No  photographic  evidence  was  provided  due  to  the  equipment 
restrictions  and  difficulty  of  removing  material  from  the  CL3  environment. Claire  Blanchard  In  vitro  recombination  Chapter  3  69 
Input  T7  RNA  transcripts  Cytopathic  effect  monitoring 
RD-ICAM  cells  HeLa  cells 
CVA21  0  N 
PV3  E  0 
pS1F  (Sabin  1) 
PV3BK 
0 
Q 
0 
Q 
PV3BKPV3P1 
PV3BKCVA21P1  1 
N 
Q 
0 
Q 
PV3BKCVA21P1  3 
PV3BKCVA21P1  4 
CVA21BK 
Q 
Q 
Q 
Q 
Q 
Q 
CVA21  BKCVA21  P1  0  N 
CVA21BKPV3P1  c6  Q  Q 
CVA21  BKSabin1P  1  61-5  Q  Q 
CVA21BKSabin1P1  61-9  Q  Q 
CVA21BKSabin1P1  66-6  Q  Q 
CVA21BKSabinIP  1  66-8  Q  Q 
CVA21BKSabin1P1  69-1  Q  Q 
CVA21BKSabin1P1  69-3  Q  Q 
PV3  linearised  in  3D  Q  Q 
Mock  transfection  Q  Q 
Cells  alone  Q  Q 
Table  3.10:  Cytopathic  readout  of  transfection  of  chimeric  T7  RNA  transcripts  into 
RD-ICAM  cells  and  HeLa  cells.  The  read-out  of  the  experiment  was  the  presence  ( ) 
or  absence  (o)  of  cytopathic  effect  observed  in  the  transfected  cell  sheet.  The  numbers 
after  each  plasmid  name  represent  individual  clone  numbers  resulting  from  the 
cloning  reaction. Claire  Blanchard  In  vitro  recombination  Chapter  3  70 
As  expected,  control  transfections  of  PV3,  CVA21  and  Sabin  1  RNAs  caused  CPE  in  cells 
after  both  transfection  and  serial  passage.  Similarly  CPE  was  observed  in  the  cells 
transfected  with  PV3BKPV3P1  and  CVA21BKCVA21P1  RNAs.  It  was  concluded  that  the 
experimental  system  allowed  virus  recovery  following  transfection  and  that  the  vectors 
could  be  used  as  a  basis  to  create  viable  recombinants.  These  were  consistent  with  the 
results  previously  seen. 
A  number  of  heterologous  P1  recombinant  clones  were  prepared  and  analysed.  These  were 
based  on  CVA21BK  and  PV3BK,  suffixed  with  clone  numbers,  and  were  expected  to 
behave  in  a  similar  manner.  RD-ICAM  cells  transfected  with  each  of  the  heterologous  P1 
recombinant  clones  RNAs  exhibited  very  low  levels.  of  CPE.  However,  serial  passage  of 
the  samples  did  not  appear  to  increase  CPE  and  it  appeared  as  though  viruses  could  not  be 
amplified.  The  initial  low  levels  of  CPE  observed  were  likely  to  have  been  induced  by  the 
production  and  activity  of  2A  protease,  a  cytotoxic  viral  protein.  The  assay  was  repeated 
on  several  occasions  and  the  same  results  were  obtained.  In  addition,  the  same 
observations  were  made  from  transfections  carried  out  in  HeLa  cells  indicating  that  the 
observed  results  were  not  cell  specific  and  were  reproducible  in  other  cell  lines.  The 
transfected  chimeric  T7  RNA  transcripts  did  not  cause  CPE  in  HeLa  cells.  The  results  were 
consistent  and  identical  to  those  observed  in  RD-ICAM  cells  (see  table  3.10).  It  is  possible 
that  the  transfection  of  recombinants  did  not  give  rise  to  viable  viruses  or  that  acytopathic 
viruses  were  produced,  explaining  the  lack  of  CPE. 
The  CVA2IBKCVA2IP1  and  PV3BKPV3P1  clones  were  viable  thus  indicating  that  there 
were  no  defects  in  the  backbone  vectors.  It  appeared  unlikely  that  the  recombinants  had 
errors  in  the  sequences  as  all  the  clones  were  derived  from  the  CVA21BK  and  PV3BK Claire  Blanchard  In  vitro  recombination  Chapter  3  71 
vectors.  Furthermore,  RFLP  analysis  and  sequencing  of  key  junctions  of  all  the  clones  and 
complete  P1  coding  region  sequencing  of  the  CVA21BKSabin1Pl  61-9, 
CVA21BKPV3P1  c6  and  PV3BKCVA21P1  3  chimeras  confirmed  there  were  no  errors  in 
the  constructed  clones.  It  therefore  seemed  likely  that  the  inability  to  produce  viable  virus 
was  due  to  a  defect  in  the  replication  cyle,  rather  than  the  chimeric  viral  genome.  Further 
characterisation  of  the  in  vitro  generated  recombinants  was  therefore  initiated.  The  possible 
acytopathogenicity  of  the  in  vitro  generated  P1  recombinants  was  investigated  by  an 
immunofluorescence  assay  to  detect  virus  antigen. 
3.3.2  Immunofluorescence  study  of  viral  protein  expression  and 
determination  of  the  acytopathogenic  phenotype  of  chimeras 
Immunofluorescence  analysis  was  carried  out  to  detect  VP  1  protein  production,  using  a 
specific  anti-enterovirus  VP1  mouse  monoclonal  antibody  (DAKO).  The  specificity  of  the 
antibody  for  the  P1  capsid  precursor  protein  was  unclear.  Subsequent  in  vitro  translation 
studies  appeared  to  indicate  that  the  antibody  was  specific  to  VP  1  as  no  extra  bands  were 
observed  in  western  blot  analysis  (see  figure  3.17). 
The  VPI  capsid  protein  production  would  be  expected  to  occur  post-transfection.  Viable 
chimeric  viruses  would  be  expected  to  produce  VPI  and  protein  expression  would  be 
detected  after  passage  of  RNAse  treated  transfected  samples.  The  detection  of  VP  I 
expression  in  both  transfected  RD-ICAM  cells  and  RD-ICAM  cells  in  which  harvested 
RNAse  treated  samples  had  been  passaged  would  suggest  that  the  chimeric  viruses  were 
acytopathic. 
Duplicates  of  the  transfected  cells  were  lysed  to  release  any  intracellular  virus  particles, 
samples  were  harvested  and  RNAse  treated  to  prevent  RNA  carry  over  onto  a  fresh  cell Claire  Blanchard  In  vitro  recombination  Chapter  3  72 
sheet.  The  harvested  samples  were  passaged  onto  fresh  cell  sheets  and  VP  1 
immunolabelling  was  conducted.  Cells  were  treated  with  a  primary  anti-VP1  DAKO 
mouse  monoclonal  antibody  followed  by  treatment  with  a  secondary  anti-mouse 
FITC-conjugated  polyclonal  antibody  (see  appendix  1).  Sample-coverslips  were  mounted 
on  slides  and  visualised  using  a  confocal  microscope.  All  the  confocal  imaging  was  carried 
out  at  the  same  time.  The  results  are  illustrated  in  figure  3.11,3.12  and  3.13  using  a  range 
of  magnifications. 
VP  1  expression  was  detected  in  cells  transfected  and  passaged  with  control  samples  PV3, 
Sabin  1  and  CVA21.  These  control  samples  are  known  to  produce  cytopathic  viruses. 
These  results  suggested  the  assay  had  been  successful.  Mock  transfection  and  passage 
controls  were  carried  out  in  parallel  as  negative  controls  for  non-FITC  labelled  cells  and 
did  not  exhibit  expression  of  VP1  after  transfection  or  passage.  A  PV3-infected  control 
singly  labelled  with  the  secondary  FITC-conjugated  antibody  was  used  as  a  control  for 
monitoring  background  levels  of  non-specific  detection  of  FITC  fluorescence. 
VP  1  expression  was  detected  in  all  cell  sheets  transfected  with  RNA  derived  from 
recombinant  cDNAs  but  not  in  other  cells.  A  weak  signal  was  detected  in  the  cells 
passaged  with  the  CVA21BKSabin1Pl  RNA  transfected  cell  harvest  solutions.  The 
detection  of  VP1  expression  in  the  transfected  cells  indicated  that  translation  had  occurred. 
The  lack  of  VP  1  expression  in  cells  passaged  with  samples  harvested  from  the  chimera 
transfections  would  suggest  that  the  recombinants  were  not  acytopathic.  If  the 
recombinants  were  acytopathic  the  levels  of  VP1  expression  in  the  passage  samples  were 
below  the  level  of  detection  by  immunofluorescence.  These  results  suggested  that  the 
defect  had  to  be  at  some  stage  post-transfection,  such  as  processing,  replication,  packaging, 
assembly,  and  release  or  host  cell  entry.  Further  experiments  were  conducted  to  investigate PV3E3KCVA21P1  3 
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Figure  3.11:  Detection  of  P\  3BK('%'.  %21P1  3  VPI  expression 
fhe  left  hand  Column  represent  the  pictures  of  transfected  cells  and  the  right  hand  column  are  pictures 
of  the  supernatant  passaged  onto  fresh  cell  sheets  RNA  transcripts  from  the  indicated  plasmids  were 
transfected  into  RD-ICA\1  cells.  The  presence  of  VP1  virus  antigen  was  determined  by 
immunotluorescence  analysis  using  as  primary  antibody  the  anti-HEV  VPI  (DAKO)  \1Ab  at  10  hours 
post-transfection  or  10  hours  after  passaging  of  RNAse-treated  culture  supernatant  to  fresh  cells.  Mock 
transfected  cells  are  also  shown. CVA2IBKSabinlPl  61-5 
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Figure  3.12:  Detection  of  CV.  &2IBkSabinIP1  61-5  and  61-9  VP1  expression 
I  he  left  hand  column  represent  the  pictures  of  transfected  cells  and  the  right  hand  column  are  pictures 
ofthe  supernatant  passaged  onto  fresh  cell  sheets.  RNA  transcripts  from  the  indicated  plasmids  were 
transfected  into  RI)-IC.  \M  cells.  The  presence  of  VPl  virus  antigen  was  determined  by 
immunotluorescence  analysis  using  as  primary  antibody  the  anti-HEV  VPI  (DAKO)  MAb  at  10  hours 
post-transfection  or  10  hours  after  passaging  of  RNAse-treated  culture  supernatant  to  fresh  cells.  Mock 
transfected  cells  are  also  shown. CVA2IE3hPV3PI  c6 
(\\,  I 
p\ 
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f Figure  3.13:  Detection  of  ('N.  121  B1:  P%  3P1  e6  VP1  expression 
The  left  hand  column  represent  the  pictures  oftransfected  cells  and  the  right  hand  column  are  pictures 
of  the  supernatant  passaged  onto  fresh  cell  sheets.  RNA  transcripts  from  the  indicated  plasmids  were 
transtected  into  RD-ICAM  cells.  The  presence  of  VPI  virus  antigen  was  determined  by 
immunotluorescence  analysis  using  as  primary  antibody  the  anti-1IEV  VPl  (DAKO)  MAb  at  10  hours 
post-transfection  or  10  hours  after  passaging  of  RNAse-treated  culture  supernatant  to  fresh  cells.  Mock 
transfected  cells  are  also  shown. Claire  Blanchard  In  vitro  recombination  Chapter  3  73 
the  defect.  As  the  results  suggested  that  translation  had  occurred,  in  vitro  translation  assays 
were  undertaken  to  confirm  the  initial  observations. 
3.3.3  In  vitro  translation 
The  processing  of  the  P1  capsid  precursor  and  its  cleavage  from  the  non-structural  proteins 
are  mediated  by  two  viral  proteases,  3C  and  2A.  The  proteases  and  the  capsid  proteins,  in 
the  in  vitro  generated  recombinants,  are  derived  from  separate  viral  sources  and  processing 
could  be  absent,  incomplete  or  inefficient  due  to  an  incompatibility  of  the  proteases  with 
the  P1  capsid  precursors.  Therefore  the  investigation  of  the  protein  processing  properties  of 
the  in  vitro  generated  chimeras,  by  in  vitro  translation  assays,  was  essential.  Initial 
characterisation  of  wild-type  viral  proteins  and  processing  pattern  was  therefore  conducted. 
3.3.3.1  Wild-type  controls  characterisation 
Radiolabelled  infected  cell  lysates  of  control  viruses  CVA21,  PV3  and  Sabin  1  were 
prepared  as  an  in  vivo  source  of  large  amounts  of  correct  processing  products  (figure  3.14). 
These  were  later  used  for  comparison  with  the  in  vitro  processing  products,  obtained  using 
HeLa  S  10  extracts.  Control  radiolabelled  infectious  virus  particles,  with  a  sedimentation 
coefficient  of  160S,  were  also  prepared  in  parallel,  to  identify  the  capsid  proteins.  VP  I, 
VP3  and  sometimes  VP2  of  the  160S  particles  were  observed  on  the  gels  and  comparison 
with  the  migration  patterns  exhibited  by  the  infected  cell  lysates  samples  enabled  the 
identification  of  capsid  proteins  (see  appendix  1).  These  are  illustrated  in  figure  3.14. 
CVA21  160S  particles  and  Sabin  1  infected  cell  lysates  consistently  labelled  poorly. 
CVA21  VP  1  and  VP3  labelled  protein  bands  are  indicated  with  dots  in  figure  3.14.  CVA21 
VP2  detection  was  not  apparent  due  to  the  poor  labelling  of  the  virus. .J 
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Figure  3.14:  Wild  ty  pe  characterisation  of  Pß'3,  CVA21  and  Sabin  1  capsid 
proteins  using  160S  %irus  particles  and  infected  cell  lysates. 
12.  E  tiUS-PAGE:  gel  ofthe  PV3,  CVA21  and  Sabin  I  processing  pattern  and 
identification  of  capsid  proteins.  CVA21  160S  particles  consistently  labelled  poorly 
and  the  labelled  VP  I  and  VP3  bands  are  highlighted  with  dots.  Overexposure  of  the  gel 
shoNNed  the  presence  of  an  extra  band  migrating  slightly  slower  than  VP3  in  the 
radiolabelled  CVA21  160S  sample  lane. 
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The  SDS-PAGE  gel  (figure  3.14)  shows  that  CVA21  and  PV3  exhibited  a  similar 
migration  pattern  for  the  P1,2BC,  2C  and  3CD  proteins.  However,  VP1,  VP3  and  2A 
proteins  of  PV3,  CVA21  and  Sabin  1  control  viruses  differed  in  their  migration  patterns 
and  were  therefore  diagnostic  for  the  relevant  parental  sequences  of  each  chimera.  CVA21 
VP1  appeared  to  migrate  faster  than  Sabin  1  VP  1,  which  itself  migrated  faster  than  PV3 
VP  1.  Similarly,  CVA21  VP3  migrated  fastest  whereas  PV3  VP3  migrated  slowest.  The 
CVA21  2A  protease  appeared  to  migrate  faster  than  PV3  2A  and  pS1F  2A,  which  migrated 
the  slowest. 
Once  characterisation  of  control  viruses  processing  patterns  was  completed,  in  vitro 
transcription/translation  assays  using  HeLa  S  10  nuclear  extracts  supplemented  with  flexi 
rabbit  reticulocyte  lysates  were  conducted  to  determine  the  products  encoded  by  the 
chimeras.  The  reactions  were  denatured  and  run  on  a  12.5%  SDS-PAGE  gel  for  analysis. 
The  results  are  shown  in  figures  3.15,3.16  and  3.18. 
3.3.3.2  PV3BKCVA21P1  recombinants 
The  in  vivo  infected  cell  lysates  samples  patterns  and  the  in  vitro  patterns  obtained  using 
HeLa  S10  nuclear  extracts  of  control  viruses  were  compared  on  the  PV3BKCVA21P1 
processing  gel  (figure  3.15).  These  patterns  were  similar,  apart  from  few  additional  cellular 
proteins  present  in  the  in  vivo  infected  cell  lysates.  The  CVA21  and  PV3  infected  cell 
lysates  samples  consistently  migrated  slightly  faster  than  other  lanes.  This  was  taken  into 
consideration  for  recombinant  sample  analysis. 
The  PV3BKCVA21P1  recombinants  appeared  to  exhibit  the  correct  processing  pattern  (see 
figure  3.15).  PV3BKCVA21P1  recombinants  should  express  a  PV3  non-structural  protein 
pattern  and  a  CVA21  capsid  protein  pattern.  3CD,  P1,2BC  and  2C  could  not  be  used  for 
comparison  purposes  since  the  migration  pattern  of  these  proteins  did  not  differ  amongst IZI 
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Figure  3.15:  PV'3Bk('\A21P1  recombinants  in  vitro  translation  reaction  (using 
Hel.  aSIll  extracts  supplemented  with  rabbit  flexi  reticulocvte  lysates). 
lOkDa 
fhc  samples  Mere  run  alongside  the  2  control  viruses.  PV3BKCVA21P1  1, 
PV3BKCV.  421  Pl3.  PV3BKCVA21  Pl  4  represent  individual  clones  isolated  from  the 
cloning  experiment.  The  arrows  highlight  the  bands  used  for  characterisation  and  analysis 
and  the  asterisk  represent  an  unidentified  band  in  one  of  the  recombinant  samples.  PV3  and 
CV112  I  infected  cell  lysates  appeared  to  migrate  faster  than  PV3  and  CVA2  I  HeLa  SIO 
samples. 
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various  samples.  PV3BKCVA21P12A  had  the  same  migration  phenotype  as  that  of  PV3 
2A  and  migrated  slightly  slower  than  the  CVA21  2A.  However,  the  CVA21  S10  sample 
consistently  labelled  poorly  and  2A  was  hardly  detectable  on  the  protein  gel.  These  results 
indicated  that  the  non-structural  proteins  of  the  PV3BKCVA21P1  recombinants  appeared 
to  be  PV3-like. 
VP1  of  CVA21  and  PV3  had  similar  migration  patterns  and  could  not  be  used  as 
identification  proteins  for  the  PV3BKCVA21P1  recombinants  analysis.  However,  VP3  of 
PV3  migrated  significantly  slower  than  CVA21  VP3  and  the  gel  demonstrated  that 
PV3BKCVA21P1  VP3  was  CVA21  VP3-like.  The  results  suggested  that 
PV3BKCVA21P1  3  and  PV3BKCVA21P14  proteins  were  correct  and  that  the  processing 
pattern  in  vitro  was  also  correct.  Therefore  the  P1  of  CVA21  was  processed  in  trans  by  the 
3CD  of  poliovirus. 
VP1  of  the  PV3BKCVA21P1  1  recombinant  migrated  slower  than  that  of  other 
recombinants  and  control  viruses  (indicated  by  an  asterisk  in  figure  3.15). 
PV3BKCVA21P1  1  VP1  was  aberrant  in  size  and  appeared  to  be  approximately  35  kDa  as 
opposed  to  native  VP1,  which  is  approximately  33  kDa.  The  2A  protease  being  correct, 
inefficient  2A-mediated  cleavage  event  could  not  have  caused  the  observed  result.  The 
2-kDa  difference  in  size  would  correspond  to  an  18  amino  acid  difference,  or 
54  nucleotides.  This  difference  in  size  would  not  have  been  apparent  during  the  RFLP 
analysis  of  the  clone.  Moreover,  initial  sequencing  analysis  of  the  constructed  clones  was 
restricted  to  the  5'UTRNP4  and  VP1/2A  junctions.  Complete  sequencing  of  the  P1-coding 
region  was  only  carried  out  on  the  clones  that  appeared  to  express  the  correct 
protein-processing  pattern  but  not  on  the  PV3BKCVA21P1  1  clone.  Either  PCR  error  or 
aberrant  processing  at  the  VP3/VP1  junction  could  account  for  the  observed  result. Claire  Blanchard  In  vitro  recombination 
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Comparison  of  the  infected  cell  lysates  with  the  HeLa  S10  samples  of  CVA21,  PV3  and 
Sabin  1  control  viruses  demonstrated  similar  processing  patterns.  The  in  vivo  samples 
consistently  migrated  slightly  faster  than  the  in  vitro  samples.  The  in  vivo  samples  are  not 
shown  in  the  CVA21BKSabinIP1  and  CVA2IBKPV3P1  SDS-PAGE  gels  due  to  poor  gel 
quality. 
The  results  of  the  CVA21BKSabin1Pl  SDS-PAGE  gel  are  illustrated  in  figure  3.16.  VP3 
and  2A  were  the  two  proteins  used  for  the  identification  and  analysis  of  the 
CVA21BKSabinlPI  recombinants  in  vitro  processing.  The  gel  shows  that  VP3  of  the 
CVA21  BKSabin  1P1  recombinants  migrated  as  Sabin  1  VP3  and  2A  migrated  as  CVA21 
2A  (see  figure  3.16).  The  presence  of  VP1,  as  opposed  to  the  uncleaved  VP1/2A  product, 
was  detected  by  DAKO  anti-VP  1  labelling  western  blot.  VP  1  was  present  in  all  the 
samples,  apart  from  the  mock,  and  was  estimated  to  be  the  correct  size  (see  figure  3.17). 
No  other  bands  were  present  on  the  western  blot,  confirming  the  specificity  of  the 
antibody,  the  correct  cleavage  of  the  P1  capsid  protein  precursor  from  the  non-structural 
proteins  and  efficient  processing  into  VP  I. 
The  CVA21  BKPV3P  1  c6  recombinant  processing  pattern  was  then  analysed  (figure  3.18). 
CVA21BKPV3P1  c6  appeared  to  express  a  PV3  VP3  migration  pattern  and  a  CVA21  2A 
migration  pattern  suggesting  that  the  recombinant  processed  efficiently  in  vitro.  It  is 
important  to  note  that  the  PV3  P1  chimera  consistently  labelled  poorly,  explaining  the  poor 
quality  of  the  SDS-PAGE  analytical  gel. 
However  in  vitro  translation  did  not  enable  the  study  of  the  kinetics  of  the  processing 
cascade  and  in  vivo  translation  should  be  investigated.  Pulse-chase  labelling  type  assays bb 
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Figure  3.16:  ('VA21  BKSabinIP1  recombinants  in  vitro  translation  reaction 
(using  HelaSIO  extracts  supplemented  with  rabbit  flexi  reticulocyte  l)'sates). 
The  sample  was  run  alongside  the  2  control  viruses.  C  VA2113KSabin  IP1  61-5.61-9, 
66-6.66-8.69-1.69-3  represent  individual  clones  isolated  from  the  cloning 
experiment.  The  arrows  highlight  the  bands  used  for  identification  and 
characterisation. 1  50  k-  Da 
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Figure  3.17:  Western  Blot  probing  for  HEM'  ß'PI 
ý 
VPI  western  blotting  using  a  11EV-specific  DAKO  anti-VP  1  mouse  monoclonal 
antibody  (1:  1000).  Samples,  generated  during  the  in  vitro  S  10 
translation/processing  assay,  were  run  on  an  SDS-PAGE  gel,  transferred  onto  a 
membrane  for  protein  analysis  and  probed  for  VP  1.  A  secondary  anti-mouse 
HRPO-conjugated  secondary  antibody  was  then  used  at  a  dilution  of  1/5000  in 
PUS-A.  The  western  blot  was  developed  with  ECL  western  blot  developing 
reagents  for  a  couple  of  minutes  and  exposed  on  an  X-Ray  film.  The  film  was 
developed  and  the  hands  represent  VP1  proteins. 
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Figure  3.18:  ('\12I  BKP\'3P1  c6  recombinant  in  vitro  translation  reaction 
(using  llelaSIO  extracts  supplemented  with  rabbit  flexi  reticulocyte  lysates). 
The  samples  were  run  alongside  the  two  control  viruses.  The  arrows  highlight  the 
hands  used  for  identification  and  characterisation  of  the  recombinant  processing 
pattern.  Poor  labelling  of  the  C  VA2I  BKPV3PI  c6  sample  was  consistently  observed. Claire  Blanchard  In  vitro  recombination  Chapter  3  77 
based  on  transfection  would  not  be  practical.  It  is  therefore  possible  that  the  recombinants 
may  have  temporal  defects  in  translation. 
In  vitro  translation  assays  suggested  that  the  correct  proteins  were  produced  and  the 
processing  pattern  appeared  to  be  authentic.  The  recombinant  proteins  were  consistently 
processed,  the  P1  and  the  VP1  proteins  released  from  the  non-structural  proteins  and  the 
proteins  involved  in  replication  expressed.  The  chimeras  would  therefore  look  like 
sub-genomic  replicons  and  would  be  expected  to  replicate.  Replication  of  the  virus 
genomes  was  therefore  analysed  by  dot  blot  hybridisation  assays. 
3.3.4  Replication  assay 
Replication  studies  were  carried  out  as  described  in  Chapter  6:  Materials  and  methods. 
RNA  samples,  normalised  to  I  µg,  were  transfected  individually  into  RD-ICAM  cells.  The 
transfected  cells  were  harvested  at  different  time  points  post-transfection  and  viral  RNA 
extraction  was  carried  out.  The  RNA  samples  were  then  transferred  and  fixed  onto  a 
membrane  and  hybridised  to  a  generic  [32P]  probe.  The  probe  was  expected  to  bind  the  3D 
polymerase-coding  region  of  all  viral  RNAs  used  in  the  reaction  and  would  therefore  be 
expected  to  enable  quantification  of  RNA  production.  The  membrane  was  exposed  to  a 
phosphoimager  screen.  Figure  3.19  shows  an  example  dot  blot  membrane.  Radioactivity 
was  then  quantified  and  plotted  onto  graphs.  The  results  are  expressed  in  percentage  fold- 
increase  of  viral  RNA  levels  and  are  illustrated  in  figures  3.20  and  3.21  and  summarised  in 
table  3.22. Claire  Blanchard  In  vitro  recombination  Chapter  3  78 
Samples  Replication  phenotype 
CVA21BKSabinlPl  61-5  +++ 
CVA21BKSabin1P1  61-9  + 
CVA21BKPV3P1  c6  +++ 
PV3BKCVA21P1  1  + 
PV3BKCVA21P1  3  + 
pRiboCVA21  ++/++ 
pS1F  ++ 
PV3  +++ 
PV3  +  4mM  GuHCI 
- 
Cells  alone  /  mock  transfection  - 
Table  3.22:  Summary  of  replication  phenotype  determination  assay  of  in  vitro  P1 
recombinants.  The  replication  phenotype  was  determined  from  graphs  obtained, 
figure  3.20  and  3.21,  based  on  [32P1  signal  detection  and  quantification.  Replication 
competent  (+)  and  replication  incompetent  (-)  samples  are  illustrated.  Number  of  + 
signs  indicate  different  levels  of  replication  (see  graphs  3.20  and  3.21). 
Graphs  summarising  the  results  of  the  time  course/dot  blot  assay  are  illustrated  figures  3.20 
and  3.21.  The  control  samples  behaved  as  expected.  The  control  CVA21  and  PV3  parental 
genomes  exhibited  an  increased  signal  over  time  indicating  that  these  were  replicating. 
PV3  transfected  in  the  presence  of  4mM  GuHCI,  an  inhibitor  of  viral  replication  (Molla  et 
al.,  1993),  did  not  replicate. 
However,  the  Sabin  1  genome  control  sample,  derived  from  the  pS1F  infectious  clone, 
showed  apparent  lower  replication  levels  than  the  PV3  and  CVA21  controls.  This  was 
surprising  considering  the  in  vitro  protein-processing  pattern  of  Sabin  1  appeared  to  be 
correct.  However,  throughout  the  project  the  pS1F  plasmid  caused  problems  and  exhibited ý 
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a  few  unexplained  abnormalities,  such  as  slow  virus  production  and  genome  replication.  It 
is  not  clear  why  this  was  the  case. 
All  the  recombinants  exhibited  different  levels  of  replication.  The  PV3BKCVA21P1  1  and 
PV3BKCVA21P1  3  recombinants  appeared  to  be  replication-competent.  However,  levels 
of  replication  were  not  as  high  as  those  observed  in  the  positive  control  samples  (see  figure 
3.20).  The  CVA21BKPV3P1  c6  recombinant  appeared  to  be  highly  efficient  at  replicating. 
The  CVA21BKSabinIP1  61-9  recombinant  replication  seemed  to  be  at  least  as  efficient  as 
the  control  virus  replication.  CVA21BKSabinlP1  61-5  was  also  replication-competent  but 
to  lower  levels  than  those  observed  in  the  other  test  samples  (see  figure  3.21).  These  results 
confirmed  the  in  vitro  translation  assay  initial  findings  whereby  the  correct  proteins  had 
been  synthesised  and  could  catalyse  the  replication  process. 
Under  the  conditions  used,  the  levels  of  replication  at  different  time  points  were 
reproducible.  Each  individual  clone  analysed  is  characteristic  and  consistent  with  previous 
assays.  The  assay  needs  to  be  repeated  for  the  data  to  be  statistical  relevant.  Repeating  the 
assay  in  L  cells  may  enable  cleaner  and  more  statistically  relevant  data  to  be  generated. 
The  defect,  which  prevented  the  chimeras  from  causing  cytopathic  effect  must  therefore  be 
due  to  a  late  event  such  as  maturation,  assembly,  packaging  or  infection  of  new  cells. 
Because  of  the  availability  of  relevant  expertise  and  reagents,  the  packaging  phenotype  of 
the  recombinants  was  analysed. 
3.3.5  Trans-encapsidation  assays 
The  trans-encapsidation  assays  were  conducted  to  determine  whether  the  P1  recombinant 
viral  genomes  had  a  packaging  defect. Claire  Blanchard  In  vitro  recombination 
3.3.5.1  Trans-encapsidation  experiment 
Chater  3  80 
3.3.5.1.1  Method 
The  trans-encapsidation  assay  was  conducted  to  monitor  whether  the  T7  RNA  transcripts 
of  the  P1  recombinants  and  progeny  RNA,  synthesised  after  transfection  of  the  transcripts 
into  RD-ICAM  cells,  could  be  encapsidated  by  CVA21  or  PV3  helper  viruses  (protocol 
described  in  figure  3.23).  Both  CVA21  and  PV3  are  infectious  and  generate  viral  capsid 
proteins  that  assemble  and  package  progeny  genomes  leading  to  the  production  of  mature 
virions.  Chimeric  genomes  being  packaged  into  the  helper  virus  empty  capsids  would 
demonstrate  that  the  recombinants  are  competent  for  packaging. 
The  recombinants  are  effectively  replicon  systems,  as  they  are  able  to  translate,  process 
and  replicate.  However,  these  lack  a  reporter  gene  or  other  readily  assayable  marker  and 
encapsidation  was  therefore  screened  for  by  PCR.  An  RFLP  type  analysis  was  then  carried 
out  to  differentiate  between  chimeric  genomes  packaged  into  helper  virus  capsids  and 
helper  viruses,  taking  advantage  of  the  differences  at  the  5'UTR/P1-coding  regions. 
T7  RNA  transcripts  derived  from  the  recombinants  and  controls  were  transfected  into 
RD-ICAM  cells.  Six  hours  post-transfection  the  samples  were  infected  with  the  helper 
viruses  and  incubated  for  8-10  hours.  Viral  RNA  was  extracted  from  the  various  samples 
and  reverse  transcribed  to  generate  cDNA.  A  900-1000  bp  window  of  the  cDNA 
5'UTR/P  1-coding  regions  were  amplified  by  PCR,  using  generic  oligonucleotide  primers 
(CVA21-CAPF  and  ENT-GEN-2R),  digested  with  Bam  HI  endonuclease  and  run  on  a  2% 
agarose  gel  for  analysis.  Predicted  RFLP  patterns  were  generated  using  Vector  NTI  and  are 
illustrated  in  figures  3.24  and  3.25.  The  ability  of  Vector  NTI  to  predict  priming  of 
oligonucleotide  to  sequences  does  not  take  into  consideration  factors  such  as  PCR Transfection  of  in  vitro  generated  recombinant  T7RNA  transcript 
1 
80%  confluent  RD-ICAM  cells 
1 
Incubation  at  37°C  for  6  hours 
1  Infection  with  helper  virus  at  an  moi  of  10 
1  Incubation  at  37°C  for  8-10  hours  to  allow  for  helper  virus 
progeny  capsids  synthesis  and  recombinant  genome  encapsidation 
1  I  lan  esting  of  viruses  and  RNase  A  treatment  to  avoid  any  carry  over  of 
RNA  and  to  ensure  only  ancapsidated  RNA  infects  the  new  cell  sheet 
1 
f'aaaýýe  Unto  a  fresh  cell  sheet  of  80%  confluent  RD-ICAM  cells 
1  I  Ian  sting  of  iruscs  and  DNase  treatment  to  avoid  detection  of 
a  non-specific  signal  in  RT-PCR  reaction 
1  Reverse  transcription  of  isolated  ,  RNA  and  newly  synthesised  cDNA 
analysis  by  PCR  amplification  and  restriction  digest 
Figure  3.23:  Flo"  chart  summarising  the  method  and  analysis  of  the  trans- 
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conditions  like  the  magnesium  concentrations  or  the  annealing  temperatures  and  does  not 
necessarily  give  a  true  representation  of  what  is  actually  generated. 
pRiboCAV21  and  pSIF  control  RNAs  were  transfected  individually  and  co-infected  with 
PV3  virus  (figure  3.28).  pT7FLC/PV3  and  pSIF  control  RNAs  were  also  transfected 
individually  and  co-infected  with  CVA21  virus  (figure  3.28).  These  control  samples  were 
carried  out  in  parallel  to  monitor  the  efficiency  of  the  assay  and  to  ensure  that  successful 
heterologous  packaging  had  occurred.  The  Bam  HI  digestion  was  carried  out  on  a  series  of 
PCR  products  amplified  from  control  plasmid  sequences:  pT7FLC/PV3,  pRiboCAV21, 
pSIF,  PV3BKCVA21P1  3,  CVA21BKSabin  1P1  61-9  and  CVA21BKPV3P1  c6  (figure 
3.27).  The  expected  sizes  of  fragments  resulting  from  both  digestion  of  the  plasmid 
amplified  sequences  and  of  the  encapsidation  samples  are  shown  in  table  3.26. ýy 
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Figure  3.24:  Predicted  RT-PCR-Bam  HI  RFLP  analysis  of  the 
trans-encapsidation  experiment  with  PV3  helper  virus. 
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Figure  3.25:  Predicted  RT-PCR-Bam  HI  RFLP  analysis  of  the 
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Trans-encapsidation  samples  :  RNA  +  virus  Bam  HI  digests  (in  kb) 
PV3BKCVA21P1  3+  PV3  virus 
0.433,0.430,0.393,0.313,0.213, 
0.133 
CVA21  SabinlP  161-9  +  PV3  virus  0.9,0.433,0.313,0.213 
CVA21BKPV3P1  c6  +  PV3  virus  0.615,0.433,0.344,0.313,0.213 
pS  IF  +  PV3  virus  0.9,0.433,0.313,0.213 
pRiboCVA21  +  PV3  virus  0.535,0.454,0.433,0.313,0.213 
PV3BKCVA21P1  3+  CVA21  virus  0.535,0.454,0.430,0.393,0.133 
CVA21  Sabin  1P  161-9  +CVA21  virus  0.9,0.535,0.454 
CVA21BKPV3P1  c6  +  CVA21  virus  0.615,0.535,0.454,0.344 
PSI  F+  CVA21  virus  0.9,0.535,0.454 
pT7FLC/PV3  +  CVA21  virus  0.535,0.454,0.433,0.313,0.213 
pT7FLC/PV3  0.433,0.313,0.213 
pRiboCVA21  0.535,0.454 
pS1F 
No  fragment  generated,  CAV21- 
CAPF  does  not  anneal  to  pS1F. 
PV3BKCVA21P1  3  0.430,0.393,0.133 
CVA21BKSabin1P1  61-9  0.9 
CVA21BKPV3P1  c6  0.615,0.344 
Table  3.26:  RFLP  analysis  of  alternative  trans-encapsidation  assay  sample  testing  for 
packaging  capacity  of  in  vitro  generated  P1  recombinant  DNAs.  Fragments  expected 
from  the  Bam  HI  restriction  digests. a 
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Figure  3.28:  Analysis  of  trans-encapsidation  assay  by  P('R  and  Bam  III  RFLP 
analysis. 
The  dots  in  figure  A  indicate  artefeacts  seen  in  the  vRNA/RT-PCR/digests  of  CVA21 
virus  sho%%n  in  figure  B.  These  were  therefore  not  taken  into  consideration  during  the 
analysis  of  results. Claire  Blanchard  In  vitro  recombination  Chapter  3  83 
3.3.5.1.2  Results  and  analysis 
3.3.5.1.2.1  Plasmid  controls 
PCR  and  Bam  HI  RFLP  analysis  of  pT7FLC/PV3,  pRiboCVA21,  pS1F,  PV3BKCVA21P1 
3,  CVA21BKSabin1P1  61-9  and  CVA21BKPV3P1  c6  control  plasmid  DNAs  are 
illustrated  figure  3.27.  The  fragment  sizes  obtained  were  as  expected  and  were  used  as 
controls  for  sample  analysis.  The  generation  of  an  unexpected  -0.9  kb  PCR  product 
resulting  from  amplification  of  pS  IF  was  surprising.  The  observed  result  could  have  been 
due  to  the  CVA21-CAPF  oligonucleotide  predicted  to  bind  pS1F  0.927  bp  upstream  of  the 
ENT-GEN-2R  pS  1  F-binding  site  with  45%  homology. 
3.3.5.1.2.2  Virus  controls 
Control  infections  of  RD-ICAM  cells  with  CVA21,  PV3  and  Sabin  1  virus  samples  were 
also  undertaken  (see  figure  3.28.8).  The  PCR/RFLP  investigation  of  the  PV3  infected 
sample  generated  the  expected  fragments.  The  CVA21  infected  sample  study  exhibited  two 
additional  unidentified  bands,  not  detected  in  the  plasmid  digests  (result  discussed  later). 
The  PCR/RFLP  analysis  of  Sabin  1  did  not  yield  fragments,  as  initially  expected.  This 
conflicted  with  the  pS1F  plasmid  control  analysis.  It  could  have  been  due  to  the 
CVA21-CAPF  oligonucleotide  having  primed  a  vector-specific  site,  not  present  in  the 
Sabin  1  viral  genome.  The  Sabin  1  data  were  not  used  for  further  analysis. 
3.3.5.1.2.3  Trans-encapsidation  by  PV3  helper  virus  capsids 
The  control  sample  of  pRiboCAV21  RNA  +  PV3  virus  showed  PV3  fragments  as  well  as 
CVA21  fragments.  It  is  important  to  emphasize  that  the  detection  of  both  CVA21  and  PV3 
bands  could  have  been  due  to  both  PV3  helper  virus  and  CVA21  virus  production  from 
pRiboCVA21  RNA  transfection.  However,  the  presence  of  both  CVA21  and  PV3  bands Claire  Blanchard  In  vitro  recombination  Chapter  3  84 
could  indicate  that  pRiboCAV21  derived  genomic  RNA  had  been  encapsidated  in  PV3 
capsids. 
The  screening  method  used  in  this  assay  did  not  enable  the  detection  of  Sabin  1-specific 
bands,  as  one  of  the  oligonucleotide  primers  used  for  amplification  was  unable  to  anneal  to 
the  Sabin  1  genome.  The  pS1F  RNA  +  PV3  virus  and  pS1F  RNA  +  CVA21  virus  samples 
were  therefore  not  used  for  the  analysis. 
The  test  samples  co-infected  with  PV3  virus  presented  a  PV3-like  RFLP  pattern.  No  other 
bands  were  observed  suggesting  that  no  recombinant  genomes  could  be  detected. 
3.3.5.1.2.4  Trans-encapsidation  by  CVA21  helper  virus  capsids 
As  expected,  the  control  sample  of  pT7FLC/PV3  RNA  +  CVA21  virus  exhibited  PV3-like 
bands  as  well  as  CVA21  virus-like  bands.  This  result  suggested  that  either  the  PV3-like 
bands  were  derived  from  PV3  virus  resulting  from  the  transfection  of  pT7FLC/PV3  RNA 
or  that  a  heterologous  packaging  event  had  occurred.  The  two  possibilities  could  not  be 
distinguished. 
Two  unidentified  bands,  absent  from  the  Bam  HI  digested  pRiboCAV21-derived  PCR 
product,  were  present  in  all  the  samples.  The  bands  were  observed  in  the  Bam  HI  digestion 
of  the  CVA21  virus  alone  control  and  were  thought  to  have  been  artefacts  resulting  from 
the  vRNA  extraction  and/or  reverse  transcription  reactions.  These  were  excluded  from  the 
characterisation  studies.  All  the  samples  co-infected  with  CVA21  virus,  only  had  a 
CVA21-like  RFLP  pattern. 
The  trans-encapsidation  assay  results  indicated  that  no  packaged  recombinant  genomes 
could  be  detected  in  the  reactions.  However,  it  is  not  possible  to  differentiate  between  lack 
of  encapsidation  and  poor  sensitivity  or  screening  of  the  experiment.  The  former  would  not Claire  Blanchard  In  vitro  recombination  Chapter  3  85 
be  surprising;  as  previous  studies  have  demonstrated  that  poliovirus  subgenomic  replicons 
could  be  encapsidated  by  poliovirus  capsids  and  to  some  levels  by  CVA21  capsids  but  no 
conclusive  evidence  was  given  for  the  encapsidation  of  a  poliovirus  subgenomic  replicon 
by  CB4  or  HRV14  heterologous  capsids  (Barclay  et  al.,  1998).  Contradictory  studies 
reporting  that  successful  encapsidation  of  a  poliovirus  subgenomic  replicon  by  CVB4  and 
HRV14  heterologous  capsid  proteins  had  occurred  (Ansardi  et  al.,  1996).  The  in  vitro 
generated  recombinants  could  lack  a  specific  functional  packaging  signal.  The  design  and 
use  of  highly  specific  primers,  amplifying  the  5'UTR/P  1  region,  may  enable  a  more 
sensitive  analysis  of  the  recombinant  genome  trans-encapsidation  experiment. 
Can  capsid  proteins,  generated  from  transcription/translation  of  the  recombinant  RNA 
genomes,  assemble  and  encapsidate  a  known  packageable  genome?  To  investigate  this,  a 
reciprocal  trans-encapsidation  experiment  was  carried  out. 
3.3.5.2  Luciferase  encapsidation  by  recombinant  capsids 
3.3.5.2.1  Method 
To  detect  whether  the  P1  recombinant  genomes  were  capable  of  providing  capsids  in  trans 
a  luciferase-encoding  subgenomic  replicon  was  provided  in  the  same  cells  (see  figure 
3.29).  To  confirm  the  packaging  assay  behaved  correctly,  a  poliovirus  type  3  packageable 
luciferase  subgenomic  replicon  (pT7REP3-L)  was  co-infected  with  PV3,  CVA21  and 
Sabin  1  control  viruses  into  RD-ICAM  cells  (figure  3.30). 
Co-transfection  of  pT7REP3-L  RNA  with  chimeric  RNA  was  then  carried  out.  The 
co-transfected  RD-ICAM  cells  were  incubated  at  37°C  overnight  to  allow  generation  of 
progeny  virus.  The  samples  were  harvested,  RNase  treated,  passaged  onto  a  fresh 
RD-ICAM  cell  sheet  and  incubated  for  6-8  hours  at  37°C  to  allow  expression  of  the Transfection  of  in  vitro  generated  Transfection  of  pT7REP3-L  T7RNA 
recombinant  T7RNA  transcript  transcript 
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Figure  3.29:  Flow  chart  summarising  the  method  and  analysis  of  the 
trans-encapsidation  assay  by  co-transfection Figure  3.30:  Trans-encapsidation  of  pT7REP3-1.  RNA  bv  control  viruses  in  RD- 
1tA\1  cells. 
The  assay  was  carried  out  five  times,  standard  deviation  values  were  calculated  and 
are  illustrated  as  error  bars  in  the  graph. Figure  3.31:  Trans-encapsidation  of  pT7REP3-L  RNA  by  recombinants:  first 
passage  into  RI)-ICA\I  cells  post-co-transfection  of  T7  RNA  transcripts. 
The  assa'  was  carried  out  five  times,  standard  deviation  values  were  calculated  and 
are  illustrated  as  error  bars  in  the  graph. Claire  Blanchard  In  vitro  recombination  Chapter  3  86 
luciferase  gene.  A  luciferase  assay  was  carried  out  and  results  were  plotted  as  histograms 
(figure  3.31).  Viable  capsid  proteins  cannot  be  produced  as  a  result  of  transfection  with  the 
poliovirus  type-3  luciferase  subgenomic  replicon,  as  most  of  the  P1-coding  region  is 
substituted  for  the  luciferase  reporter  gene.  The  recombinant  genomes  are  unable  to 
produce  progeny  viruses.  Any  transfer  of  the  luciferase  signal  onto  a  fresh  cell  sheet,  after 
RNAse  treatment,  would  be  expected  to  be  due  to  a  luciferase  genome  packaged  into 
capsids  derived  from  the  chimeras. 
The  assay  was  also  conducted  on  L20B  cells  (figure  3.33)  and  L  cells  (data  not  shown), 
cell  lines,  which  could  only  be  used  to  test  PV3-  containing  capsid  sequences.  The 
PV3BKCVA21P1  3+  pT7REP3-L  sample  would  therefore  not  be  expected  to  yield  a 
luciferase  signal  in  L20B  cells  and  was  used  as  a  negative  control  monitoring  for  the 
detection  of  non-specific  luciferase  activity.  These  were  first  passage  samples. 
Samples  passaged  for  the  first  time  onto  a  fresh  RD-ICAM  cell  sheet  were  incubated  for 
12-16  hours  at  37°C,  harvested,  RNAse  treated  and  passaged  for  the  second  time  onto  a 
third  RD-ICAM  cell  sheet.  Should  a  luciferase  signal  be  detected  in  the  first  passage  of  the 
test  recombinant  samples,  transfer  onto  a  third  cell  sheet  should  not  occur  as  the 
recombinants  are  unable  to  make  viable  viruses  that  would  enable  the  signal  transfer.  The 
assay  was  repeated  five  times. 
3.3.5.2.2  Results  and  analysis 
3.3.5.2.2.1  Control  samples  of  transfected  pT7REP3-L  RNA  co-infected  with  helper 
virus 
As  expected,  the  control  sample  co-infected  with  PV3  virus  exhibited  a  significant 
luciferase  activity.  The  control  sample  co-infected  with  CVA21  virus  exhibited  a 
detectable  but  low  luciferase  signal  indicating  poor  encapsidation  of  the  poliovirus  replicon Claire  Blanchard  In  vitro  recombination  Chapter  3  87 
by  heterologous  capsids.  The  sample  co-infected  with  Sabin  1  virus  exhibited  very  low 
luciferase  activity  indicating  poor  if  not  non-existent  trans-encapsidation.  The  consistent 
abnormal  pS1F  and  Sabin  1  virus  behaviour  could  not  be  explained. 
The  control  assay  demonstrated  efficiency  of  the  method  and  was  applied  to  the 
recombinant  samples. 
3.3.5.2.2.2  Co-transfection  of  pT7REP3-L  RNA  with  Sabin  1,  CVA21  and  PV3 
control  RNAs 
Genomic  RNA  derived  from  PV3,  CVA21  and  pS1F  co-transfected  with  pT7REP3-L  RNA 
exhibited  the  expected  luciferase  activities  in  all  the  cell  lines  tested  and  confirmed  the 
success  of  the  trans-encapsidation  assay.  As  expected,  no  luciferase  signal  was  detected  in 
any  cell  line  tested  after  passage  of  the  transfected  pT7REP3-L  alone  sample  and  mock 
transfections. 
3.3.5.2.2.3  Co-transfection  of  pT7REP3-L  RNA  with  PV3BKCVA21P13  RNA 
No  luciferase  signal  was  detected  in  the  co-transfection  of  luciferase  type  3-replicon  RNA 
with  PV3BKCVA21P1  3  RNA  (pT7REP3-L  +  PV3BKCVA21P1  3)  samples  in  RD-ICAM 
cells  (see  figure  3.31).  This  could  be  due  to  inability  of  PV3BKCVA21P13  capsid  proteins 
(CVA21-like)  to  package  the  luciferase  genome.  In  fact  previous  reports  showed  that 
CVA21  capsids  appeared  to  reproducibly  package  poliovirus  subgenomic  replicons  at  very 
low  levels  (Barclay  et  al.,  1998). 
3.3.5.2.2.4  Co-transfection  of  pT7REP3-L  RNA  with  CVA21BKSabinlPl  61-9  RNA 
Significant  luciferase  signals  were  detected  in  RD-ICAM  cells,  from  the  co-transfected 
luciferase  type  3-replicon  RNA  and  CVA21BKSabin1P1  61-9  RNA 
(pT7REP3-L+CVA21BKSabinIP1  61-9).  The  CVA21BKSabinIP1  61-9  recombinant Claire  Blanchard  In  vitro  recombination  Chapter  3  88 
should  synthesise  Sabin  1-like  capsids.  The  luciferase  signal  was  also  detected  in  L20B 
cells  (figure  3.33),  but  not  L  cells  (data  not  shown),  implying  that  virus  entry  was 
PVR-dependent.  Only  very  low  amounts  of  viral  RNA  could  be  extracted  and  reverse 
transcribed.  PCR  amplification  of  a  range  of  windows  of  the  5'UTR/P  1,  P1/P2  and 
3D-coding  regions,  RFLP  and  sequencing  analysis  of  the  samples  were  inconclusive. 
When  the  samples  were  passaged  for  the  second  time  onto  a  fresh  RD-ICAM  cell  sheet,  a 
very  low  luciferase  signal,  close  to  background  levels  and  considered  as  negative,  was 
detected  in  the  pT7REP3-L  +  CVA21BKSabin1P1  61-9  sample  (figure  3.32).  These  results 
suggested  that  CVA21BKSabin1P1  61-9  was  capable  of  encapsidating  the  luciferase  type 
3-replicon  genome. 
3.3.5.2.2.5  Co-transfection  of  pT7REP3-L  RNA  with  CVA21BKPV3P1  c6  RNA 
The  samples  co-transfected  with  T7  RNA  transcripts  of  the  luciferase  type  3-replicon  and 
CVA21  BKPV3P  1  c6  exhibited  a  high  luciferase  signal  in  both  RD-ICAM  cells  and  L20B 
cells  (figures  3.31  and  3.33)  but  not  L  cells  (data  not  shown),  again  implying  a 
PVR-dependent  signal.  The  CVA2IBKPV3P1  c6  recombinant  seemed  to  be  able  to 
generate  capsid  proteins  that  were  then  able  to  assemble  and  encapsidate  the  luciferase 
type  3-replicon  progeny  RNA.  The  output  luciferase  signal  of  the  CVA21BKPV3P1  c6  + 
pT7REP3-L  sample  passaged  onto  a  second  cell  sheet  was  strikingly  high  (figure  3.32). 
This  was  confirmed  by  repeating  the  entire  trans-encapsidation  assay  several  times. 
A  possible  contamination  event  with  an  infectious  virus  could  explain  this  result.  However, 
a  contamination  with  poliovirus  seemed  unlikely  as  all  the  test  samples  were  put  in  an 
incubator  prior  to  handling  the  control  samples,  samples  that  would  generated  a  positive 
signal.  Moreover,  ART-filter  tips  were  used  throughtout  the  experiments  to  avoid  aerosol 
contamination  of  the  pipettes. Figure  3.32:  Trans-encapsidation  of  pT7REP3-L  RNA  by  recombinants:  second 
passage  into  RI)-I('A\I  cells  post-co-transfection  of  T7  RNA  transcripts. 
The  assay  N%  as  carried  out  five  times.  standard  deviation  values  were  calculated  and  are 
illustrated  as  error  bars  in  the  graph. Figure  3.33:  Trans-encapsidation  of  pT7REP3-L  RNA  by  recombinants:  first 
passage  into  1.20B  cells  post-co-transfection  of  T7  RNA  transcripts. 
The  assay  %N  as  carried  out  five  times,  standard  deviation  values  were  calculated  and 
are  illustrated  as  error  bars  in  the  graph. Claire  Blanchard  In  vitro  recombination  Chapter  3  89 
Further  investigation  of  this  surprising  result  was  conducted.  Viral  RNA  extraction,  reverse 
transcription,  amplification  of  the  5'UTR/P  1  -coding  region,  P1/P2  and  3D-coding  regions 
by  PCR,  RFLP  and  sequencing  analysis  of  the  sample  were  carried  out.  The  P1/P2  and  3D 
coding-regions  had  a  PV3  RFLP  and  sequencing  pattern  (data  not  shown),  strongly 
suggesting  a  contamination  event.  However,  the  5'UTR/P  1  PCR  amplification 
(ID-1/ENT-GEN-2R)  and  the  Bam  HI  RFLP  analysis  indicated  that  the  samples  had  a 
CVA21  5'UTR  and  a  PV3  P1  pattern  (see  figure  3.34.1  and  3.34.2).  This  suggested  that  a 
recombination  event  between  the  CVA2IBKPV3P1  c6  recombinant  and  the  pT7REP3-L 
replication-competent  RNA  genomes  had  occurred.  This  resulted  in  the  generation  of  a 
recombined  chimera  containing  a  CVA215'UTR  and  the  reminder  of  the  genome  of  PV3 
(CVA215'UPTR/PV3).  Sequencing  data  analysis  was  poor,  as  it  was  apparent  that  mixed 
viral  sequences  were  present,  probably  corresponding  to  the  presence  of  both 
CVA2IBKPV3P1  c6  and  CVA215'UTR/PV3  sequences  (data  not  shown).  A  series  of 
analyses  were  conducted  in  order  to  further  investigate  these  observations. 
Interestingly,  the  sample  with  high  luciferase  activity  also  caused  CPE  when  passaged  onto 
fresh  cell  sheets.  It  should  be  noted  that  neither  input  genome  alone  caused  CPE  (see  table 
3.10  and  table  4.3).  The  samples  were  harvested,  isolated  and  plaqued.  A  mixed  plaque 
phenotype  was  observed  with  a  population  of  small  plaques  (see  figure  3.35  and  3.36)  that 
were  consistently  smaller  than  those  seen  in  a  typical  PV3  infection  (data  not  shown). 
Previous  studies  demonstrated  that,  when  220  nucleotides  of  the  5'UTR  of  CVB3  were 
changed  for  PV  1,  the  viability  of  the  virus  was  maintained.  These  viruses,  however,  had 
smaller  plaques  than  that  of  PV3  wild-type  plaques  (Zell  et  al.,  1995).  Replacement  of  the 
complete  PV3  5'UTR  with  the  CVB4  5'UTR  was  demonstrated  not  to  affect  sub-genomic 
replicon  replication  (Rohll  et  al.,  1994).  Furthermore,  chimeric  CVB4/PV3  5'UTR  did  not 
appear  to  affect  levels  of  virus  production  (Rohll  et  al.,  1994). 5'UTR  pt 
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Infectious  recombined  chimeric  viruses  would  have  been  able  to  infect  the  third  cell  sheet 
and  provide  capsids  in  trans  as  they  appear  to  cause  CPE.  Furthermore  it  is  likely  that  the 
luciferase  subgenomic  replicon  was  packaged  into  CVA215'UTR/PV3  capsids  during  the 
first  passage.  The  particles  were  then  able  to  attach,  enter  and  release  the  replicon  into 
fresh  cells.  This  could  explain  the  transfer  of  a  luciferase  signal  onto  a  third  cell  sheet. 
Another  possible  explanation  is  that  a  recombination  event  occurred  generating  a  large 
genome  containing  both  the  luciferase-coding  gene  and  the  complete  genome  coding 
sequence.  This  is  improbable,  as  a  larger  genome  is  less  likely  to  be  packaged  into  the 
empty  virus  particles,  as  it  is  not  an  evolutionary  advantage.  The  plaque  purified  isolated 
viruses  were  passaged  onto  a  fresh  cell  sheet  and  luciferase  activity  detection  assay  was 
carried  out.  No  luciferase  signal  was  detected  thereby  suggesting  the  absence  of  a  large 
super-recombinant  genome. 
The  elevated  luciferase  signal  seen  after  the  first  passage  could  also  be  due  to  the 
CVA21BKPV3P1  c6  recombinant  capsid  proteins  assembling  to  form  a  virus  particle 
packaging  the  luciferase  replicon  genome  (see  figure  3.30).  This  could  also  have  been  the 
case,  as  similar  results  were  observed  in  the  case  of  CVA21BKSabin1P1  61-9  (see  figure 
3.30).  It  is  likely  that  the  two  events  together-  trans-encapsidation  and  subsequent  transfer 
of  the  luciferase  genome  and  recombination  to  form  a  viable  CVA215'UTR/PV3 
genome-were  responsible  for  the  present  observations.  The  latter  would  amplify  the 
former.  However,  it  is  still  unclear  why  such  high  readings  were  observed. 
3.4  Discussion 
In  vitro  generated  recombinants  between  polioviruses  and  a  HEV-C,  with  a  perfect 
exchange  of  the  complete  P  1-coding  region,  were  unable  to  cause  cytopathic  effect  when Figure  3.35:  Plaque  phenotype  determination 
in  RI)  cells  of'plaque  purified  virus  isolated  after  the  second  passage  of 
('V:  \2l  I3KP\'3Pl  c6  +  pT7REP3-L  samples  and  plaque  purified  twice: 
A-  h'l-7RI-:  P  3-l.  +  C'V:  N?  I  E3KPV3PI  c6  4, 
E3-  p1  7RE:  P3-I.  +  C'V>2I  E3E:  PV3PI  c6  8 Figure  3.36:  Plaque  phenotype  determination  (continued) 
in  RI)  cells  of  plaque  purified  virus  isolated  after  the  second  passage  of 
L'V:  \2113KPV3PI  c6  +  pT7REP3-L  samples  and  plaque  purified  twice: 
:  ý-  p  1'7RE:  P3-1.  +  CVA?  1  BhPV3P1  c6  11, 
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transfected  into  permissive  cell  lines.  The  generated  chimeras  were  initially  thought  to  be 
acytopathic  or  replication-defective  due  to  a  combination  of  protein  coding  regions  leading 
to  the  generation  of  non-viable  viruses.  Immunofluorescence  studies  suggested  that  the 
chimeras  were  not  acytopathic  but  that  VP1  was  generated  and  that  translation  had 
occurred.  Therefore  a  defect  must  have  affected  a  post-translation  event  of  the  life  cycle 
such  as  processing,  replication,  assembly,  encapsidation,  maturation  or  entry  of  progeny 
virions  into  uninfected  cells.  A  series  of  assays  were  undertaken  to  determine  the  nature 
and  location  of  the  defect  affecting  the  recombinants. 
In  vitro  translation  assays  were  conducted  to  confirm  the  immunofluorescence  study 
results.  Results  indicated  that  the  recombinants  appeared  to  translate  efficiently  and  exhibit 
the  correct  in  vitro  protein-processing  pattern.  In  vivo  control  samples  appeared  to  have 
identical  protein  processing  patterns  as  the  in  vitro  translation  control  samples.  The  in  vitro 
translation  assay  data  suggested  that  the  correct  viral  proteins  had  been  made  thereby 
implying  that  proteins  derived  from  chimeras  were  likely  to  be  able  to  drive  genome 
replication.  However,  the  translation  assay  was  carried  out  in  vitro  and  it  is  possible  that  in 
a  particular  cellular  environment  the  polyprotein  processing  would  not  occur  as  efficiently 
or  would  be  unable  to  generate  functional  proteins. 
Recombinant  genome  replication  was  then  checked  by  dot  blot  hybridisation.  The 
experiment  confirmed  that  the  in  vitro  generated  recombinants  were  replication-competent. 
Some  replicated  to  wild-type  genome  levels,  whilst  others  were  shown  to  be  less  efficient 
at  replicating.  These  observations  indicated  that  the  defect  was  either  located  at  maturation, 
assembly,  and  packaging  processes  or  affected  the  infection  of  new  cells. 
The  level  of  expertise  in  the  laboratory  enabled  trans-encapsidation  assays  to  be  conducted. 
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genomes  and  for  the  capacity  to  encapsidate  a  replicon  genome  by  the  capsid  proteins 
synthesised  from  the  chimeric  genomic  RNA,  were  carried  out.  Trans-encapsidation  of 
recombinant  genomes  by  infectious  helper  viruses  was  investigated  first.  No  packaged 
recombinant  genomes  were  detected  from  the  RT-PCR  and  RFLP  screening.  However,  the 
sensitivity  of  the  technique  was  not  evident,  as  control  samples  did  not  enable  a  definite 
conclusion.  Subsequent  co-transfection  of  a  luciferase  type-3  poliovirus  replicon  with  the 
recombinant  RNA  genomes  into  RD-ICAM  cells,  sample  harvesting,  RNAse  treatment  and 
passage  onto  a  fresh  cell  sheets  constituted  the  second  trans-encapsidation  assay.  The 
results  obtained  from  this  assay  suggested  that  both  a  recombination  event  and  the  P1 
recombinants  generating  capsids  were  likely  to  account  for  encapsidation  of  the  luciferase 
subgenomic  replicon.  This  could  be  explained  by  the  recombinant  genomes  lacking  a 
packaging  signal  or  having  an  incompatibility  essential  for  key  interactions  involved  in 
encapsidation.  This  defect  would  have  prevented  the  formation  of  viable  virions. 
Studies  investigating  poliovirus  packaging  have  not  yet  provided  a  detailed  understanding 
of  this  mechanism  and  the  proteins  involved  in  such  processes  have  yet  to  be  identified. 
The  poliovirus  packaging  signal  was  shown  not  to  be  located  in  the  2A-coding  region  or  in 
the  P1  minus  the  last  few  amino  acids  of  VP  1-coding  region  and  was  suggested  to  be 
located  elsewhere  in  the  remainder  of  the  genome  (Kuge  et  al.,  1986;  Barclay  et  al.,  1998). 
However,  packaging  may  be  more  complex  and  dependent  on  a  number  of  factors. 
Infectious  cVDPVs,  isolated  from  the  Haiti  outbreaks,  were  shown  to  be  recombinants 
between  Sabin  poliovirus  type  1  and  HEV-Cs,  with  a  crossover  site  located  in  the 
2A/2B-coding  regions  (Kew  et  at.,  2002  see  figure  3.37).  In  vitro  generated  recombinants 
and  the  Haiti  isolates  differed  in  the  location  of  their  crossover  sites.  Similar  recombination 
events  were  observed  in  Madagascar  cVDPVs  isolates  that  proved  to  be  Sabin  poliovirus 5  -UTR  10  4 
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Figure  3.37:  Location  of  recombination  breakpoints  of  the  four  different 
recombinant  classes  found  among  Hispaniola  VDPV  isolates. 
In  the  schematic  of  the  poliovirus  genome,  the  single  open  reading  frame  is 
indicated  by  a  rectangle.  flanked  by  the  5'-  and  3'-untranslated  regions  (UTR). 
In  rectangles  A  to  E.  Sabin  I  -derived  sequences  are  indicated  by  white  fill, 
and  sequences  derived  from  enteroviruses  other  than  the  Sabin  OPV  strains 
are  indicated  by  shaded  or  hatched  fills.  The  rectangles  symbolize  sequences 
of  A.  Sabin  1:  B.  DOR00-013:  C.  DOR00-041  c  1:  D,  HA100-003;  and  E. 
HA101-007.  Figure  and  legend  taken  from  Kew  et  al.  (2002). 
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type  2/HEV-Cs  chimeras,  with  a  non-specified  crossover  site  within  the  2A-coding  region 
(Rousset  et  al.,  2004). 
The  studied  viable  cVDPVs  had  P  1,2A  and/or  part  of  the  2B-coding  regions  derived  from 
the  same  source  genomes.  The-non-viable  in  vitro  generated  P1  recombinants  differed 
from  the  cVDPVs  as  the  P1  and  2A/2B-coding  regions  were  derived  from  separate  source 
genomes.  In  light  of  these  results,  packaging  may  be  more  complex  than  initially  thought. 
A  packaging  signal  may  depend  on  localisation  of  genomes  and  proteins  and/or  on 
compatibility  required  for  specific  interactions  to  occur.  It  is  possible  that  the  genome  and 
the  capsid  proteins  of  a  particular  virus  localise  in  specific  intracellular  areas.  These 
intracellular  areas  may  differ  between  viruses,  which  may  prevent  specific  interactions, 
and  thus  packaging  from  occurring.  Compatibility  between  the  P1  with  some  of  the 
2A/2B-coding  regions  may  be  necessary  for  efficient  packaging  to  occur,  whether  the 
compatibility  is  based  on  RNA  structures,  protein-RNA  or  protein-protein  interactions. 
Unassembled  or  partially  assembled  capsid  proteins  could  exhibit  high  specificity  for  a 
particular  RNA  structure,  RNA  sequence  or  protein  present  within  homologous 
2A/2B-coding  regions.  This  would  explain  the  discrepancy  seen  between  the  results 
presented  in  this  thesis  and  those  observed  in  Haiti  and  Madagascar  (Kew  et  al.,  2002; 
Rousset  et  al,  2004). 
A  repeat  of  the  assay  by  sequential  transfection  as  opposed  to  simultaneous  co-transfection 
may  prevent  the  occurrence  of  recombination  events  between  the  chimeric  genomes  and 
the  luciferase  genomes  and  ensure  a  better  data  interpretation. 
Further  investigations  need  to  be  carried  out  in  order  to  determine  the  exact  nature  of  the 
defect  and  to  enable  a  better  understanding  of  this  particular  stage  of  enterovirus  life  cycle. 
Electron  microscopy  (EM)  studies  should  enable  the  detection  of  mature  virus  particles. Claire  Blanchard  In  vitro  recombination  Chapter  3  94 
The  absence  of  mature  virions  would  support  the  existence  of  a  packaging  defect.  If  such 
virions  were  to  be  detected  in  the  supernatant  of  transfected  cells,  then  the  defect  would 
have  to  be  at  the  attachment  and  entry  level  of  the  next  cell  sheet,  since  they  cannot  infect 
fresh  cell  sheets.  If  no  virions  were  to  be  detected  in  the  supernatant  but  were  present  in  the 
lysed  cell  suspension,  this  would  imply  that  the  mature  virions  could  not  be  released  into 
the  extracellular  environment  or  that  the  production  or  release  of  such  virus  particles  would 
be  much  slower.  Due  to  equipment  breakdown  and  restrictions  of  EM,  such  experiments 
were  not  completed.  Should  microscopy  studies  confirm  the  absence  of  mature  virus 
particles,  the  detection  of  assembly  intermediates  would  be  undertaken. 
The  detection  of  assembly  intermediates  by  sedimentation  coefficient  assay  should  enable 
the  determination  of  the  particular  stage  of  the  life  cycle  affected  by  the  defect  and 
potentially  the  assembly  step  at  which  packaging  of  the  genomic  RNA  occurs.  The 
determination  of  the  presence  of  assembly  precursors  by  density  gradients  would  also 
establish  whether  there  was  a  defect  in  the  maturation  process  or  whether  the  lack  of 
maturation  was  a  consequence  of  a  packaging  defect.  The  method  used  would  be  designed 
based  on  early  experiments  (Moscufo  et  al.,  1991)  whereby  radiolabelled  HeLa  cell 
suspension  cultures,  infected  with  a  high  MOI  of  control  viruses  or  transfected  with  high 
concentrations  of  recombinant  RNA,  would  be  harvested  and  lysed.  Alternatively, 
microinjection  of  high  concentrations  of  sample  RNA  into  oocytes,  supplemented  with 
HeLa  nuclear  extracts  necessary  for  initiation  of  translation  and  RNA  synthesis  (Gamarnik 
et  al.,  1996),  may  be  conducted  to  ensure  a  more  efficient  delivery  of  the  samples.  Samples 
would  then  be  centrifugated  to  eliminate  cell  debris  and  the  supernatants  would  then  be 
applied  to  6-25%  and  10-30%  sucrose  gradients.  Centrifugation  to  allow  separation  of 
different  assembly  intermediates  with  different  sedimentation  coefficients  would  then  be 
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pentamers  and  the  10-30%  gradient  would  allow  isolation  of  80S  empty  capsids  and  160S 
mature  virions.  The  detection  of  160S  particle  production  would  suggest  that  assembly  and 
packaging  had  occurred.  However,  the  detection  of  assembly  intermediates  may  give  an 
insight  into  what  stage  of  assembly  was  affected  by  the  defect.  Results  could  be  interesting 
for  the  understanding  of  the  picornavirus  packaging  and  assembly. 
In  the  present  assays,  the  cells  were  lysed  by  freeze  thawing,  thereby  releasing  any 
intracellular  viable  and  infectious  progeny  virions.  An  incapacity  of  recombinant  viruses  to 
attach  and  enter  cells  was  not  likely,  as  the  entire  P  1-coding  sequence  of  the  in  vitro 
generated  recombinants,  checked  in  its  entirety  by  sequencing,  remained  unchanged.  The 
capsids,  being  identical  to  source  capsids,  would  be  expected  to  have  wild-type  infectious 
parent  virion  conformation  and  to  attach  and  enter  cells. 
A  number  of  experiments  need  to  be  conducted  in  order  to  get  a  better  understanding  of  the 
defect  seen  in  the  in  vitro  generated  P1  recombinants  and  the  requirements  necessary  for 
packaging  to  occur.  One  way  to  investigate  this  would  be  the  generation  of  P  1/2A 
recombinants  where  P1  and  2A-coding  regions  would  be  swapped  between  CVA21  and 
PV3  or  Sabin  1.  The  in  vitro  generation  of  such  recombinants  might  give  us  an  insight  into 
the  localisation  of  an  encapsidation  signal  and  the  compatibility  requirements  for  efficient 
encapsidation  of  the  genomes  to  occur.  This  would  also  represent  a  scenario  closer  to  that 
described  in  nature  (Kew  et  al.,  2002;  Rousset  et  al.,  2003;  Rousset  et  al.,  2004). 
The  selection  of  novel  tropic  recombinant  viruses  in  vivo,  enabling  the  generation  of 
recombinant  viruses  without  predetermining  crossover  sites,  and  the  in  vitro  generation  of 
P  1/2A  chimeras,  may  enable  a  better  understanding  of  the  results  described  in  this  chapter 
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4  Results  3:  In  vivo  recombination 
4.1  Introduction 
Since  the  introduction  of  the  OPV,  vaccine-derived  polioviruses  (VDPVs)  have  been 
reported  to  cause  vaccine-associated  paralytic  poliomyelitis  (VAPP)  in  both 
immunocompromised  patients  and  healthy  individuals  (see  chapter  1:  Introduction).  The 
recent  outbreaks  of  VDPVs  in  Hispaniola  (Kew  et  al.,  2002),  Madagascar  (Rousset  et  al., 
2003),  the  Philippines  (MMWR,  2001)  and  Egypt  (Yang  et  al.,  2003)  have  raised  concerns 
about  the  WHO  eradication  program  and  have  highlighted  the  threat  VDPVs  cause  and  the 
need  for  a  better  understanding  of  such  viruses. 
A  variety  of  reports  (see  chapter  1:  Introduction)  have  shown  that  human  enteroviruses  can 
recombine  in  the  natural  host.  In  fact,  intraspecies  recombination  is  a  common  occurrence 
in  nature,  and  has  been  reported  in  human  enterovirus  species  A  (Oberste  et  al.,  2004b), 
human  enterovirus  species  B  (Oprisan  et  al.,  2002;  Oberste  et  al.,  2004a)  and  human 
enterovirus  species  C  (Brown  et  al.,  2003).  Moreover  recent  studies  provided  evidence  that 
intertypic  recombination  could  occur  between  a  HEV-C  and  a  poliovirus.  In  fact,  the 
poliomyelitis-causing  VDPVs  isolated  in  Haiti  and  Madagascar  were  shown  to  be 
recombinants  between  poliovirus  Sabin  type  1/poliovirus  Sabin  type  2  and  human 
enteroviruses  species  C  (Kew  et  al.,  2002,  Rousset  et  al.,  2004). 
When  recombinants  between  a  poliovirus  and  a  HEV-C  with  a  precise  exchange  of  the 
P1-coding  region  were  generated  in  vitro,  these  proved  to  be  non-viable.  Can  viable 
recombinants  between  poliovirus  and  non-poliovirus  human  enteroviruses  occur  in  a  tissue 
culture  environment?  Can  recombination  occur  in  a  particular  cellular  environment  such  as 
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vivo  recombination  studies  could  provide  valuable  information  and  determine  whether 
recombination  can  occur  in  RD-ICAM  cells  or  whether  these  cells  lack  specific 
requirements,  only  found  in  the  gut  environment,  necessary  for  a  recombination  event  to 
occur.  What  viruses  are  most  likely  to  recombine?  The  experiments  described  in  this 
chapter  were  designed  to  select  for  viable  recombinant  viruses  in  a  tissue  culture 
environment  by  co-transfecting  two  impaired  genomes  in  the  same  cellular  environment. 
Two  selectable  defective  genomes  unable  to  make  viable  virus  progeny  would  be 
introduced  to  the  same  cellular  environment,  passaged  and  growing  viruses  isolated.  This 
would  bias  the  assay  and  recombination,  where  the  crossover  sites  have  not  been 
pre-determined,  would  therefore  be  more  likely  to  occur  in  the  particular  cellular 
environment.  The  choice  of  input  genome  was  critical.  Various  defects  such  as  in-frame 
deletion  within  the  capsid-coding  region,  mutations  preventing  a  complete  replication 
cycle  or  sensitivity  to  a  particular  drug,  such  as  GuHC1,  were  considered  for  these 
experiments.  Should  recombinant  viruses  arise  from  the  experiment,  these  would  be 
isolated,  analysed,  characterised,  the  exact  location  of  the  crossover  points  identified,  and 
the  existence  of  recombination  hot  spots  and  the  relevance  of  these  in  virus  evolution 
would  be  identified.  In  this  chapter,  assays  carried  out  in  a  tissue  culture  environment  are 
defined  as  in  vivo. 
The  successful  selection  and  characterisation  of  capsid  recombinants  in  tissue  culture 
without  predetermining  crossover  points  and  exact  recombination  sites  should  provide  very 
valuable  information  on  properties  of  interspecies  recombinant  viruses,  tropism,  viability 
and  fitness  determinants.  Previous  findings,  described  in  chapter  3,  showed  that 
recombinants  engineered  in  vitro  to  have  a  precise  exchange  of  the  P1-coding  region  were 
non-viable.  These  were  suggested  to  have  a  late  replication  defect  such  as  packaging.  In 
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recombinants  and  may  provide  valuable  information  on  sequences  and  interactions 
involved  in  processes  such  as  encapsidation. 
4.2  Experimental  model 
In  the  model  used  here,  two  impaired  viral  genomes  were  co-transfected  in  an 
80%-confluent  cell  monolayer.  The  co-transfected  cell  sheets  were  incubated  for  3  to  5 
days  at  37°C  to  allow  for  recombination,  recovery  and  multiplication  of  novel  chimeras  to 
occur.  Any  virus  recovered  would  be  isolated,  analysed  and  characterised. 
The  model  was  designed  based  on  a  number  of  studies.  Evidence  of  the  generation  of 
recombinants  resulting  from  the  co-transfection  of  two  impaired  viral  DNA  sequences, 
with  an  efficiency  of  80-100%,  has  been  provided  in  baculoviruses  (Chaabihi  et  al.,  1997) 
and  adenoviruses  (Elahi  et  al.,  2002).  The  study  of  poliovirus  5'  and  3'  overlapping  RNA 
fragments  (Gmyl  et  al.,  2003)  conclusively  demonstrated  the  production  of  recombinants 
resulting  from  a  co-transfection  assay.  Furthermore,  recent  experiments  describe  the 
generation  of  cytopathic  recombinant  viruses  from  in  vivo  co-transfection  of 
non-replicating  subgenomic  transcripts  of  the  pestivirus  BVDV  (bovine  viral  diarrhea 
virus)  (Gallei  et  al.,  2004).  The  described  method  can  therefore  lead  to  cell  death  due  to  the 
emergence  of  chimeric  viruses.  This  suggested  that  the  proposed  model  offered  a  suitable 
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4.2.1  Strategy  and  experimental  evidence 
In  order  to  test  the  viability  of  the  experimental  system  two  impaired  poliovirus  type  3 
Leon  genomes  were  chosen,  based  on  availability  of  infectious  cDNAs,  subgenomic 
replicons  and  replication-incompetent  clones  in  the  laboratory.  A  PV3  subgenomic 
replicon  (REP3-L)  was  selected  as  one  of  the  parental  genomes.  This  replicon  lacks  all  but 
82  nucleotides  encoding  the  P1  region,  but  replicates  well  upon  transfection  of  permissive 
cell  lines.  The  second  chosen  parental  impaired  viral  genome  was  a 
replication-incompetent  full-length  poliovirus  type  3  genome  (SL3),  derived  from  the 
plasmid  pT7/SL3.  pT7/SL3  has  eight  mutations  in  the  2C  CRE  region  preventing  the 
formation  of  the  stem  loop  structure  thereby  inhibiting  the  formation  of  the  VPg-pUpU 
primer  and  thus  the  initiation  of  the  positive-sense  strands  synthesis.  However,  the  SL3 
genome  is  still  capable  of  generating  negative-sense  strands,  a  process  required  for 
replication-dependent  recombination  (Goodfellow  et  al.,  2003),  and  the  remainder  of  the 
genome  is  PV3  sequences.  Interestingly,  SL3  revertants  to  replication-competency  could 
not  be  recovered  (Goodfellow  et  al.,  2000). 
4.2.2  Transfection  efficiency  calculation 
The  transfection  efficiency  of  poliovirus  type  3  in  RD-ICAM  cells  was  calculated  by  blue 
cell  assay,  to  determine  favourable  experimental  conditions.  Transfection  by  CaPO4 
precipitation  (Elahi  et  al.,  2002),  DOTAP  (Chaabihi  et  al.,  1996),  electroporation  (Gallei  et 
al.,  2004)  and  DEAE-dextran  (Gmyl  et  al.,  2003)  have  all  been  shown  to  be  successful  at 
generating  recombinants.  The  use  of  Lipofectamine  2000  is  another  very  efficient  RNA 
transfection  method.  To  maximise  the  chances  of  observing  a  recombination  event  a 
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concentrations  were  tested.  Transfection  method  and  RNA  concentrations  test  results  are 
illustrated  in  table  4.2. 
Transfection  method 
[PV3  T7  RNA]  transfected  into 
RD-ICAM  cells 
Oµg  1µg  5µg  10µg 
DEAE-dextran  1%  10-20%  30-40%  30-40% 
Lipofectamine  2000  5%  50%  70-90%  70-90% 
Electroporation  (250V,  40052,250pF)  5%  60%  70-90%  70-90% 
Table  4.2:  Summary  of  in  situ  ß-galactosidase  detection  of  a  bound  ligand  assay  to 
determine  the  conditions  for  efficient  transfection  of  PV3  T7  RNA  transcript  in 
RD-ICAM  cells.  The  values  represent  the  percentage  of  blue  cells  in  each  sample. 
The  negative  controls  for  transfection  surprisingly  exhibited  reasonably  high  background 
level  for  the  samples  transfected  by  electroporation  and  Lipofectamine  2000.  This  was 
thought  to  be  due  to  non-specific  staining  of  unattached  cells.  Transfection  by 
electroporation  often  results  in  a  significant  number  of  dead  or  unattached  cells  that  never 
recover.  Similarly,  large  numbers  of  Lipofectamine  2000  liposomes  fuse  with  the  cell 
membranes,  which  can  disrupt  these  structures  resulting  in  significant  levels  of  cell  death. 
The  background  levels  of  blue  cell  staining  observed  in  DEAE-dextran  transfected  cells 
was  significantly  lower  than  that  seen  post-electroporation  and  Lipofectamine  2000 
treatment.  This  is  because  dextran  permeabilises  the  cell  membrane  allowing  entry  of  RNA 
and  results  in  very  little  cell  death.  However,  the  transfection  of  poliovirus  type  3  into 
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more  efficient  than  transfection  by  DEAF-dextran  (30-40%).  The  amounts  of  RNA  that 
yielded  greater  transfection  efficiency  were  that  of  5µg  and  10µg. 
However,  these  figures  were  calculated  based  on  transfection  of  one  parent  and,  due  to 
time  restrictions,  co-transfection  efficiency  was  not  determined.  Assuming  the  transfection 
efficiency  was  equally  high  for  other  genomes  the  theoretical  co-transfection  efficiency 
was  calculated.  Around  49%  (70%  of  70%)  of  the  transfected  cells  would  be  expected  to 
contain  copies  of  both  parental  genomes.  This  figure  was  thought  to  be  sufficiently  high 
since  recombination  is  a  frequent  event.  The  parameters  (electroporation  of  a  total  of  10µg 
of  RNA  into  106-107  cells/ml)  were  standardised  and  applied  to  the  experimental  model. 
4.2.3  Co-transfection  of  SL3  and  REP3-L  genomes  in  L20B  cells 
The  experimental  model  is  described  in  figure  4.1.  A.  RNA  synthesised  in  vitro  from 
pT7/SL3  and  pT7REP3-L  were  co-transfected  by  electroporation  into  L20B  cells  (kindly 
provided  by  Dr  A.  Macadam,  National  Institute  for  Biological  Standards  and  Control),  a 
murine  cell  line  expressing  the  PVR.  To  ensure  that  the  differences  in  transfection 
efficiencies  would  not  bias  the  assay,  different  ratios  of  normalised  concentrations  of  RNA 
transcripts  derived  from  the  two  parental  genomes  were  used.  RNAs  synthesised  from 
individual  control  plasmids  pT7/SL3  and  pT7REP3-L  were  transfected  in  parallel  and  a 
mock  transfection  was  carried  out  to  monitor  the  effect  of  the  transfection  conditions  on 
L20B  cells.  A  parallel  control  transfection  of  the  pT7FLC/PV3  RNA  transcript  positive 
control  was  conducted  under  the  same  experimental  conditions  at  a  different  time  to  ensure 
no  carryover.  The  results  are  listed  in  table  4.3. A 
Transfection  of  poliovirus  Transfection  of  replication 
type  3  luciferase  replicon  incompetent  poliovirus  type  3 
pT7REP3-L  T7  RNA  SL3  pT7/SL3  T7  RNA 
(electroporation)  (electroporation) 
S  l 
80%  confluent  L20B  cells 
i  Incubation  at  37°C  for  3  to  5  days  to  allow 
recombinants  to  appear 
Reverse  transcription  of 
isolated  vRNA  and  cDNA 
analysis  by  PCR  amplification, 
restriction  digest  and 
sequencing. 
Neutralisation  assay  and  blocking 
assay  to  verify  that  recombinant 
viruses  were  PVR-tropic  and 
poliovirus  type  3  like  and  not 
poliovirus  type  1  thereby  ruling  out 
contamination  with  PV  1. 
E3  Transfection  of  CVA21 
. 
4ge  I  Transfection  of  replication 
deletion  clone  T7  RNA  or  EV7  incompetent  poliovirus  type  3 
. 
Vsi  I  deletion  clone  T7  RNA  SL3  pT7/SL3  T7  RNA 
(electroporation)  (electroporation) 
80%  confluent  RD-ICAM  cells 
i  Incubation  at  37°C  for  3  to  5  days  to  allow  for 
recombinants  to  arise 
i 
Figure  4.1:  Experimental  model 
Data  analysis 
I  \pcnmental  procedure  of  co-transfection  experiments  for  the  selection  of 
recombinant  viruses.  A-  Co-transfection  method  of  the  pT7REP3-L  T7  RNA  transcript 
and  pT7/SL3  T7  RNA  transcript.  B-  Co-transfection  method  of  the  CVA21  Age  I 
deletion  clone  T7  RNA  transcript  or  EV7  Nsi  I  deletion  clone  T7  RNA  transcript  and 
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Amounts  of  RNA  (in  µg) 
Transfection  of  L20B 
cells 
pT7/SL3  RNA  pT7REP3-L  RNA  PT7FLC/PV3  RNA  CPE  readout 
5  5  0 
2  8  0  " 
8  2  0  " 
10  0  0  ° 
0  10  0  ° 
0  0  10  " 
0  0  0  ° 
Table  4.3:  Results  of  co-transfection  by  electroporation  of  pT7FLC/SL3  RNA  with 
pT7REP3-L  RNA  in  L20B  cells.  The  read-out  of  the  experiment  was  the  presence    
or  absence  Q  of  cytopathic  effect  observed  in  the  transfected  cell  sheets.  The  amount 
of  RNA  transfected  is  expressed  in  pg. 
4.2.3.1  Analysis  of  recovered  recombinant  viruses 
As  expected,  no  CPE  or  very  low  levels  of  CPE  were  observed  in  the  negative  control 
samples.  The  very  low  levels  of  CPE  observed  were  thought  to  be  induced  by  SL3  and 
REP3-L  production  of  the  cytotoxic  functional  viral  2A  protein.  Complete  CPE  was 
observed  in  cells  transfected  with  the  positive  control  full-length  wild-type  PV3.  Finally, 
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comparable  to  wild-type  levels.  The  viruses  were  isolated  from  the  samples,  analysed  and 
characterised. 
The  co-transfection  of  a  replication-impaired  SL3  genome  with  a  REP3-L  luciferase 
replicon  in  vivo  led  to  the  successful  generation  of  viable  recombinant  viruses  (SL3-L) 
with  PV3-like  sequences  and  properties.  The  expectation  that  two  impaired  PV3  viral 
genomes  can  recombine  in  vivo  was  confirmed  and  the  viable  recombinant  viruses  were 
analysed  by  receptor  blocking,  virus  neutralisation,  plaque  phenotype,  RFLP  and 
sequencing  studies. 
4.2.3.2  Receptor  blocking  assay 
Infections  with  the  viruses  resulting  from  the  co-transfection  of  pT7/SL3  RNA  and 
pT7REP3-L  RNA  were  blocked  by  treatment  with  an  anti-PVR  monoclonal  antibody  (see 
table  6.1)  indicating  that  the  isolated  viruses  were  PVR-binding  viruses  (see  figure  4.4).  In 
the  absence  of  an  anti-PVR  polyclonal  antibody  PV3,  PV  1  and  the  isolated  recombinant 
viruses  (SL3-L)  were  able  to  exert  a  cytotoxic  effect  on  L20B  cells.  In  the  presence  of  the 
anti-PVR  polyclonal  antibody  infections  by  PV3,  PV  1  and  the  SL3-L  viruses  were  blocked 
and  no  cytolysis  was  observed.  This  result  confirmed  that  SL3-L  viruses  were  PVR-tropic. 
4.2.3.3  Neutralisation  assay 
SL3-L  recombinant  viruses  had  a  PV3-like  antigenicity  as  neutralisation  of  virus  infection 
in  L20B  cells  was  observed  in  the  presence  of  an  anti-PV3  antibody  but  not  in  the  presence 
of  an  anti-PV  1  antibody  (see  figure  4.4).  PV  1  infection  was  neutralised  by  anti-PV  1 
antibody,  PV3  infection  was  neutralised  by  anti-PV3  antibody  and  no  antibody 
cross-reactivity  was  observed. B-  Anti-PV3  polyclonal 
antibody  dilutions 
1  :  20(1  No  Ah 
A-  Anti-PVR  pol}clonal 
antibod\  dilutions 
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Figure  4.4:  Phenotypic  analysis  of  viruses  generated  by  co-transfection  of 
p"1'7/SL3  '1'7  R\:  A  With  p7'7REP3-1,  "1'7  RNA. 
Neutralisation  and  blocking  assay  of  plaque  purified  viruses  generated  by  co- 
translection  of  p'1'7/SL3  T7  RNA  transcript  with  pT7REP3-L  T7  RNA 
transcript.  A-  Blocking  assay  using  anti-PVR  polyclonal  antibody.  B- 
Neutralisation  assay  using  an  anti-PV3  polyclonal  antibody.  C-  Neutralisation 
assay  using  an  anti-PV  1  polyclonal  antibody. 
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4.2.3.4  Plaque  phenotype 
The  plaque  phenotype  of  SL3-L  viruses  was  indistinguishable  from  that  of  PV3  viruses 
(see  figure  4.5  and  4.6). 
4.2.3.5  Genetic  analysis 
SL3-L  viral  RNA  was  extracted,  reverse  transcribed  and  amplified  for  further  analysis. 
RFLP  and  sequencing  studies  were  carried  out  in  order  to  determine  the  genotype  of  the 
SL3-L  viable  recombinant  viruses  isolated  from  the  in  vivo  co-transfection  assay.  The 
cDNA  generated  from  the  reverse  transcription  reaction  was  then  amplified  by  PCR  and 
the  product  was  purified  and  submitted  to  RFLP  analysis  and  sequencing.  Both  analyses 
confirmed  the  SL3-L  sequences  were  poliovirus  type  3-like  (data  not  shown). 
To  check  the  capsid-coding  region  of  the  genome  was  derived  from  the  SL3 
replication-defective  genome  Sac  I  digests  were  carried  out.  Both  pT7FLC  and  pT7/SL3 
have  a  Sac  I  site  within  the  P  1-coding  region  (confirmed  by  sequencing).  However,  it  is 
unclear  as  to  why  but  the  former  can  be  cut  whereas  the  latter  cannot.  This  Sac  I  site  was 
therefore  used  for  identification  purposes.  Sequencing  data  demonstrated  the  presence  of  a 
Sac  I  site  within  the  P1-coding  region  of  the  SL3-L  cDNA.  This  site  was  not  digested  by 
Sac  I  confirming  that  the  SL3-L  viruses  isolated  had  SL3  P1-coding  region  sequences. 
The  SL3  clone  has  a  Siva  I  site,  situated  in  the  mutated  2C-coding  region.  Screening  for  the 
absence  of  that  site  in  the  SL3-L  virus  sequences  verified  that  the  2C  CRE  region  was 
PV3-like  and  not  SL3-like.  Indeed  the  PV3  cDNA  and  SL3-L  cDNA  sequences  were  not 
digested  by  the  Siva  I  restriction  endonuclease  whereas  SL3  control  sequences  were. 
Partial  genome  sequencing  data  further  supported  the  result;  the  Siva  I  site  was  absent  from 
the  SL3-L  cDNA.  Contamination  with  wild-type  poliovirus  type  3  could  not  be  excluded  in Figure  4.5:  Plaque  phenotype  of  recombinant  viruses  generated  by  co-transfection 
of  R\.  %  transcripts  derived  from  pT7/SL3  with  pT7REP3-1,. 
'1-%No  of  the  plaque  purified  viruses  are  illustrated  here.  The  plaque  phenotypes  of 
control  N  iruses  PV3  and  SL3  are  also  illustrated  here.  The  plaque  assays  were  carried 
out  on  1.2013  cells.  A-  Plaque  assay  of  two  of  the  plaque  purified  SL3-L  viruses 
generated  from  co-transtection  of  RNA  transcripts  derived  from  pT7/SL3  with 
p  T7Rl:  P3-1..  1:  I  and  1:  6  represent  initial  ratios  of  RNA  used  for  transfection.  B-  Plaque 
assay  of  pT7Fl.  C'PV3  T7  RNA  transcript  transfection.  C-  Plaque  assay  of  pT7/SL3  T7 
RNA  transcript  transfection. Figure  4.6:  Titration  of  virus  resulting  from  pT7/SL3  RNA  and  pT7REP3-l. 
10A  co-transfection. 
Titration  hN  plaque  assay  of  the  third  passage  of  plaque  purified  viruses  generated 
by  transfection  of  17  RNA  transcripts  in  L2013  cells.  A-  Plaque  assay  of  one  of  the 
passaged  (p3)  plaque  purified  viruses  generated  by  co-transfection  of  pT7/SL3  T7 
RNA  transcript  %N  ith  pT7Rf:  P3-L  T7  RNA  transcript  on  L20ß  cells: 
1.2ýx  107pfu  ml.  ß-  Plaque  assay  of  the  passaged  (p3)  plaque  purified  virus 
venerated  by  transfection  of  pT7FLC/PV3  T7  RNA  transcript  on  L20ß  cells: 
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these  experiments  but  was  very  unlikely  due  to  the  precautions  taken  whilst  carrying  out 
the  experiment  and  control  transfections.  Further  analysis  of  possible  crossover  sites  was 
impractical  as  both  parental  impaired  genomes  had  type  3  sequences. 
Repeating  the  experiment  with  defective  genomes  derived  from  different  poliovirus 
serotypes  could  enable  a  more  detailed  analysis.  Indeed,  the  successful  recovery  of  viable 
recombinant  viruses  from  co-transfection  of  a  poliovirus-type  1  impaired  parent  with  a 
poliovirus-type  3  impaired  parent,  could  lead  to  the  identification  of  recombination 
crossover  points  and  the  potential  identification  of  recombination  hot  spots  due  to  the 
sequence  differences  exhibited  by  the  parental  genomes.  Time  constraints  and  lack  of 
availability  of  defective  type  1-genomes  prevented  this  assay  from  being  carried  out.  This 
additional  assay  would  add  little  to  the  aims  of  the  study.  However,  the  present  result 
indicated  that  successful  recombination  between  two  homologous  defective  poliovirus 
type-3  RNAs  could  occur  in  vivo,  in  L20B  cells. 
4.3  In  vivo  selection  for  recombinants  between  poliovirus  and 
enterovirus  species  C  and  enterovirus  species  B 
Can  a  non-poliovirus  enterovirus  recombine  with  poliovirus  in  tissue  culture?  The  in  vivo 
selection  for  viable  recombinant  viruses  between  a  poliovirus  and  a  non-poliovirus 
enterovirus  was  therefore  carried  out  using  the  experimental  system  as  previously 
described  and  tested.  Before  initiating  the  assays  the  appropriate  and  available  impaired 
parental  genomes  were  carefully  chosen  and  designed.  The  aim  was  to  choose  a  human 
enterovirus  C,  closely  related  to  poliovirus.  These  would  be  expected  to  recombine  in  vivo, 
as  HEV-C  are  known  to  recombine  with  poliovirus  vaccine  strains  in  nature  (Kew  2002, 
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poliovirus,  was  also  chosen  for  the  assay,  as  it  would  be  equally  interesting  in  the  selection 
for  recombinants  in  vivo. 
The  choice  of  available  impaired  parental  genomes  was  limited  as  there  are  very  few  or  no 
current  replicon  or  SL3  versions  of  HEV-Cs  or  HEV-Bs.  One  of  the  parent  genomes  was 
required  to  be  poliovirus  capsid-encoding  as  the  aim  was  to  select  for  PVR-tropic  viruses. 
The  poliovirus  SL3  replication  incompetent  clone  was  chosen  as  one  of  the  impaired 
parents.  l  lEV  representatives  were  chosen  based  on  availability  of  infectious  clones  in  our 
laboratory  and  homology  levels  to  PV3.  CVA21,  a  HEV-C  closely  related  to  polioviruses, 
has  an  84.2%  polyprotein  amino  acid  identity  with  PV3,  and  EV7,  a  HEV-B  more  distantly 
related  to  polioviruses,  only  has  a  64%  amino  acid  identity  with  PV  1.  CVA21  and  EV7 
were  the  chosen  as  HEV  representatives  and  best  available  parents  for  the  experiment. 
CVA21  and  EV7  cDNAs  were  genetically  engineered  to  create  an  in-frame  deletion  within 
the  capsid-coding  regions  so  that  infectious  wild-type  virus  could  not  be  generated  due  to 
the  absence  of  functional  capsid  proteins.  Due  to  time  constraints  the  replication  phenotype 
of  the  P1-deletion  clones  could  not  be  tested.  Their  competence  to  replicate  was  assured 
from  knowledge  of  the  poliovirus  and  poliovirus  sub-genomic  replicon  system  and  from 
the  sequencing  to  verify  an  in-frame  deletion  was  present.  The  cloning  strategies  are 
illustrated  in  figure  4.7  and  4.8  and  described  in  section  4.3.1.1  and  4.3.1.2. 
4.3.1  Design  of  defective  genomes 
4.3.1.1  Cloning  strategy  for  the  generation  of  in-frame  deletion  within  the  Pl-capsid 
coding  region  of  CVA21  (enterovirus  C) 
A  pT7CVA21AP  1  deletion  clone  was  derived  from  the  pCAV21  plasmid,  which  contains 
an  infectious  CVA21  cDNA.  pCAV21  has  three  Age  I  sites  within  the  VP2  and  VP4 Claire  Blanchard  In  vivo  recombination  Chapter  4  107 
coding  regions  of  the  genome.  Following  Age  I  digestion  of  pCAV21,  T4  DNA 
polymerase  treatment  was  carried  out  to  fill  in  5'overhangs  to  form  blunt  ends,  which  were 
ligated  together.  The  ligation  reaction  was  then  transformed,  amplified  in  ER2738  bacterial 
cells  and  the  DNA  was  purified.  The  clones  were  screened  by  standard  digestion  with 
Nco  I,  Bam  HI  and  Eag  I,  a  site  created  upon  ligation  (data  not  shown),  and  sequence 
analysis  of  PCR  amplified  VP4/VP3  coding  regions  (see  figure  4.7).  A  window  of  the 
5'LTTR/P1-coding  region  spanning  the  in-frame  deletion  was  amplified  by  PCR  (using 
forward  and  reverse  oligonucleotide  primers  CAV21-CAPF  and  ENT-GEN-2R)  and 
sequenced.  The  analysis  confirmed  that  the  constructed  clones  were  correct.  The  5'UTR/P  1 
junction  coding  region  of  pT7CVA21  AP  1  clones  6  and  7  sequences  contained  the  Eag  I 
site  and  were  as  predicted.  The  PCR  fragment,  were  approximately  600bp-long  suggesting 
that  clones  6  and  7  did  contain  a  deletion,  compared  to  the  wild-type  pCAV21  PCR 
product,  which  was  approximately  900bp-long. 
4.3.1.2  Cloning  strategy  for  the  generation  of  an  in-frame  deletion  within  the  P1 
capsid  coding  region  of  EV7  (enterovirus  B) 
A  pT7EV7iP1  deletion  clone  was  derived  from  the  pT7EV7  plasmid,  containing  the 
complete  infectious  EV7  cDNA.  pT7EV7  was  digested  with  Nsi  I,  purified  and 
self-ligated.  The  ligation  reaction  was  digested  with  Sal  I  preventing  religated  vector  from 
being  recovered.  The  reaction  was  then  transformed  and  amplified  in  ER2738  bacterial 
cells  and  the  DNA  was  purified.  The  clones  were  screened  by  standard  restriction  digest 
reactions  with  Bam  HI,  Nco  I  and  Sal  I  (data  not  shown)  and  sequenced.  The  sequencing 
analysis  of  a  PCR  amplified  window  of  the  5'UTR/P  1  coding  region  (using  specific 
forward  and  reverse  oligonucleotide  primers  CB3-1F  and  591-5R:  see  figure  4.8) 
confirmed  that  the  recovered  clones  had  in-frame  deletions  and  that  the  sequences  were 
correct.  Sequencing  of  PCR  products  generated  with  primers  specific  for  sequences  coding Age  l  Age  I  Age  I  pCAV21  (Glyn  Stanway) 
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Figure  4.  ":  Cloning  strategy  of  CNA21.:  \P1  at  the  nucleotide  level . 
Vsi  I  Sac  I  Nsi  I 
(1292)  (1878)  (3020) 
pT7  EV7 
------ 
A'S  I1  : VSI  I 
(1292) 
\ 
(1292) 
EV70P1 
------  CNAS  K---n---  GNAYSN  ------ 
5'  ------  TGCAATGCATCTAAA---n---GGCAATGCA'TATAGCAAC------  3' 
---  3'  ------  ACGTTACGTAGATTT---n---CCGTTACGTATATCGTTG------  5' 
Nsi  II  Nsi  I 
Nsi  I  digestion 
1 
Zý'  ------TGCAATGCA  TATAGCAAC------  3' 
3'  ------ACGTT  ACGTATATCGTTG------  5' 
1 
Ligation 
1 
------  CNAYS  N------ 
5'  ------TGCAATGCATATAGCAAC------  3' 
-----  3'  ------ACGTTACGTATATCGTTG------  5' 
Nsi  I 
Figure  4.8:  Cloning  strategy  of  EV7API  at  the  nucleotide  level Claire  Blanchard  In  vivo  recombination  Chapter  4  108 
for  the  5'LTTR/P  1  junction  of  pT7EV7A  P1  clones  3  and  4  was  carried  out.  The  sequences 
were  identical  to  the  theoretical  expected  sequence  generated  from  the  cloning  technique. 
The  PCR  fragments  sent  for  sequencing  were  approximately  750bp-long  suggesting  that 
the  pT7EV70P  1  clones  3  and  4  did  contain  a  deletion,  compared  to  the  2500bp  fragment 
obtained  from  amplification  of  wild-type  pT7EV7  sequences. 
4.3.1.3  Co-transfection  of  defective  T7  RNA  transcripts  derived  from  engineered 
plasmid  DNAs 
The  co-transfection  experiment  was  carried  out  as  shown  in  figure  4.1.  B.  RD-ICAM  cells 
were  chosen  because  they  would  support  growth  of  potential  recombinant  viral  genomes 
and  both  parental  genomes  from  which  the  impaired  genomes  were  derived  and  would  be 
expected  to  support  growth  of  potential  recombinant  viral  genomes  resulting  from  the 
reaction.  RD-ICAM  cells  also  have  a  great  ability  to  recover  post-electroporation.  The 
laboratory  HeLa  cell  line,  another  permissive  cell  line,  exhibited  higher  levels  of  cell  death 
post-electroporation  and  was  therefore  not  used  for  the  assay.  RNA  synthesised  in  vitro 
from  pT7CVA2I  AP  1-6  and  -7,  pT7EV7AP  1-3  and  -4,  pT7/SL3  were  DNase  treated, 
purified,  measured  using  a  spectrophotometer  and  co-transfected  into  RD-ICAM  cells.  The 
RNA  derived  from  each  individual  clone  as  well  as  RNA  derived  from  pCAV2  1,  pT7EV7, 
pT7FLC/PV3  control  plasmids  were  synthesised  and  transfected.  Mock  transfections  of 
RD-ICAM  cells  were  also  carried  out  to  monitor  background  levels  of  cytolysis 
post-transfection.  The  test  transfections  were  carried  out  first  and  removed  from  working 
environment  to  a  37°C  incubator.  The  controls  were  then  transfected  under  the  same 
conditions.  The  results  are  shown  in  table  4.9  and  4.10. Claire  Blanchard  In  vivo  recombination  Chapter  4  109 
Amounts  of  RNA  transfected  into  RD-ICAM  cells  (in  µg) 
pT7CVA21dP16  pT7CVA21AP17  pT7/SL3  pCVA21  pT7FLC/PV3 
CPE 
readout 
5  0  5  0  0  Q 
2  0  8  0  0  Q 
8  0  2  0  0  Q 
0  5  5  0  0  Q 
0  2  8  0  0  Q 
0  8  2  0  0  Q 
10  0  0  0  0  Q 
0  10  0  0  0  Q 
0  0  10  0  0  Q 
0  0  0  10  0    
0  0  0  0  10    
0  0  0  0  0  Q 
Table  4.9:  Results  of  co-transfection  of  the  CVA21AP1  RNA  with  the  SL3  RNA  in 
RD-ICAM  cells.  The  read-out  of  the  experiment  was  the  presence     or  absence  o  of 
cytopathic  effect  observed  in  the  transfected  cell  sheet.  The  amounts  of  RNA 
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Recovery  of  recombinant  viruses  generated  in  vivo  between  a  replication-incompetent  PV3 
and  CVA21  with  an  in-frame  deletion  within  the  P1-coding  region  was  unsuccessful.  The 
CPE  status  of  control  samples  was  as  expected,  however  no  CPE  was  observed  in  the 
dually  transfected  samples. Claire  Blanchard  In  vivo  recombination  Chapter  4  111 
Amounts  of  RNA  transfected  into  RD-ICAM  cells  (in  µg) 
pT7EV7AP1-3  pT7EV74P1-4  pT7/SL3  pT7EV7  pT7FLCIPV3 
CPE 
readout 
5  0  5  0  0  Q 
2  0  8  0  0  Q 
8  0  2  0  0  Q 
0  5  5  0  0  Q 
0  2  8  0  0  Q 
0  8  2  0  0  Q 
10  0  0  0  0  Q 
0  10  0  0  0  Q 
0  0  10  0  0  Q 
0  0  0  10  0    
0  0  0  0  10    
0  0  0  0  0  Q 
Table  4.10:  Results  of  co-transfection  of  the  EV7AP1  RNA  with  the  SL3  RNA  in 
RD-ICAM  cells.  The  read-out  of  the  experiment  was  the  presence     or  absence  Q  of 
cytopathic  effect  observed  in  the  transfected  cell  sheet.  The  amounts  of  RNA 
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As  expected,  the  negative  controls  did  not  induce  CPE  in  the  transfected  cells  whereas 
transfection  with  RNA  transcripts  derived  from  the  complete  cDNAs  of  control  viruses 
caused  full  CPE  of  the  transfected  cells.  The  absence  of  CPE  observed  in  the  test  samples 
suggested  that,  under  the  conditions  used,  no  viable  recombinant  viruses  could  be 
recovered  between  a  replication-incompetent  PV3  and  EV7  with  an  in-frame  deletion 
within  the  P1-coding  region. 
4.4  Discussion 
Viable  recombinant  viruses  were  successfully  recovered  from  in  vivo  selection  experiments 
using  two  impaired  PV3  viral  RNA  genomes.  The  experimental  model  was  then  applied  to 
human  enterovirus  species  C  and  species  B  defective  genomes.  Co-transfection  of 
CVA21  AP  1  and  SL3  defective  genomes  and  EV7AP  1  and  SL3  defective  genomes  in 
RD-ICAM  cells  failed  to  generate  viable  recombinant  viruses  under  the  conditions  used. 
Previous  studies  have  shown  the  successful  generation  of  recombinants  resulting  from 
co-transfection  of  two  impaired  viral  genomes  in  vivo  (Chaabihi  et  al.,  1997;  Elahi  et  al., 
2002;  Gmyl  et  al.,  2003;  Gallei  et  al.,  2004).  Furthermore,  the  Hispaniola  (Kew  et  al., 
2002)  and  Madagascar  (Rousset  et  al.,  2004)  outbreaks  were  demonstrated  to  have  been 
caused  by  viable  circulating  VDPV  strains  that  had  emerged  as  a  result  of  recombination 
between  poliovirus  vaccine  strains  and  human  enterovirus  species  C  strains.  It  was 
therefore  surprising  that  co-transfection  of  CVA21  and  PV3  did  not  give  rise  to  a 
recombination  event  leading  to  the  generation  of  viable  viruses. Claire  Blanchard  In  vivo  recombination  Chapter  4  113 
4.4.1  Further  investigations  of  the  experimental  conditions 
Further  control  experiments  are  required  to  investigate  whether  the  results  seen  were  due  to 
the  defective  clones  being  unable  to  generate  functional  proteins  and  replicate  or  whether 
recombination  between  CVA21  and  PV3  is  not  possible  under  the  conditions  used.  Study 
of  CVA2IAP1  and  EV7AP1  translation  needs  to  be  carried  out  by  in  vitro  translation 
assays  using  HeLa  S  10  nuclear  extracts  and  rabbit  flexi-reticulocyte  lysates.  The 
replication  competence  of  the  generated  defective  RNAs  also  need  to  be  determined  by 
dot-blot  assay  or  replication  assay  using  HeLa  S10  nuclear  extracts,  as  the  unsuccessful 
generation  of  viable  recombinant  viruses  from  the  in  vivo  selection  experiment  could  have 
been  due  to  the  P1-deletion  genomes  having  a  defect  at  the  level  of  replication.  Such  a 
defect  could  have  prevented  replicative  recombination  from  occurring. 
The  precise  co-transfection  efficiency  needs  to  be  determined  to  ensure  that  the  conditions 
used  are  optimal.  Introduction  of  a  tag-epitope  during  the  in  vitro  generation  of  the  P1 
deletion  defective  CVA21  (CVA21-tag)  and  co-transfection  of  SL3  RNA  with  the 
CVA21-tag  RNA  into  RD-ICAM  cells  or  L20B  cells  would  constitute  the  basis  of  a 
specific  probing  assay.  Eight  hours  post-transfection  the  cells  would  be  fixed  and 
permeabilised.  Transfected  cells  would  then  be  treated  with  both  anti-VP  1  DAKO  mouse 
monoclonal  antibody  (detecting  the  SL3  VP1  proteins),  followed  by  treatment  with  a 
secondary  anti-mouse  antibody  conjugated  with  FITC  for  example,  and  an  anti-tag 
polyclonal  antibody  (probing  for  the  CVA21-tag  genome),  followed  by  treatment  with  a 
secondary  anti-polyclonal  antibody  conjugated  with  a  different  fluorochrome  like  TRITC. 
Confocal  microscopy  analysis  would  then  be  carried  out  to  detect  the  percentage  of  dually 
transfected  cells  detected  by  co-localisation  of  the  two  different  fluorochromes.  The  use  of 
a  fluorescence  activated  cell  sorter  (FACS)  would  enable  detection  and  a  more  accurate 
quantification  of  dually-transfected  cells.  Once  the  co-transfection  efficiency  has  been Claire  Blanchard  In  vivo  recombination  Chapter  4  114 
determined,  an  improved  design  of  the  transfection  technique  will  be  possible  thereby 
increasing  the  efficiency  at  which  recombinants  are  generated. 
Recent  studies,  have  provided  definitive  evidence  that  recombination  could  occur  via  a 
replication-independent  pathway  (Gallei  et  al.,  2004),  probably.  involving  cellular 
processes,  suggesting  that  even  in  the  event  of  the  P1  deletion  genomes  being 
replication-incompetent,  recombination  could  have  occurred  in  a  replication-independent 
manner.  This  hypothesis  is  further  supported  by  the  fact  that  defective  RNA  molecules  can 
exert  a  complementing  effect  in  a  cellular  environment  and  lead  to  cytopathic  cell  death 
(Garcia-Arrazia  et  al.,  2004).  The  cellular  environment  used  could  have  affected  the  results 
seen.  The  use  of  caco-2  cells,  lining  the  intestinal  epithelium,  or  pharyngeal  cell  lines  may 
provide  a  more  favourable  environment  for  recombination  between  enteroviruses  to  occur. 
Moreover  using  such  cell  lines  may  better  reflect  a  natural  environment  as  it  is  in  the  sites 
of  infection  that  recombination  between  two  enteroviruses  is  more  likely  to  occur. 
Co-transfection  of  defective  EV7  RNA  with  SL3  replication-incompetent  RNA  did  not 
generate  viable  viral  genomes.  This  could  be  due  to  the  distant  genetic  relationship 
between  EV7,  a  human  enterovirus  type  B,  and  PV3.  As  we  were  unable  to  reproduce  the 
situation  observed  in  nature  for  human  enterovirus  species  C  in  vivo  or  in  vitro  such  a 
conclusion  could  not  be  made.  However,  it  is  possible  that  human  enterovirus  species  B 
will  never  be  able  to  recombine  with  human  enterovirus  species  C.  Because  different 
species  use  different  cell  surface  receptors  for  infection,  it  may  be  impossible  for  both 
genomes  to  be  present  in  the  same  cell  type  at  any  one  time.  If  the  genomes  are  not  in  the 
same  cellular  environment  they  may  never  be  able  to  recombine  and  could  be  why  there 
has  been  no  reported  evidence  of  such  an  event  happening  in  nature. Claire  Blanchard  In  vivo  recombination  Chapter  4  115 
4.4.2  Speculations 
There  exist  differences  between  SL3  and  PV3  P1-coding  regions.  For  example,  the  Sac  I 
site  present  in  the  middle  of  the  P1-coding  region  is  not  digested  in  the  SL3,  as  opposed  to 
the  PV3  genome.  It  is  known  that  these  do  not  affect  the  production  of  viable  viruses 
(Goodfellow  et  al.,  2003;  table  3.10;  table  4.3). 
It  is  possible  that  the  lack  of  pre-determined  crossover  sites  and  the  randomness  of 
recombination  sites  could  have  affected  RNA  structures  preventing  viable  viruses  from 
being  generated. 
It  is  also  possible  that  acytopathic  recombinant  viral  genomes  were  generated  in  these 
experiments.  The  CVA21  2C  CRE  may  have  been  unable  to  interact  with  the  rest  of  the 
SL3  genome  and  therefore  unable  to  take  part  in  key  interactions  necessary  for  the 
generation  of  viable  viruses.  The  primary  screening  method  used  in  the  described 
experiment  did  not  enable  the  detection  of  acytopathic  recombinant  viruses  and  testing  to 
determine  whether  the  samples  contained  acytopathic  viruses  was  not  carried  out  due  to 
time  restrictions  and  prioritisation  of  other  parts  of  the  project. 
Recombination  during  mixed  infection  with  various  strains  of  poliovirus  has  been  known 
to  be  a  common  occurrence  in  vaccinees.  Recombination  has  also  been  shown  to  occur 
during  mixed  infection  with  various  strains  of  poliovirus,  where  both  genomes  replicated 
in  the  same  compartments  (Egger  et  al.,  2002).  However,  no  study  so  far  has  provided 
proof  of  different  enterovirus  species  replicating  in  the  same  compartments  and  it  could  be 
that  strains  belonging  to  either  the  same  species  (CVA21  and  PV3)  or  different  species 
(EV7  and  PV3)  replicate  in  separate  replication  compartments  thereby  making 
replication-dependent  recombination  impossible. Claire  Blanchard  In  vivo  recombination  Chapter  4  116 
4.4.3  Alternative  reference  genomes 
It  is  expected  that  a  genome  exhibiting  high  homology  with  that  of  poliovirus  would  be 
more  likely  to  recombine.  Recent  sequence  analysis  studies  in  which  mass  sequencing  of 
complete  genomes  of  the  human  enterovirus  species  A  (Oberste  et  al.,  2004b),  human 
enterovirus  species  B  (Oberste  et  al.,  2004a)  and  human  enterovirus  species  C (Brown  et 
al.,  2003)  was  carried  out  and  inter-  and  intra-species  amino  acid  percentage  identity 
deduced  from  nucleotide  sequences  were  calculated.  These  studies  provided  a  better 
insight  on  evolutionary  stages  of  human  enteroviruses  and  a  very  useful  report  of 
homology  levels  that  exist  between  enteroviruses.  Some  BEV-Cs,  other  than  CVA21,  have 
been  shown  to  exhibit  greater  homology  to  PV3.  CVA20,  for  example,  would  have  been 
expected  to  be  a  better  member  to  choose  for  the  experiment,  as  it  is  90.2%  identical,  based 
on  complete  amino  acid  sequence,  to  PV3.  A  more  detailed  comparison  between  CVA21, 
CVA20  and  PV3  is  described  in  table  4.11,  based  on  the  published  data  (Brown  et  al., 
2003).  The  way  the  assay  was  conducted  did  not  enable  us  to  use  CVA20,  as  no  infectious 
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Amino  acid  identity  with 
PV3  (in  %) 
CVA21  CVA20 
5'UTR  79  81 
3'UTR  97  99 
P1  70  78 
P2  79  96 
P3  96  97 
Complete  polyprotein  84.2  90.2 
Table  4.11:  Amino  acid  sequence  relationships  (percent  identity)  between  two 
members  of  the  human  enterovirus  species  C  (CVA21  and  CVA20)  and  PV3  (data 
adapted  from  Brown  et  al.,  2003). 
An  interesting  alternative  assay  would  be  the  transfection  of  SL3  RNA  and  subsequent 
co-infection  with  CVA20  virus.  The  progeny  viruses  would  be  harvested  and  passaged 
onto  L20B  cells,  assuming  CVA20  does  not  infect  L20B  cells,  thereby  only  selecting 
PVR-binding  viruses.  It  is  unlikely  that  CVA20  would  infect  L20B  cells  as  these  are  L 
cells  expressing  the  PVR  on  their  cell  surface  and  that  L  cells  are  non-permissive  for 
infection  with  any  human  enteroviruses.  This  would  enable  the  selection  of  infectious 
recombinant  viruses  that  have  acquired  an  SL3  P1  coding  region.  This  alternative  assay 
may  allow  for  recombination  to  occur.  The  characterisation  of  viable  in  vivo  recombinants 
would  then  allow  the  mapping  of  recombination  crossover  sites  and  potential 
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4.4.4  Suppression  of  synonymous  sequence  variation  (SSSV) 
Suppression  of  synonymous  sequence  variation  (SSSV)  is  a  program  designed  by  David 
Evans.  The  program  differentiates  equal  distribution  of  the  codons  encoding  a  single  amino 
acid  from  bias  towards  the  use  of  a  preferred  codon  encoding  for  an  amino  acid  in  a 
particular  area  of  the  genome.  If  there  is  equal  distribution  of  codons  encoding  an  amino 
acid,  no  bias  towards  use  of  a  particular  codon  exists  and  therefore  no  suppression  of 
synonymous  sequence  variation  is  observed.  This  is  represented  by  high  synonymous 
variation  values.  However,  a  trough  would  indicate  a  region  where  synonymous  sequence 
variation  was  suppressed  and  a  bias  towards  the  use  of  a  particular  codon  was  observed.  A 
trough  is  a  region  where  there  is  less  variation  in  the  sequence  then  the  amino  acid 
sequence  would  allow.  These  troughs  are  thought  to  represent  conserved  regions  that  may 
play  key  roles  in  the  virus  life  cycle.  This  has  been  confirmed  to  be  the  case  of  the  first 
trough  observed  on  the  graphs  (figure  4.12).  The  trough  corresponds  to  the  2C  CRE 
stemloop  structure,  a  structure  essential  for  priming  and  initiating  genome  replication.  It  is 
possible  that  other  regions  of  synonymous  sequence  variation  are  structured  regions. 
HEV-Bs  and  HEV-Cs  sequences  have  been  submitted  to  the  SSSV  analysis  and  the  results 
are  plotted  on  graphs  illustrated  figure  4.12.  HEV-Bs  and  HEV-Cs  exhibit  different  SSSV 
patterns  in  the  non-structural  coding  region.  The  graph  of  HEV-Bs  exhibits  one  trough, 
whereas  the  graph  of  HEV-Cs  exhibits  an  additional  two  areas  of  strong  suppression  of 
synonymous  variation.  The  trough  present  in  both  HEV-Bs  and  HEV-Cs  graphs  represents 
the  region  corresponding  to  the  2C  CRE.  The  functions  fulfilled  by  the  two  additional 
regions  where  troughs  were  observed  are  unknown,  however  sequence  and  maybe  structure 
conservation  suggests  a  functional  role.  If  the  HEV-Bs  have  a  similar  life  cycle  to  that  of 
HEV-Cs,  some  reactions  are  likely  to  be  carried  out  in  different  ways,  explaining  the  lack A 
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Figure  4.12:  Suppression  of  synonymous  sequence  variation  analysis, 
comparison  of  human  enterovirus  genera  (figure  generated  by  David 
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of  troughs.  Should  one  of  these  functions  involve  interaction  with  homologous  capsid 
proteins,  this  would  explain  the  absence  of  recombinants  between  HEV-Bs  and  HEV-Cs. 
4.4.5  Future  experiments 
Should  recombinant  viruses  be  generated  in  vivo  using  a  more  accurately  designed  method 
or  alternative  assays,  a  series  of  characterisation  experiments  would  be  carried  out.  A 
number  of  sequencing  studies  would  be  initiated  in  order  to  determine  the  location  and 
nature  of  the  recombination  crossover  sites.  Analysis  and  comparison  of  various 
recombinants  may  enable  determination  of  recombination  hotspots  and  the  implications  of 
such  hotspots  in  enteroviral  evolution.  Comparison  of  viable  in  vivo  generated  recombinant 
viruses  with  the  non-viable  in  vitro  generated  P1  recombinants,  described  in  Chapter  3, 
may  enable  identification  of  the  defect  affecting  the  latter  and  give  insights  into 
picornaviral  research. 
An  infectious  centre  type  assay  could  also  be  undertaken  to  try  and  generate  in  vivo 
recombinants.  Co-transfection  of  L  cells,  which  have  been  shown  to  support  replication  of 
human  enteroviruses  post-transfection,  with  the  two  impaired  parental  genomes,  could  be 
carried  out.  4-6  hours  post-transfection,  time  point  at  which  the  cells  would  have  recovered 
following  the  transfection  but  no  newly  generated  virus  would  have  been  released,  the 
co-transfected  L  cells  would  be  lifted  from  the  transfection  flasks  and  transferred  onto  an 
80%-confluent  monolayer  of  L20B  cells,  cell  line  supporting  poliovirus  recombination, 
RD-ICAM  cells  or  RD  cells.  Overlay  media  would  be  added  and  the  samples  would  then 
be  incubated  at  37°C  for  three  to  five  days  to  allow  plaque  formation  of  any  in  vivo 
generated  recombinants.  These  would  then  be  isolated  from  plaques,  purified,  amplified 
and  characterised.  This  method  is  an  alternative  to  the  technique  described  in  this  chapter Claire  Blanchard  In  vivo  recombination  Chapter  4  120 
and  may  enable  isolation  of  in  vivo  generated  recombinant  viruses  as  opposed  to 
populations  of  mixed  recombinants. 
The  advantage  of  generating  recombinants  in  vivo  is  that  a  scenario  closer  to  that  seen  in 
nature  is  reproduced  in  a  tissue  culture  environment.  As  opposed  to  in  vitro  generation  of 
recombinants  the  crossover  sites  are  not  pre-determined  and  are  more  likely  to  mimic  a 
natural  situation.  However,  the  use  of  novel  techniques  such  as  small  interfering  RNAs 
(siRNAs)  and  DNA  shuffling  to  select  for  recombinants  between  human  enterovirus 
species  in  a  laboratory  environment  are  interesting  alternatives  to  the  method  used  in  this 
chapter  (see  chapter  5:  General  discussion). Claire  Blanchard  General  Discussion 
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In  view  of  the  poliomyelitis  eradication  program,  several  issues  have  become  major 
concerns.  What  are  the  chances  of  a  non-poliovirus  enterovirus  evolving  to  use  the 
poliovirus  receptor?  Would  such  a  virus  cause  poliomyelitis?  What  are  the  implications  of 
such  recombinants?  The  project  aimed  to  investigate  some  of  these  issues. 
It  was  initially  proposed  to  use  DNA  shuffling  to  create  chimeric  mosaic  capsids  that  may 
interact  with  different  cell  surface  receptors.  DNA  or gene  shuffling  is  an  elegant  process 
that  enables  the  production  of  in  vitro  recombinants  with  mosaic  sequences  of  gene 
families  and  diverse  libraries  of  progeny  genes.  This  technique  is  very  ambitious,  as  it 
requires  very  technically  demanding  DNA  manipulations,  and  a  number  of  different  stages 
could  become  problematic.  Firstly,  stop  codons,  truncation  of  the  sequences  and  incorrect 
open  reading  frames  leading  to  inefficient  translation  could  arise  from  DNA  shuffling 
experiments.  Secondly,  full-length  nonsense  sequences  encoding  the  capsid  proteins  could 
have  been  generated  rendering  any  resulting  viruses  non-viable.  Finally,  full-length 
in-frame  generated  sequences  of  the  capsid  protein-coding  regions  could  be  processed 
inefficiently  by  heterologous  3C  and  3CD  proteases.  It  was  therefore  important  to  study 
processing  requirements  closely.  To  do  so,  recombinants  with  a  precise  exchange  of  the 
P1-coding  region  between  poliovirus  type  3  and  CVA21,  a  HEV-C,  were  generated  in 
vitro.  The  experiment  developed  into  a  very  interesting  analysis  of  chimeras.  The  in  vitro 
generated  recombinants  were  unable  to  cause  cytopathic  effects  upon  transfection  and 
passage  into  cell  lines  permissive  for  infection  and  replication  of  both  parental  genomes. 
However,  the  chimeras  appeared  to  produce  the  correct  proteins  and  to  exhibit  the  correct 
protein-processing  pattern.  Further  assays  indicated  that  the  recombinants  were 
replication-competent  and  suggested  that  these  may  have  had  a  late  replication  defect  such Claire  Blanchard  General  Discussion  Chapter  5  122 
as  a  packaging  defect.  These  results  indicated  that  relatively  divergent  capsids  could  be 
processed  by  viral  proteases  suggesting  that  the  heterologous  mosaic  capsids  created  by 
DNA  shuffling  may  also  be  processed  by  3CD  protease. 
The  DNA  shuffling  technique  has  been  applied  to  create  recombinants  of  single  genes  such 
as  cytokine  (Chang  et  al.,  1999),  thymidine  kinase  (Christians  et  al.,  1999),  green 
fluorescence  protein  (Crameri  et  al.,  1996),  subtilisin  (Ness  et  al.,  1999)  and  a  fucosidase 
(Zhang  et  al.,  1997).  However,  until  recently  DNA  shuffling  had  not  been  applied  to  viral 
genes.  In  2000,  studies  described  the  use  of  the  method  to  alter  receptor  tropism  of  a 
retrovirus  by  creating  a  recombinant  mosaic  of  the  envelope  glycoprotein  gene  (Soong  et 
al.,  2000).  Since  then,  a  variety  of  studies  have  used  DNA  shuffling  for  recombinant 
generation,  functional  gene  analysis  and  other  purposes.  RACHITT  (RAndom 
CHImeragenesis  on  Transient  Templates)  is  one  of  the  best  available  DNA  shuffling 
techniques  (Pelletier  et  al.,  2001;  Coco  et  al.,  2001;  Coco  et  al.,  2003)  and  it  was  planned 
to  use  this  approach  for  the  project. 
RACHITT,  a  templated  assembly  of  mosaic  sequences,  could  be  used  to  generate 
HEV-C/PV  recombinants  with  a  mosaic  P1-coding  region,  by  shuffling  several  HEV-Cs  or 
polioviruses  P1  genes.  Although  ambitious,  the  potential  recovery  and  characterisation  of  a 
PVR-tropic  recombinant  HEV-C  virus  would  be  very  valuable. 
A  range  of  relatively  closely  related  input  polioviruses  and  non-poliovirus  HEV-Cs  would 
be  used  for  the  experiment.  The  entire  capsid-coding  gene  or  a  range  of  individual  capsid 
genes  of  various  polioviruses  would  be  shuffled  and  introduced  into  a  non-poliovirus 
HEV-C  backbone  vector  containing  the  remainder  of  the  coding  and  non-coding 
sequences.  The  experimental  method  is  illustrated  figure  5.1.  First,  top  strands  of  the 
P1-coding  regions  of  heterologous  polioviruses  would  be  partially  digested  with  DNAse  I. Fop  strand  of  P1  region  of  heterologous  poliovirus  viruses 
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Figure  5.1:  DNA  shuffling 
I)NA  shuffling  using  RACHITT:  Random  chimeragenesis  on  transient  templates, 
method  first  used  by  Stemmer  et  al.  (1994)  for  retroviruses.  Adapted  for  accelerated 
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The  digested  fragments  would  then  be  hybridised  to  a  uracil-containing  bottom  scaffold 
strand  of  the  P1-coding  region  of  a  HEV-C.  The  flaps  would  then  be  digested,  the  gaps 
filled  and  the  nicks  ligated.  Uracil-DNA-glycosylase  treatment  of  the  heterologous  hybrid 
would  destroy  the  HEV-C  PI-coding  region  scaffold  strand  allowing  for  the  synthesis  of  a 
double  stranded  mosaic  recombinant  fragment.  The  fragment  would  then  be  cloned  into  a 
HEV-C  P  1-coding  region  deleted  backbone  and  screened  for  viability  on  a  variety  of  celI-- 
lines.  An  ideal  cell  line  for  PVR-tropic  viruses  screening  is  the  L20B  cell  line.  L20B  cells 
are  murine  fibroblasts  (L  cells)  expressing  the  PVR.  Therefore,  a  virus  that  grows  on  L20B 
cells  but  not  on  L  cells  would  be  PVR-tropic.  Further  screening  utilising  neutralisation 
assays,  using  a  cocktail  of  non-poliovirus  REV-C  specific  antibodies,  could  be  conducted. 
The  method  presents  a  few  drawbacks.  DNA  shuffling  would  yield  large  populations  of 
chimeras  that  would  not  be  subjected  to  screening  until  later  on  in  the  experiment.  Because 
of  the  sizes  of  the  fragments  composing  the  mosaic,  a  very  high  number  of  different 
combinations  of  sequences  could  result  from  the  assay  and  inevitably  non-viable  sequences 
would  be  generated.  However,  DNA  shuffling  enables  the  dramatic  acceleration  of  gene 
evolution. 
Other  approaches  to  DNA  shuffling  such  as  random  mutagenesis  studies  using  ribavirin  are 
possible.  This  assay  is  discussed  in  Chapter  2.  Certain  aspects  of  the  experiment  need  to  be 
more  formally  tested.  Such  a  method  combined  with  the  use  of  PVR  covalently-bound  to 
affinity  chromatography  column  would  make  the  screening  process  more  stringent  and 
could  increase  the  chances  of  selecting  for  novel  tropic  viruses.  However,  upon  binding  to 
PVR  viral  uncoating  occurs  and  the  chromatography  isolation  of  mutated  virus  populations 
binding  the  PVR  with  different  degrees  of  affinity  would  need  to  be  carried  out  at  0-4°C. 
Elution  of  low-affinity  PVR-bound  viruses  using  high  salt  concentrations  and  RNA 
extraction  for  subsequent  transfection  would  then  be  carried  out.  Following  transfection  the Claire  Blanchard  General  Discussion  Chapter  5  124 
samples  would  be  submitted  to  several  rounds  of  replication  thereby  enhancing  the  affinity 
for  PVR  of  the  isolated  viruses.  This  method  may  enable  isolation  and  study  of  novel 
tropic  mutated  viruses. 
Although  the  project  diverged  from  the  initial  aim,  the  results  obtained  from  the  in  vitro 
generated  recombinant  studies  were  very  interesting  and  could  be  very  valuable  for 
poliovirus  research.  Further  investigations  could  lead  to  the  identification  of  a,  yet  to  be 
determined,  specific  encapsidation  signal  and/or  interactions  involved  in  packaging  of  the 
viral  genome.  In  order  to  investigate  this  result  further,  forced  recombination  in  a  tissue 
culture  environment  without  predetermining  the  crossover  sites  should  to  be  carried  out.  In 
vivo  recombination  experiments  did  not  yield  any  significant  data.  However,  there  are 
alternate  ways  of  applying  selective  pressure  and  forcing  recombination  between  two  _  ___ 
viruses  in  tissue  culture,  such  as  RNA  interference. 
RNA  interference  (Fire  et  al.,  1998)  is  a  very  useful  tool  for  functional  gene  analysis,  gene 
silencing  and  therapeutic  use  (Cheng  et  al.,  2003).  Small  double  stranded  fragments  of 
RNA  (small  interfering  RNAs:  siRNAs)  have  been  shown  to  induce  sequence  specific 
degradation  of  RNA.  In  fact,  binding  of  siRNAs  to  single  genes  leads  to  suppression  of 
gene  expression.  RNA  interference  has  been  identified  in  many  organisms  such  as  plants, 
trypanosomes  and  fungi  and  is  thought  to  be  a  means  of  protecting  an  organism  against 
viral  infection  (reviewed  Saleh  et  al.,  2004).  Recent  studies  indicated  that 
19-23  nucleotide-long  synthetic  siRNA  fragments  could  trigger  strong  and  specific  gene 
silencing  (Elbashir  et  al.,  2001). 
The  use  of  siRNAs,  in  a  tissue  culture  environment,  may  enable  the  generation  of 
recombinant  viruses  with  altered  tropism,  and  more  specifically  may  allow  recovery  of  a 
PVR-tropic  non-poliovirus  HEV-C.  An  experimental  assay  was  designed  to  investigate  this Claire  Blanchard  General  Discussion  Chapter  5  125 
and  is  illustrated  in  figure  5.2.  Recent  studies  have  demonstrated  the  existence  of  siRNA 
escape  mutants  that  are  resistant  to  specific  RNA  degradation  necessitating  the  use  of 
multiple  siRNAs  for  efficient  silencing  of  the  input  genome  (Gitlin  et  al.,  2005).  Hence, 
several  siRNAs  would  be  synthesised  to  bind  a  number  of  genes:  CVA21  VP1,  VP2,  VP3 
and  VP4-coding.  regions.  binding  siRNAs  and  PV3  2C  CRE  and  3C-specific  binding 
siRNA  fragments.  Due  to  the  highly  specific  nature  of  RNA  interference,  any  input 
sequence  could  be  used  and  a  range  of  genomes  could  be  tested.  Initial  silencing  would  be 
carried  out  on  both  CVA21  and  PV3  genomes  in  a  tissue  culture  environment,  thereby 
disabling  the  genomes  to  yield  viable  viruses.  These  two  partners,  when  present  in  the 
same  cellular  environment,  should  be  subjected  to  sufficient  selective  pressure  to  generate 
chimeras.  The  assay  could  then  be  extended  to  a  wider  range  of  different  partners. 
The  emergence  of  siRNA  escape  mutants,  the  need  for  high  numbers  of  siRNAs  and-the- 
off-target  effects  exerted  by  siRNAs  on  host  cells  should  not  be  ignored  (Couzin  et  al., 
2004).  However,  the  method  would  allow  a  forced  recombination  event  between  different 
junctions  points.  Analysis,  identification  of  crossover  points,  characterisation  of  the 
biology  of  potentially  viable  in  vivo  generated  recombinants  and  comparison  with  the  in 
vitro  generated  precise  exchange  of  the  P1-coding  region  recombinants  may  give  an  insight 
into  different  areas  of  picornavirus  research  such  as  genome  cellular  localisation,  cis-acting 
replication  and  encapsidation  of  progeny  viral  genomes  into  newly  synthesised  capsids. CVA21  genome 
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Figure  5.2:  siR\A  gene  silencing  recombination  in  tissue  culture 
Diagram  illustrating  the  use  of  siRNAs  in  tissue  culture  as  means  of  obtaining 
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6  Materials  and  Methods 
6.1  Standard  solutions  and  chemical  suppliers 
All  chemicals  were  supplied  by  Sigma-Aldrich  or  BDH.  All  enzymes  were  supplied  by 
Invitrogen,  NEB,  Promega  and  Roche. 
Phenol:  chloroform 
25  parts  phenol:  25  parts  chloroform:  1  part  isoamyl  alcohol 
lOx  Grin!  o 
250  mM  Tris-base,  2.5  M  Glycine,  35  mM  Sodium  Dodecyl  Sulphate  made  up  to  51  in 
dH2O 
Destain  buffer 
10%  (v/v)  Methanol,  10%  (v/v)  Acetic  acid  and  80%  (v/v)  dH2O 
Crystal  Violet 
0.5  g  Crystal  violet  in  20m1  of  Ethanol,  880  ml  dH2O,  10%  (v/v)  of  37%(w/v) 
Formaldehyde  and  15  mM  Sodium  Chloride. 
50x  TAE 
2M  Tris-base,  57.1  ml  Glacial  Acetic  Acid,  10  mM  EDTA  (pH  8.0)  made  up  to  11  in 
dH2O 
Mini-prep  solutions 
Solubilisation:  solution  1  (4°C) 
50  mM  Glucose,  25  mM  Tris-HC1  (pH  8.0)  and  10  mM  EDTA  (pH  8.0) 
Cell  lysis: Solution  2  (room  temperature) 
200  mM  Sodium  Hydroxide  and  1%  SDS 
Neutralisation:  Solution  3  (4°C) 
3M  Potassium  Acetate,  11.5  ml  Glacial  Acetic  Acid  and  28.5  ml  dH2O Claire  Blanchard  Materials  and  Methods 
RNase  A 
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2g  RNase  A  (SIGMA,  kept  at  -20°C)  in  200  mis  10  mM  Tris  (pH  7.8)  and  15  mM  Sodium 
Chloride.  Boiled  for  15  minutes  to  destroy  DNase  and  allow  to  cool  slowly.  Store  at  -20°C 
DEPC-treated  water 
0.1%  DEPC  (SIGMA)  to  dH2O.  Left  at  37°C  overnight  and  autoclaved  twice. 
2x  protein  reducing  gel  loading  buffer 
2  ml  Glycerol,  1.5  ml  10%  Sodium  Dodecyl  Sulphate,  0.625  ml  1M  Tris  (pH  6.8), 
0.375  ml  dH2O,  a  spatula's  worth  of  Bromophenol  Blue  and  50  µl  Mercaptoethanol  was 
added  to  every  1  ml  of  solution. 
Guanidine  Hydrochloride  (GuHCI)(SIGMA) 
100  mM  GuHCI  in  dH2O 
6x  DNA  gel  loading  buffer 
7  ml  dH2O,  3  ml  Glycerol  and  a  spatula's  worth  of  Bromophenol  Blue  or  Orange  G. 
10%  (w/v)  Ammonium  Persulfate 
20%SSC 
3M  Sodium  Chloride,  300  mM  Sodium  Citrate  made  up  to  500  mis  in  dH2O. 
Hybridisation  buffer 
Rapid-hyb  buffer  supplied  by  Amersham  Biosciences. 
RNA  denaturation  buffer 
660  µl  Formamide,  210  pl  37%(w/v)  Formaldehyde  and  130  µ1  lOx  MOPS  electropheresis 
buffer. 
10,  MOPS 
200  mM  MOPS,  80  mM  Sodium  Acetate,  1  mM  EDTA  and  100  ml  of  dH2O. Claire  Blanchard  Materials  and  Methods 
Western  Blot  Transfer  buffer 
1%  (w/v)  Sodium  Dodecyl  Sulphate,  570  mM  Glycine,  50  mM  Tris-base, 
20%  (v/v)  Methanol  and  160  ml  dH2O. 
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Western  Blot  Blocking  buffer 
5%  (w/v)  dried  skimmed  milk,  0.1%  (v/v)  Tween  20  in  Phosphate  Buffered  Saline  (PBS). 
Cell  lysis  buffer 
50  mM  Tris-HC1  (pH  8.0),  1  mM  EDTA  (pH  8.0)  and  100  mM  Sodium  Chloride. 
"Spiller"  radiolabelling  buffer 
1M  Sodium  Chloride,  20  mM  Tris-HC1(pH  7.5)  and  0.1%  BSA  in  dH2O. 
Blue  cell  assay  developing  solution 
9.560  ml  PBS,  2.500  ml  0.5M  Potassium  Ferrocyanide,  2.500  ml  0.5M  Potassium 
Ferricyanide,  0.500  ml  1M  Magnesium  Chloride  and  6.250  ml  X-gal  (1,4-O-ß-D- 
galactopyranosyl-D-glucose)  (20  mg/ml). 
Plaque  overlay  media 
10%  (v/v)  l  Ox  EMEM:  Eagle's  minimum  essential  medium  (GIBCO  Life  technologies), 
50%  (v/v)  dH2O,  1%  (v/v)  L-  glutamine  (GIBCO  Life  technologies),  2%  (v/v)  FCS  (Foetal 
calf  serum),  1%  (v/v)  Penicillin/  Streptomycin  (GIBCO  Life  technologies),  3%  (v/v)  of 
7.5%  Sodium  bicarbonate  (GIBCO  Life  technologies)  and  30%  (v/v)  of  2%  Bactoagar. Claire  Blanchard  Materials  and  Methods 
6.2  List  of  antibodies 
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Database 
Antibodies  Dilution  Usage 
reference 
Anti-PVR  280  A-AB-5H  1  in  50/  lin  200  Monoclonal  antibody  to  PVR 
Anti-PV3  A-AA-lE  1  in  200  Rabbit  polyclonal  antibody  to 
oliovirus  type  3 
Anti-Polio  A-AB-1D  1  in  200  Sheep  16-  sheep  polyclonal  to 
type  1  oliovirus  type  1 
Western  blot:  1  in  1000 
Anti-VP  I  DAKO  mouse  monoclonal  antibody 
DAKO  Immunoflu  cence:  1  in 
against  enterovirus  VP  1 
400 
Anti-mouse  1  in  200  ti-mouse  FITC  conjugated 
FITC  olyclonal  antibody 
Anti-mouse  1  in  5000  ti-mouse  HRPO  conjugated 
HRPO  olyclonal  antibody 
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6.3  List  of  oligonucleotide  primers 
Name  of 
oligonucleotide 
Database 
reference 
Nucleotide  sequence 
ID6  O-AB-91  GGTGTTAGAGAAAATTGGTTTTGG 
R3D  O-AD-9C  GGGATATCACTCAGCATAATAATGAGTCAAGCCAAC 
GEN-3'BK'F  O-AA-2F  TATGAGCTCACCACWCCCGGGTTTGGSCAYCAG 
GEN-3'BK-R  O-AA-7E  CCYACATACATGTTGGGGTACTTACTAGTGTTC 
-F 
O-AA-7H  TACGACTCACTATAGGGCG 
CA21-5'-BK-R  O-AA-1  F  CTTGCGCTCCCATTTGCAC 
GEN-3'BK-F-Nae  O-AB-7C  RASGAGCTCACCACWGCCGGCTTYGGMCACCARAAC 
GEN-3'BK-R  O-AA-7E  CCYACATACATGTTGGGGTACTTACTAGTGTTC 
P1-GEN-F  O-AA-8E  TGGGAGCTCARGTDTC 
PV3-P1-R  O-AD-6D  TATGTGGTCAAACCTTTCTC 
CA21-P1-R  O-AC-3B  AAAAGTGGTAATTGAGTCTAC 
PV3/CA21-PI-R  O-AA-3F  TGSCCAAATACGTAWGTGG 
Sabinl-PI-R  O-AC-4B  TATGTGGTCAGATCCTTG 
NT  GEN  2F  O-AA-9C  GGAACCGACTACTTTGGG 
ENT  GEN  2R  O-AA-1D  TCNGGNARYTTCCACCAC 
ENT  PCD  6R  O-AA-5E  TGGTARTTRCWRATYTTG 
CAV21  FO  O-AA-6G  CGGTGCACACGAGAATCAAA 
CAV21  R11  O-AA-5G  CGACTGGAAGTCATCAGATG 
CVA21  P1  de1DJE  1  O-AE-8E  CCGGGATCTCGAGG 
CVA21  P1  delDJE2  O-AE-9E  CTAGCCTCGAGATC 
Polio-End  O-AA-7B  TAAGTCGACTTTTTTTTTTTTTTTTTTTTTTTTCCT 
CCGAATTAAAGAAAAATTTACC 
ENT  PCD  6F  O-AA-6E  TMACHGCHGTBGARACWGG 
ID1  O-AB-21  TTAAAACAGCTCTGGGGT 
LUCF  O-AB-9I  CATCTTCGACGCGGGCGT 
PV3-VP2-F  O-AD-8D  GCCATTCTGCCCTTATCACCG 
PV3-VP3-R  O-AD-9C  CATTACTAATCCACGGCAC 
PV33D-T7R 
PV3-VP3-3F 
O-AD-9D 
O-AD-7D 
GGGATATCACTCAGCATAATAATGAGTCAAGCCAAC 
GCCAATGACCAGATTGGTG 
CAV21  CAPF  O-AA-1H  CTTCGAGAAGCCTAGTATCG 
CB3-1F  O-AB-8A  TCCGGTGACCAATAGAGC 
591-SR  O-AD-5C  TGTCTGAAGTACAGCTTGCC 
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Plasmid  name  Description  Simplified  plasmid 
name 
pS1F 
Full  length  poliovirus  Sabin 
S1F 
e1  infectious  clone 
CAV21 
CVA21  full-length  infectious 
CAV21 
clone 
Full  length  poliovirus  type  3 
pT7FLC  Leon  P3/Leon/37  infectious  T7FLC 
clone 
Poliovirus  type  3  Leon 
T7FLC/REP3  P3/Leon/37  CAT  replicon  T7FLC/REP3 
derived  from  pT7FLC 
Backbone  vector  lacking  the 
pT7FLC/REP3-BK  complete  P1-coding  gene  PV3BK 
derived  from  pT7FLC/REP3 
Backbone  vector  PV3BK  with 
pT7REP3-BK-SL3-P1 
insertion  of  the  complete  PV3 
PV3BKPV3P1  P1-coding  region  introduction 
derived  from  pT7/SL3 
Backbone  vector  PV3BK  with 
insertion  of  the  complete 
pT7REP3-BK-CA21-PI  CVA21  P1-coding  region  PV3BKCVA21P1 
introduction  derived  from 
CAV21 
Full  length  poliovirus  type  3 
T7/SL3 
Leon  P3/Leon/37with 
T7/SL3 
mutations  in  the  2C  CRE 
derived  from  pT7FLC 
Poliovirus  type  3  Leon 
T7REP3-L  P3/Leon/37  luciferase  replicon  T7REP3-L 
derived  from  T7FLC/REP3 
pRibol 
Vector  containing  a  ribozyme  Ribol  hammerhead 
CVA21  full-length  infectious 
clone  introduced  in  a  ribozyme 
pRibo-CAV21  hammerhead-containing  vector  Ribo-CAV21 
derived  from  CAV21  and 
pRibol 
CVA21  full-length  infectious 
pRibo-CAV21-NaelDel  clone  with  a  deletedNae  I  site,  Ribo-CAV21-NaelDel 
derived  from  pRibo-CAV21 
CVA21  backbone  vector 
pRibo-CAV21-NaelDel-  lacking  the  complete  P1- 
backbone  coding  gene,  derived  from  CVA21BK 
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Plasmid  name  Description 
Simplified  plasmid 
name 
CVA21  backbone  vector  with 
insertion  of  the  complete 
Ribo-CAV2I-BK/CA21  P1 
CVA21  P1  -coding  region,  CVA21BKCVA21P1 
derived  from  pRibo-CAV21- 
ae  1  Del-backbone  and 
CAV21 
CVA21  backbone  vector  with 
insertion  of  the  complete  PV3 
Ribo-CAV21-BK/PV3-P1  P1-coding  region,  derived  from  CVA2IBKPV3P1 
Ribo-CAV21-Nae1Del- 
backbone  and  pT7/SL3 
CVA21  backbone  vector  with 
insertion  of  the  complete 
Ribo-CAV2I-BK/Sabinl  P1  SabinI  P1-coding  region,  CVA21BKSabin1P1 
derived  from  pRibo-CAV21- 
ae  1  Del-backbone  and  pS  1F 
T7EV7 
Full  length  echovirus  7 
T7EV7  infectious  clone 
EV7  genome  with  an  in-frame 
EV7AP  1  si  I  deletion  in  the  P  1-coding  EV7AP  1 
region,  derived  from  pT7EV7 
CVA21  genome  with  an  in- 
CVA21  AP  1 
frame  Age  I  deletion  in  the  P1- 
CVA21  AP  1 
coding  region,  derived  from 
CAV21 
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6.5  Cell  culture  and  virological  methods 
6.5.1  Digestion  of  DNA  with  restriction  endonucleases 
Restriction  digest  reactions  were  carried  out  in  the  lx  buffer  recommended  by  the 
manufacturers  in  the  presence  of  1  unit  (U)  of  restriction  enzyme  per  µg  of  DNA.  The 
reactions  were  made  up  to  final  volumes  of  20  µ1  in  the  case  of  analytical  digests  or  50  Al 
in  the  case  of  preparative  digests  and  were  carried  out  at  the  temperatures  recommended  by 
the  manufacturers  for  1  to  4  hours. 
6.5.2  Plasmid  DNA  preparation  for  in  vitro  transcription 
5  pg  of  plasmid  DNA,  containing  a  T7  promoter,  was  linearised  with  the  appropriate 
restriction  endonuclease,  phenol-chloroform  extracted  and  ethanol  precipitated.  After 
washing  in  70%  ethanol,  the  DNA  was  pelleted,  dried  and  resuspended  in  20  p1  clean 
dH2O. 
6.5.3  In  vitro  transcription  using  T7  RNA  polymerase 
1  Vg  of  resuspended  DNA  was  incubated  in  lx  transcription  buffer  (NEB),  1mM  rNTPs, 
0.5  pl  of  RNAse  OUT  (Invitrogen),  1  pl  of  T7  DNA  polymerase  (NEB)  made  up  to  a  final 
reaction  volume  of  25  pl  with  clean  dH2O.  The  reaction  was  incubated  at  37°C  for  2  hours. 
10%  of  the  reaction  volume  was  checked  on  an  agarose  gel  and  quantified  on  a 
spectrophotometer. Claire  Blanchard  Materials  and  Methods 
6.5.4  In  vitro  transcription  using  Ribomax 
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1  µg  of  linearised  DNA  was  incubated  in  6  µl  of  5x  T7  buffer,  2.3  µl  rATP,  2.3  µl  rGTP, 
2.3  µl  rCTP,  2.3  pl  rUTP,  3  pl  of  T7  enzyme  mix  and  clean  dH2O  (30  pl  reaction  mix) 
provided  in  the  RiboMAXTh  Large  scale  RNA  Production  Systems-T7,  for  2  hours  at 
37°C.  The  newly  transcribed  RNA  reactions  were  then  RQ1Dnase  treated  (1  U/µg  of  DNA 
transcribed)  for  30  minutes  at  37°C  and  heat  inactivated  at  65°C  for  15  minutes.  Samples 
were  checked  on  an  agarose  gel  and  quantified  in  a  spectrophotometer. 
6.5.5  RNA  transfection  of  mammalian  cell  lines 
6.5.5.1  DEAE-dextran 
1-10  µg  of  T7  RNA  transcripts  was  incubated  in  lxHepes-buffered  saline,  pH  7.1  in  clean 
dH20  with  200  pg/ml  DEAE-dextran  and  10  pl  lOx  filtered  glucose  solution  on  ice  for 
30  minutes.  Prior  to  cell  transfection,  the  pre-seeded  80%  confluent  6-well  dish  cell 
monolayers  (RD-ICAM  cells,  Hela  cells,  RD  cells)  were  washed  with  Serum  Free  DMEM 
(SF-DMEM).  To  each  well,  100  µ1  of  the  reaction  mix  was  added  and  incubated  at  room 
temperature  for  30  minutes  ensuring  the  cell  monolayers  did  not  dry  out.  The  transfection 
mix  was  then  removed  and  4  ml  of  DMEM  supplemented  with  10%  FBS  (Foetal  Bovine 
Serum)  were  added  to  each  well  and  the  dishes  were  incubated  at  37°C  in  a  humidified  5% 
CO2  incubator. 
6.5.5.2  Electroporation 
Cells  of  a  confluent  T175  flask  were  resuspended  using  PBS-125mM  EGTA  and 
centrifuged  at  2000  rpm  for  5  minutes  (Multifuge  3  S-R  Heraeus).  The  cell  pellet  was 
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electroporation  cuvettes  for  mammalian  cells  (CLP).  The  settings  used  for  transfection 
were:  250  V,  400  12,250  µF.  The  cells  were  then  added  to  a  T25  tissue  culture  flask 
containing  4.5  ml  of  10%  DMEM  and  incubated  at  37°C  in  a  humidified  5%  CO2 
incubator. 
6.5.5.3  Lipofectamine  2000 
10-15  pg  of  RNA  in  solution  was  made  up  to  100  p1  in  OPTIMEM  medium  (GIBCO)  and 
mixed  and  vortexed  with  a  solution  of  10-15  p1  of  LipofectamineTm  2000  (Invitrogen)  and 
90-85  pl  of  OPTIMEM.  The  mixture  was  incubated  at  room  temperature  for  10-15  minutes 
and  a  further  800  p1  of  OPTIMEM  was  added  to  the  mix.  Before  transfection  the 
80%-confluent  cell  sheet  was  washed  with  OPTIMEM.  1  ml  of  the  vortexed  solution  was 
added  to  each  well  of  a  6-well  dish  and  incubated  at  37°C  for  4-5  hours.  The  mix  was 
removed  and  4  ml  of  10%  DMEM  was  added  to  each  well  and  incubated  at  37°C. 
6.5.6  Infection  of  cell  monolayers  with  virus 
80%  confluent  cell  monolayers  were  pre-washed  with  SF-DMEM,  virus  was  added  to  an 
MOI  (multiplicity  of  infection)  of  1-10  and  incubated  at  37°C  in  a  humidified  5%  CO2 
incubator  for  30  minutes.  The  virus  supernatant  was  discarded  and  DMEM  supplemented 
with  10%  FBS  was  added  to  the  infected  cell  sheet. 
6.5.7  Purification  of  viral  RNA 
6.5.7.1  Using  Trizol1  Reagent 
Flasks  of  virus-infected  cells  were  frozen  and  thawed  twice.  750  µl  Trizol®  Reagent 
(Invitrogen)  was  added  to  virus-infected  cells,  vortexed  and  left  at  room  temperature  for  10 
minutes  to  ensure  homogenisation  and  degradation  of  DNA.  200  µl  of  chloroform  was Claire  Blanchard  Materials  and  Methods  Chapter  6  136 
added  and  centrifuged  for  15  minutes  at  13,000  rpm  (in  a  Biofuge  pico  Heraeus 
instruments)  at  4°C.  The  upper  phase  was  added  to  isopropanol  and  left  at  room 
temperature  for  10  minutes  before  precipitation  by  centrifugation  at  13,000  rpm  for  a 
further  10  minutes  at  4°C  (in  a  Biofugepico  Heraeus  instruments).  The  RNA  pellet  was 
washed  with  75%  ethanol  and  then  the  pellet  was  left  to  air-dry.  The  air-dried  pellet  was 
resuspended  in  50  µl  clean  dH2O  and  incubated  at  55°C  for  10  minutes  to  ensure  correct 
solubilisation  of  the  extracted  viral  RNA. 
6.5.7.2  Using  QIAamp®  Viral  RNA  mini  kit 
vRNA  extraction  was  carried  out  using  a  QIAamp®  Viral  RNA  mini  kit.  A  volume  of 
140  µl  of  harvested  virus  was  added  to  560  pl  of  prepared  Buffer  AVL  containing  carrier 
RNA  in  a  1.5  ml  clean  tube.  The  mixture  was  mixed  by  pulse-vortexing  for  15  seconds  and 
incubated  at  room  temperature  for  10  minutes.  The  samples  were  centrifuged  briefly  to 
remove  drops  from  the  inside  of  the  lid  and  560  pl  of  100%  ethanol  were  added  to  each 
tube.  The  mixture  was  mixed  by  pulse-vortexing  for  15  seconds  and  centrifuged  briefly. 
630  µl  of  the  mix  were  carefully  applied  to  a  QIAamp  spin  column,  which  were  then 
centrifuged  at  8000  rpm  for  1  minute  (in  a  Biofugepico  Heraeus  instruments).  This  step 
was  repeated  with  the  remainder  of  the  sample  and  using  a  clean  collection  tube.  Clean 
collection  tubes  were  used  for  individual  steps.  500  µl  of  Buffer  AW  1  were  then  added  to 
each  column  and  these  were  centrifuged  at  8000  rpm  for  1  minute  (in  a  Biofuge  pico 
Heraeus  instruments).  500  µl  of  Buffer  AW2  were  added  to  each  column  and  these  were 
centrifuged  at  13000  rpm  for  3  minutes  and  then  at  13000  rpm  for  1  minute  (in  a  Biofuge 
pico  Heraeus  instruments).  60  µl  of  Buffer  AVE  or  elution  buffer  were  added  to  each 
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1  minute  and  centrifuged  at  8000  rpm  for  1  minutes  (in  a  Biofuge  pico  Heraeus 
instruments). 
6.5.8  TCIDm 
Infectious  titre  of  virus  was  routinely  calculated  by  TCID50  (Tissue  culture  infectious  dose 
50).  One  tenth  of  a  confluent  T75  tissue  culture  flask  of  cells  was  evenly  distributed  in 
100  µl  volumes  across  a  96-well  plate  containing  quadruplicates  of  50  µl  set  of  serial 
10-fold  dilutions  of  virus.  Three-to  four  days  post  infection  crystal  violet  stain, 
supplemented  with  formaldehyde,  was  added  to  the  monolayers  for  two  to  three  hours.  The 
non-infected  cell  sheets  were  stained  and  the  cells,  killed  by  infection,  did  not  retain 
staining.  The  virus  titre  was  expressed  as  the  dilution  of  the  virus  required  to  infect  50%  of 
the  cultures  (Reed  &  Muench,  1938).  If  CPE  was  observed  in  half  of  the  wells  at  a  dilution 
of  10'7,  the  titre  was  107  TCID50  units  in  50  µl.  If  all  wells  show  CPE  at  10"7  and  none  at 
10$,  the  titre  is  107'5  TCID50  units  in  50  µl.  One  well  corresponds  to  approximately 
l0°-25TCID5o  units.  Titres  were  expressed  as  TCID50/ml. 
6.5.9  Plaque  Assay 
RD,  Hela,  L20B  or  RD-ICAM  cells  as  appropriate  were  seeded  into  6-well  plates  and 
grown  to  80%  confluent  monolayers.  Serial  10-  to  100-fold  dilutions  of  the  virus  stocks 
were  made  in  serum-free  media.  The  cell  sheets  were  then  washed  a  couple  of  times  in 
serum  free  media  and  inoculated  with  200  µl  of  the  diluted  virus.  The  virus  was  allowed  to 
absorb  for  30-45  minutes  at  room  temperature  and  the  plaque  overlay  media  was  added  to 
the  infected  monolayers.  The  inverted  dishes  were  incubated  for  three  to  four  days  at  37°C 
in  a  humidified  5%  CO2  incubator.  Crystal  violet  solution  was  added  to  the  dishes  for  two 
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to  three  hours.  The  plaques  were  counted  and  expressed  as  plaque  forming  units  per  ml 
(pfu/ml). 
6.5.10Virus  neutralisation  assay 
Viruses  were  pre-incubated  with  two-fold  serial  dilutions  (50  µl)  of  neutralising  antibody 
in  serum  free  DMEM  starting  at  1:  50  for  one  hour  at  37°C.  100  µl  of  cells  were  added  to 
the  wells  and  infection  was  allowed  to  proceed  for  24-48  hours  prior  to  crystal  violet 
staining. 
6.5.11  Virus  blocking  assay 
Monolayers  of  the  appropriate  cell  line  in  a  96-well  plate  were  incubated  with  two-fold 
serial  dilutions  (50  µl)  of  neutralising  antibody  in  serum  free  DMEM  starting  at  1:  50  for 
one  hour  at  37°C.  104  TCID50  (100  µl)  of  virus  was  added  to  the  wells  and  infection  was 
allowed  to  proceed  for  24-48  hours  prior  to  crystal  violet  staining. 
6.5.12  Synthesis  of  radiolabelled  virus 
RD,  RD-ICAM  or  Hela  cells  were  pre-treated  with  Methionine-free  Minimum  Essential 
Medium  Eagle  (MEM)  (Sigma)  for  one  hour  at  37°C  in  a  humidified  5%  CO2  incubator. 
The  80%  confluent  cell  sheet  of  a  T75  tissue-culture  flask  was  infected  with  virus  at  an 
MOI  of  10.  The  virus  was  adsorbed  at  room  temperature  for  30  minutes  and  the  cells  were 
washed  and  incubated  with  l  Oml  Methionine-free  MEM  for  2  hours.  10  ml 
Methionine-free  MEM  supplemented  with  200  µCi  [35S]  methionine  was  added  to  the 
infected  cells  and  this  was  incubated  overnight  at  37°C  in  a  humidified  5%  CO2  incubator. 
The  virus  was  then  harvested  after  2  freeze-thaws  and  filtered  through  a  0.20  µm  filter.  The 
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gradient  at  40,000  rpm  (Sorvall  Ultra  Pro  80  centrifuge)  using  a  TH641  rotor  at  4°C  for 
6  hours.  The  CVA21  pellet  was  resuspended  in  300  µl  Spiller  buffer.  All  other  viruses 
were  resuspended  in  300  µl  of  PBS-BSA. 
The  virus  was  further  purified  by  centrifugation  through  a  12  ml  linear  10-25%  sucrose 
gradient  at  40,000  rpm  (Sorvall  Ultra  Pro  80  centrifuge)  using  a  TH641  rotor  at  4°C  for 
1  hour  and  20  minutes  to  obtain  infectious  160S  particles.  The  gradient  was  harvested  from 
the  bottom  in  500  µl  aliquots.  5  µl  of  each  fraction  was  counted  in  3  ml  of  scintillant 
(Ecosint  A  scintillation  fluid  by  National  Diagnostics)  by  scintillation  counting  (Beckman 
LS5000CE  machine).  160S  particles,  detected  by  a  peak  reading,  were  typically  found  in 
fractions  5  and  6.  The  sucrose  was  removed  by  washing  with  PBS-BSA  or  Spiller  buffer 
and  loaded  into  1.5  ml  Beckman  Ultracentrifuge  tubes  in  equal  portions  and  centrifuged 
overnight  at  40,000  rpm  (Beckman  TL-100  Ultracentrifuge)  using  a  TLS55  rotor  at  4°C. 
The  160S-pelleted  particles  were  carefully  resuspended  in  100  µl  of  PBS-BSA  and  stored 
at  -20°C  for  up  to  4  weeks. 
6.5.13  Synthesis  of  infected  cell  lysates 
An  80%-confluent  cell  sheet  was  infected  at  an  MOI  of  10  for  30  minutes  at  room 
temperature  and  washed  with  SF-DMEM.  1  ml  of  10%  DMEM  was  added  to  the  infected 
cells  and  incubated  for  2  hours  at  37°C  in  a  humidified  5%  CO2  incubator.  Timing  enabled 
viral  proteases-mediated  host  cell  shut  off  and  insured  that  the  proteins  labelled  were  of 
virus  origin.  The  washed  cells  were  supplemented  with  I  ml  of  Methionine-free  MEM  for 
30  minutes  at  37°C  in  a  humidified  5%  CO2  incubator.  The  medium  was  removed  and  1  ml 
of  Methionine-free  MEM  supplemented  with  100  µCi  [35S]  methionine  was  added  and 
incubated  at  37°C  for  30  minutes  to  1  hour.  The  cells  were  washed  and  resuspended  in  1  ml 
PBS  using  cell  scrapers.  Cells  were  pelleted  by  centrifugation  in  a  Biofuge  pico  microfuge Claire  Blanchard  Materials  and  Methods  Chapter  6  140 
(Heraeus  instruments)  at  5,000  rpm  for  5  minutes  and  resuspended  in  100  µl  of  lx  Cell 
Lysis  Solution  (CLS)  and  incubated  at  room  temperature  for  5  minutes.  Cell  debris  were 
removed  by  centrifugation  and  the  supernatant  added  to  100  µ12x  reducing  SDS-PAGE 
loading  buffer. 
6.5.14Immunostaining  assays 
6.5.14.1  "Blue  cell"  assay 
"Blue  cell"  assay  is  a  rapid  and  sensitive  method,  known  as  CELICS  (cloning  by 
enzyme-linked  immunocolourimetric  screening  (Evans  et  al.,  1998)).  10  to  12  hours  post 
RNA-transfection,  the  transfected  cells  were  fixed  in  Methanol:  Acetone  (1:  1)  for 
10  minutes  at  room  temperature  and  washed  with  PBS.  The  cells  were  then  incubated 
overnight  in  PBS-BSA  (0.5%)  at  room  temperature.  The  cells  were  washed  and  incubated 
with  DAKO  mouse  anti-enterovirus  VP1  antibody  (diluted  to  1:  400  in  PBS-BSA)  for 
2  hours  at  room  temperature.  The  cells  were  washed  3  times  in  PBS-BSA  and  incubated 
for  a  further  2  hours  at  room  temperature  in  the  presence  of  anti-mouse  ß-galactosidase 
antibody  (diluted  to  1:  800  in  PBS-BSA).  The  cells  were  washed  and  incubated  for 
30  minutes  to  1  hour  at  37°C  in  colour  developing  solution. 
6.5.14.2  Immunofluorescence  assay 
6.5.14.2.1  Cell  preparation 
13  mm  coverslips  (VWR  international)  were  flame  sterilised  and  put  into  a  24-well  tissue 
culture  plate.  RD-ICAM  cells  were  then  seeded  so  as  to  reach  50%  confluency  on  the  day 
of  infection  and  were  incubated  in  10%  FCS  DMEM  supplemented  with  Penicillin: 
streptomycin  at  37°C  in  a  humidified  5%  CO2  incubator. Claire  Blanchard  Materials  and  Methods  Chapter  6  141 
6.5.14.2.2  Fixation  and  immunofluorescence  labelling 
10  hours  post  RNA-transfection  the  transfected  cells  were  fixed  in  1  ml  per  well  of 
Methanol:  Acetone  (1:  1)  mix  for  30  minutes  at  -20°C  and  rehydrated  with  1.5  ml  of  PBS 
for  10  minutes.  The  transfected  cells  were  then  blocked  in  PBS  +  2%  FCS  for  10  minutes 
on  a  rotating  shaker.  The  cells  were  incubated  with  DAKO  mouse  anti-enterovirus  VP1 
antibody  (diluted  to  1:  400  in  PBS  +  2%  FCS)  for  2  hours  at  room  temperature  on  a  rotating 
shaker.  The  cells  were  washed  3  times  in  PBS  +  2%  FCS  and  incubated  for  a  further 
2  hours  at  room  temperature  in  the  presence  of  anti-mouse  FITC  conjugate  antibody 
(diluted  to  1:  400  in  PBS  +  2%  FCS).  The  24-well  dish  was  wrapped  in  tin  foil,  as  FITC  is 
light  sensitive.  The  cells  were  washed  three  times  in  PBS  +  2%  FCS  and  once  with  PBS. 
6.5.14.2.3  Analysis  on  the  confocal  microscope 
The  coverslips  were  rinsed  in  dH2O  and  mounted  onto  a  drop  of  PBS-glycerol  on  a  glass 
slide,  cells  facing  down.  The  coverslips  were  fixed  by  applying  nail  varnish  around  the 
edges  of  the  coverslips.  Slides  were  labelled  and  allowed  to  dry  in  a  dark  environment  for 
15-30  minutes.  The  slides  were  then  analysed  using  a  confocal  microscope  set  to  detect 
FITC  wavelength.  The  samples  were  photographed  and  analysed  using  LSM  Meta  510. 
The  figures  were  prepared  with  Adobe  Illustrator  10. 
6.5.15  Packaging  assays 
The  trans-encapsidation  assays  were  adapted  from  methods  described  in  (Barclay  et  al., 
1998;  Percy  et  al.,  1992).  T7  RNA  transcripts  were  transfected  into  permissive  cell  lines 
and  either  co-transfected  with  helper  T7  RNA  transcript  or co-infected  6  hours 
post-transfection  with  a  helper  virus.  The  samples  were  then  incubated  in  a  37°C 
humidified  5%  CO2  incubator  until  CPE  was  seen.  The  samples  were  freeze-thawed  and Claire  Blanchard  Materials  and  Methods  Chapter  6  142 
clarified.  Each  sample  was  then  digested  with  400  pg/ml  of  RNase  A  for  30  minutes  at 
37°C.  The  RNAse  digested  samples  were  passaged  onto  a  fresh  cell  sheet  of  RD-ICAM 
cells.  The  infected  cells  were  incubated  in  a  37°C  humidified  5%  CO2  incubator  for  8-10 
hours.  The  samples  were  harvested  and  screened  by  RT-PCR  and  RFLP  analysis  or  by 
Luciferase  assay. 
6.5.15.1  Luciferase  assay 
The  supernatants  of  the  passaged  samples  were  discarded  and  the  cells  were  scraped  off 
and  resuspended  in  1  ml  of  PBS.  The  cells  were  pelleted  by  centrifugation  at  6000  rpm  for 
5  minutes  (in  a  Biofugepico  Heraeus  instruments).  The  supernatant  was  discarded  and  the 
cells  were  resuspended  in  lx  cell  lysis  buffer  (Promega(V).  Luciferase  activity  was  detected 
from  10  µl  of  the  lysed  samples,  using  a  TD20/20  luminometer  (Promega),  after  the 
addition  of  100  µl  of  room  temperature  luciferase  assay  substrate  +  luciferase  assay  buffer 
solution  (Luciferase  assay  system,  Promega®).  The  Luciferase  activity  was  measured 
using  a  luminometer  and  the  data  was  expressed  in  relative  light  units. 
6.6  Molecular  techniques 
6.6.1  Isolation  of  plasmid  DNA 
10  ml  and  100  ml  overnight  cultures  of  transformed  E.  coli  in  Luria  broth  with  the 
appropriate  antibiotic  selection  medium  were  used  to  perform  small  or  medium-scale 
isolations  of  plasmid  DNA.  These  were  carried  out  following  the  alkaline  lysis  protocol 
described  by  Sambrook  (Sambrook  et  al.,  1989). Claire  Blanchard  Materials  and  Methods 
6.6.2  Restriction  endonuclease  digestion 
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Restriction  digests  were  carried  out  using  1  unit  of  the  appropriate  enzyme  per  µg  of  DNA 
in  the  buffer  and  at  the  temperature  recommended  by  the  manufacturer  for  one  to  three 
hours.  Samples  were  visualised  by  electrophoresis  on  a  1%  agarose  gel  in  TAE  buffer 
(40  mM  Tris-acetate,  2  mM  EDTA)  containing  0.5  pg/ml  ethidium  bromide.  The  DNA 
was  visualised  on  a  UV  transilluminator.  The  size  of  the  DNA  fragments  was  estimated 
using  commercially  available  size  markers,  (GIBCO  1  kb  ladder). 
6.6.3  Isolation  of  DNA  fragments  from  an  agarose  gel 
DNA  fragments  were  isolated  from  agarose  gel  using  QlAquick®  PCR  and  gel  purification 
kit  (QIAGEN).  To  an  agarose  slice  containing  the  required  DNA  fragment  in  an  eppendorf 
tube  three  volumes  of  Buffer  QG  were  added  and  incubated  at  50°C  for  10  minutes  to 
dissociate  the  agarose.  The  solubilised  sample  was  then  applied  through  a  purification 
column,  washed  with  buffer  PE  and  eluted  in  30  µl  of  buffer  EB.  A  fraction  of  the  purified 
DNA  sample  was  then  checked  by  visualisation  on  an  agarose  gel. 
6.6.4  Ligation  of  DNA  fragments 
All  ligation  reaction  were  performed  in  10  µl  volumes  at  a  molar  ratio  of  insert  to  vector  of 
3:  1  in  lx  ligation  buffer  (10  mM  MgC12,200  mM  Tris-HC1  pH  7.6,50  mM  DTT,  1  mM 
ATp)  with  1  unit  of  T4  DNA  ligase.  Reactions  were  incubated  at  16°C  for  2  hours  or  at 
4°C  overnight.  Ligation  reactions  were  always  purified  by  ethanol  precipitation  and 
resuspended  in  5  µl  clean  dH2O  for  transformation. Claire  Blanchard  Materials  and  Methods 
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A  single  colony  of  Escherichia  coli  ER2738  or  DH5a  was  picked  and  inoculated  in  10  ml 
of  LB,  containing  the  appropriate  antibiotic  selection  medium,  overnight  at  37°C  on  an 
orbital  shaker.  The  10ml  was  added  to  11  of  LB  with  antibiotic  and  incubated  at  37°C  on 
an  orbital  shaker  until  the  solution  reached  an  OD600  of  0.5-0.7  before  being  pelleted  for 
10  minutes  at  3000  rpm  in  a  Beckman  bench-top  centrifuge  at  4°C.  The  bacteria  were 
resuspended  in  100  ml  of  ice-cold  dH2O  and  centrifuged  again  at  3000  rpm  for  10  minutes 
at  4°C  (Multifuge  3  S-R  Heraeus).  The  cells  were  then  resuspended  in  100  ml  of  ice-cold 
autoclaved  10%  Glycerol  solution  and  centrifuged  at  2000  rpm  for  20  minutes  at  4°C 
(Multifuge  3  S-R  Heraeus).  The  pellet  was  resuspended  in  2  ml  10%  Glycerol  solution. 
Aliquots  were  snap-frozen  in  liquid  N2  and  stored  at  -70°C  for  up  to  three  months.  The 
cells  were  tested  for  their  efficiency  the  following  day  by  transforming  10  pg  of  pUC  19 
and  plating  it  onto  an  LB  agar  plate  containing  ampicillin.  Electro-competent  cells 
routinely  produced  107-108  colony  forming  units  per  µg  of  DNA  transformed. 
6.6.6  Transformation  of  plasmid  DNA  in  electrocompetent  E.  coli 
45  pl  of  thawed  electro-competent  E.  coli  cells  were  added  to  each  5  µl  purified  ligation 
reaction  and  electroporated  in  a1  mm  electroporation  cuvette  (CLP)  at  1600  V,  400  fl, 
25  pF  with  a  time  constant  of  7-l  Oms.  The  reaction  were  transferred  to  500  µL  of  LB  and 
incubated  at  37°C  for  45  minutes  before  plating  on  to  LB  agar  plates  containing  50  gg/ml 
ampicillin  (or  other  appropriate  antibiotic  selection)  and  incubating  at  37°C  overnight. 
6.6.7  Amplification  of  DNA  by  PCR  (Polymerase  Chain  Reaction) 
3  pg  of  template  DNA  was  added  to  a  reaction  mix  containing  lx  Thermopol  buffer 
(10  mM  KCI,  20  mM  Tris-HC1(pH  8.8  at  25°C),  10  mM  (NH4)2SO4,2  mM  MgSO4, Claire  Blanchard  Materials  and  Methods  Chanter  6  145 
0.1%  Triton  X-100  ),  2.5  mM  dNTPs,  20  pmoles  of  the  relevant  forward  and  reverse 
primers  and  1  unit  of  VentR®  proof-reading  DNA  Polymerase  (New  England  BioLabs 
NEB)  in  a  50  µl  reaction  volume.  The  DNA  was  preheated  at  95°C  for  3  minutes  prior  to 
adding  the  polymerase  and  amplified  by  6-15  (for  further  cloning)-25  (analysis  and 
sequencing)  cycles  at  95°C  for  45s,  45-55°C  for  45s,  73°C  for  2-3  minutes  (extension  step 
was  extended  for  longer  products)  followed  by  a  final  extension  step  at  73°C  for 
10  minutes  in  a  PTC-200  Peltier  Thermal  Cycler.  The  amplified  DNA  was  analysed  by  gel 
electrophoresis  in  a  1%  TAE  agarose  gel  and  purified  following  the  isolation  of  DNA 
fragments  from  an  agarose  gel  protocol. 
6.6.8  DNA  sequencing 
200-300  ng  of  purified  PCR  products  or  double  stranded  midi  plasmid  DNA  along  with 
3.2  pM  forward  and  reverse  oligonucleotides  were  sent  to  the  University  of  Dundee 
Sequencing  Service  for  sequencing.  Data  was  analysed  using  Bio  Edit  and  aligned  with  the 
appropriate  DNA  sequence,  from  the  Vector  NTI  database. 
6.6.9  Western  immunoblotting 
6.6.9.1  Preparation  of  samples 
Appropriate  samples  were  mixed  in  a  2x  reducing  SDS-PAGE  gel-loading  buffer.  The 
samples  were  then  heated  at  99°C  for  a  few  minutes  to  denature  proteins. 
6.6.9.2  Western  blotting 
Protein  samples,  normalised  for  total  amount  of  protein,  were  subjected  to  SDS-PAGE  on 
a  10%  or  12.5%  polyacrylamide  gel  and  transferred  to  a  nitrocellulose  membrane  for  ECL 
(Amersham  Pharmacia)  using  a  Bio-Rad  Transfer  Blot  at  200  V  for  an  hour.  The Claire  Blanchard  Materials  and  Methods  Chapter  6  146 
membrane  was  then  soaked  in  blocking  buffer  at  room  temperature  for  about  one  hour,  and 
washed  three  times  in  PBS-0.1%  Tween  20.  Incubation  with  a  primary  antibody  diluted  in 
blocking  buffer  to  obtain  a  1:  1000  dilution  was  carried  out  at  room  temperature  for  two 
hours.  The  membrane  was  washed  three  times  in  PBS-0.1%  Tween  20  and  incubated  with 
a  secondary  antibody  HRP,  diluted  to  1:  5000  in  blocking  buffer,  at  room  temperature  for 
two  hours.  A  fmal  three  washes  with  PBS-0.1%  Tween  20  were  carried  out  prior  to 
detection  using  an  Amersham  Biosciences  ECLTM  Western  Blotting  Detection  Kit.  The 
blots  were  exposed  to  a  Kodak  X-omat  UV  film  and  developed. 
6.6.1ODot  blot  replication  assay 
6.6.10.1  Preparation  of  DNA  probe 
The  sequences  for  the  probe  were  obtained  from  the  pT7FLCIPV3  by  amplifying  the  3D 
polymerase  using  primers  T7R3D  and  ID6.  To  3  pg  DNA  was  added  lx  Thermopol  buffer 
(10  mM  KCI,  20  mM  Tris-HC1  (pH  8.8  at  25°C),  10  mM  (NH4)2SO4,2  mM  MgSO4,0.1% 
Triton  X-100  ),  2.5  mM  dNTPs,  20  pmoles  of  the  relevant  forward  and  reverse  primers  and 
1  unit  of  VentR®  proof-reading  DNA  Polymerase  (New  England  BioLabs  NEB)  in  a  50  µl 
reaction  volume.  The  PCR  conditions  were  as  follows:  95°C-3mins,  25  cycles  of  95°C- 
45secs,  45°C-45secs,  73°C-2mins  and  a  single  final  extension  step  at  73°C  for  10  minutes. 
The  PCR  fragment  was  gel  purified  using  a  QIAquick®  PCR  and  gel  purification  kit 
(QIAGEN)  according  to  manufacturers  instructions. 
25  ng  of  template  DNA  were  mixed  in  dH2O  to  a  final  volume  of  11  µl.  The  DNA  was 
denatured  by  heating  in  boiling  water  for  10  minutes  and  quickly  chilling  on  ice.  4  µl  of 
High  Prime,  supplied  by  Roche,  were  mixed  thoroughly  and  added  to  the  denatured  DNA 
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5'  Triphosphate  (NEN  [32P]  a-rCTP).  The  solution  was  then  mixed,  briefly  centrifuged  and 
incubated  at  37°C  for  10  minutes.  The  reaction  was  stopped  by  heating  at  65°C  for 
10  minutes.  The  DNA  probe  was  then  purified  through  a  Sephadex  G-50  column  to 
remove  unbound  nucleotides. 
6.6.10.2  Northern  type  hybridisation 
10  pl  of  RNA  samples  was  added  to  30  µl  of  RNA  denaturation  buffer,  incubated  at  65°C 
for  5  minutes  and  quenched  on  ice.  A  HybondTM-N  Nylon  membrane  optimised  for  nucleic 
acid  transfer  (Amersham  Pharmacia)  was  presoaked  with  dH2O  before  being  placed  on  the 
BioRad  Bio-DotTM  microfiltration  apparatus.  The  membrane  was  washed  with  IOxSSC 
buffer  and  the  denatured  RNA  samples  were  added  and  dotted  onto  it  by  vacuum.  Further 
washes  with  l  Ox  SSC  buffer  were  carried  out  and  the  membrane  was  dried  and  samples 
were  fixed  by  UV  cross-linking  at  1200  pJoules  x  100  for  30  seconds  in  a  UVStratalinker 
1800  (Stratagene).  The  membrane  was  transferred  to  a  hybridisation  chamber  containing 
10  ml  of  Rapid-Hyb  buffer  (Amersham  Pharmacia)  and  incubated  at  65°C  for  2  hours. 
The  DNA  probe  mixture  was  added  to  the  membrane  in  the  hybridisation  chamber  and 
incubated  at  65°C  for  12-18  hours.  The  membrane  was  then  washed  with  1xSSC-0.1%SDS 
three  times  and  with  0.5xSSC-0.1%SDS  twice.  The  membrane  was  covered  in  cling  film 
and  exposed  to  phosphoimager  screen  for  30  minutes  to  1  hour  before  visualising  with 
BioRad  Quantity  One  software. 
6.6.11Lt-vitro  translation  assay 
A  mix  of  30  µl  of  Hela  S10  extracts,  5  µl  of  Flexi®Rabbit  Reticulocyte  Lysate  System 
(Promega),  5  µl  of  l0xbuffer  (10  mM  rATP,  2.5  mM  rCTP,  2.5  mM  rGTP,  600  mM 
KOAc,  300  mM  Creatine  phosphate,  15  mM  Hepes  pH  7.0  made  to  1  ml  in  dH2O) Claire  Blanchard  Materials  and  Methods  Chanter  6  148 
supplemented  with  Phosphocreatine  kinase  (Sigma),  191  of  100  mM  GuHCI,  3  µl  of 
dH2O,  501Ci  of  [35S]  Methionine  and  1  gg  of  Ribomax  prepared  RNA  diluted  in  1  µl  of 
dH2O  was  incubated  at  30°C  for  5  hours.  60  pl  of  2x  SDS  reducing  protein  gel  loading 
buffer  was  added  to  the  reaction  mix  post-incubation  and  samples  were  denatured  by 
incubation  at  100°C  for  a  few  minutes.  Samples  were  then  run  on  an  SDS-PAGE  gel  and 
visualised  using  Quantity  One  software  after  exposure  to  a  phosphoimager  screen  for  10  to 
12  hours. Claire  Blanchard  Bibliomnhy 
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Appendix  1 
Viral  protein  sizes  (in  kDa) 
Poliovirus  Leon  Sabin  poliovirus  Coxsackievirus 
Control  virus  ty  ty  A21 
Viral  proteins 
PI  95.9  97.3  97 
VPp  37.4  37.6  37.5 
VPl  32.3  33.4  33 
VP3  26.2  26.3  26.5  ,  .: 
VP2  29.7  30.1  29.9 
VP4  7.4  7.5  7.4 
VPI-2A  48.6  49.9  49.4 
P2  63.4  63.7  63.3 
2A  16.4  16.5  16.4 
2B  10.6  10.8  10.6 
2C  36.4  36.4  36.3 
2BC  47  47.2  46.9 
P3  82.8  83.5  82.8 
3A  9.5  9.7  9.5 
3B  2.3  2.4  2.3 
3C  20  20.2  20 
3D  51  51.  51 
3CD  71  71.4  71 
3AB  11.8  12.1  11.8 
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Plasmid  name  Description  Published 
Full  length  poliovirus  Sabin  Provided  by  A.  Macadam 
pS1F  tvpe  1  infectious  clone  NIBSC,  London 
CAV21 
CVA21  full-length  infectious 
Hughes  et  al.,  1989 
clone 
Full  length  poliovirus  type  3 
pT7FLC  Leon  P3/Leon/37  infectious  Goodfellow  et  al.,  2000 
clone 
Poliovirus  type  3  Leon 
pT7FLC/REP3  P3/Leon/37  CAT  replicon  Barclay  et  al.,  1998 
derived  from  pT7FLC 
Backbone  vector  lacking  the 
pT7FLC/REP3-BK  complete  P1-coding  gene 
derived  from  pT7FLC/REP3 
Backbone  vector  PV3BK 
with  insertion  of  the  complete 
pT7REP3-BK-SL3-P1  PV3  P1-coding  region 
introduction  derived  from 
pT7/SL3 
Backbone  vector  PV3BK 
with  insertion  of  the  complete 
pT7REP3-BK-CA21-P1  CVA21  P1-coding  region 
introduction  derived  from 
CAV21 
Full  length  poliovirus  type  3 
pT7/SL3 
Leon  P3/Leon/37with  Goodfellow  et  al.,  2000 
mutations  in  the  2C  CRE 
derived  from  pT7FLC 
Poliovirus  type  3  Leon 
pT7REP3-L 
P3/Leon/37  luciferase 
Goodfellow  et  al.,  2003 
replicon  derived  from 
T7FLC/REP3 
pRibol 
Vector  containing  a  ribozyme  Constructed  by  Simmonds 
hammerhead  2001 
CVA21  full-length  infectious 
clone  introduced  in  a 
pRibo-CAV21  ribozyme  hammerhead- 
containing  vector  derived 
from  CAV21  and  Ribo1 
CVA21  full-length  infectious 
pRibo-CAV21-NaelDel 
clone  with  a  deleted  Nae  I 
site,  derived  from  pRibo- 
CAV21 
pRibo-CAV21-  CVA21  backbone  vector Claire  Blanchard  Appendices  178 
NaelDel-backbone  lacking  the  complete  P1- 
coding  gene,  derived  from 
Ribo-CAV21-Nae  1  Del 
CVA21  backbone  vector  with 
insertion  of  the  complete 
pRibo-CAV2I-BK/CA21  PI 
CVA21  P1-coding  region, 
derived  from  pRibo-CAV21- 
ae1De1-backbone  and 
CAV21 
CVA21  backbone  vector  with 
insertion  of  the  complete  PV3 
pRibo-CAV2I-BK/PV3-P1 
PI-coding  region,  derived 
from  pRibo-CAV21- 
aelDel-backbone  and 
pT7/SL3 
CVA21  backbone  vector  with 
insertion  of  the  complete 
pRibo-CAV21-BK/Sabin1  PI  Sabinl  P1-coding  region, 
derived  from  pRibo-CAV  21- 
ae  1  Del-backbone  and  SIF 
pT7EV7 
Full  length  echovirus  7  Lindberg  et  al.,  1997 
infectious  clone 
EV7  genome  with  an  in- 
EVMP  1 
frame  Nsi  I  deletion  in  the 
P1-coding  region,  derived 
from  pT7EV7 
CVA21  genome  with  an  in- 
CVA21AP1 
frame  Age  I  deletion  in  the 
P1-coding  region,  derived 
from  CAV21 
Table  listing  plasmids  used  for  this  project Claire  Blanchard  Appendices 
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Appendix  4:  Phylogenetic  relationship  based  on  P2, 
2A  and  2B  coding  sequence  comparison  studies. 
A  CAV16 
CAV19  CAV1 
ioo\  `%`--CAV22 
PV2 
PV1- 
0.1 
B 
CAV21  CAV24 
CAV21"'"/!  j  jooj;  Z--CÄV17 
CAV24"  81  I'n'  CAV11 
CAV13PV3  CAV20 
CAV13 
0.1  C  CAV22 
CAV1J  CAV13 
PV1 
PV2-"\  /  ýCAV17 
CAV11 
PV3  CAV20  I  -**'`CAV24 
Phylogenetic  relation  ship  of  l1EV  C  based  on  A:  P2  coding  region  B:  2A  coding  region 
and  C:  2B  coding  region  sequence  analysis  comparison  from  Brown  et  al.  (2003). Claire  Blanchard  Appendices 
Appendix  5:  Phylogenetic  relationship  based  on 
P3  and  3D  coding  sequence  comparison  studies. 
A 
t:  AYIL  l©ci 
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CAV1I 
CAV17 
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Phylogenetic  relation  ship  of  HEV  C  based  on  A:  3D  coding  region  and  B:  complete 
P3  coding  region  sequence  analysis  comparison  from  Brown  et  al.  (2003). 
CAV21 
CAV11 